Abstract Funding Sources* AGA Oral and Poster ......Abstract Funding Sources* AGA Oral and Poster Presentations at DDW ® 2017 AGA Institute 4930 Del Ray Avenue Bethesda, MD 20814

Abstract Funding Sources*

AGA Oral and Poster Presentations at DDW® 2017

AGA Institute 4930 Del Ray Avenue Bethesda, MD 20814 301.654.2055 (National Office) 301.654.3978 (Fax) www.gastro.org

* Information contained in this report is current as of March 9, 2017.

http://www.gastro.org/

AGA Oral Presentations

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

1. . . . . A NOVEL MULTI-MATRIX FORMULATIONOF THE…(3*)| Dr. Falk Pharma GmbH, Freiburg, Germany 2. . . . . BILE ACID DIARRHEA: PATIENT-REPORTEDSYMPTOMS AND…(5*) 3. . . . . PREVALENCE AND DISTRIBUTION OFGASTROINTESTINAL PATHOGENS…(5*) 4. . . . . ADULT AUTOIMMUNE ENTEROPATHY MIMICSREFRACTORY CELIAC…(5*) 5. . . . . HIGH RESOLUTION MANOMETRY ISSUPERIOR TO…(5*) 6. . . . . RESPONSE TO OPTIMAL PPITHERAPY, ASSOCIATION…(5*) 7. . . . . OBESITY AND GERD IMPAIRESOPHAGEAL EPITHELIAL…(5*) 8. . . . . TRAJECTORY ASSESSMENT OF PROLONGEDWIRELESS PH…(2*) 9. . . . . THE SIGNIFICANCE OF POSTPRANDIALACID POCKET…(5*) 10. . . . . INCREASED ACID EXPOSURE ONPRE-TRANSPLANT REFLUX…(5*) 11. . . . . GLP-2 ACUTELY ENHANCES DUODENALSGLT1-MEDIATED GLUCOSE…(2*)|(7) 12. . . . . THE OPTIMAL TIMING OFINTESTINAL TRANSPLANTATION…(5*) 13. . . . . CLINICAL CHARACTERISTICS OF INFLAMMATORYBOWEL DISEASE…(5*) 14. . . . . HOW USEFUL IS HISTOLOGICALTESTING OF…(5*) 15. . . . . PREDICTORS AND CHARACTERISTICS OFEARLY RESPONDERS…(3*)| Shire Development LLC., Lexington, MA, USA) 16. . . . . COST ANALYSIS OF LONG-TERMPARENTERAL NUTRITION…(4*)

17. . . . . THE PRESENCE OF ADHERENT-INVASIVEESCHERICHIA COLI…(4*) 18. . . . . ADVANCED AGE IS ANINDEPENDENT PREDICTOR…(3*) Takeda Pharmaceuticals USA 19. . . . . VALIDATION OF A TOOLPREDICTING COMPLICATIONS…(5*) 20. . . . . CROHN'S DISEASE RISK PREDICTIONMODEL APPROPRIATELY…(2*) 21. . . . . CROHN'S DISEASE PATIENTS WITHA CONCORDANT…(2*) 22. . . . . CLINICAL UTILITY OF ROUTINEPOUCHOGRAPHY PRIOR…(4*)|(2) |This research was supported in part by the NIH NIDDK grant #T35DK062719-29. 23. . . . . MAZ PROMOTES COLITIS-ASSOCIATED COLONTUMORIGENESIS THROUGH…(2*) 24. . . . . NUCLEAR-TO-CYTOSOLIC SHUTTLING OF THEDNA MISMATCH…(2*)|(4) 25. . . . . LOSS OF TFF1 ACTIVATESSTAT3 THROUGH…(2*) 26. . . . . FL3, A LIGAND OFTHE SCAFFOLD…(2*)|(4) 27. . . . . MMP9 FAVORS MICROBIOTA ADHERENCEAND MODULATES…(2*) 28. . . . . PLAGL2 PROMOTES A STEMCELL PHENOTYPE…(2*)|(6) 29. . . . . THE ROLE OF KERATIN-19POSITIVE CELLS…(2*)|(4) 30. . . . . NEUROD1-EXPRESSING MATURE ENTEROENDOCRINE CELLSCONTRIBUTE TO…(2*) 31. . . . . THE ERBB3 RECEPTOR TYROSINEKINASE RESTRICTS…(2*)

32. . . . . EPIGENETIC ALTERATIONS IN MUCOSALSTEM CELLS…(7*)|(4) 33. . . . . THE ENTERIC MICROBIOTA REGULATESPANETH CELL…(2*) 34. . . . . HIGH AFFINITY NGF TRKARECEPTORS ARE…(2*) 35. . . . . SEROTONIN RELEASED BY FFA2ACTIVATION STIMULATES…(2*) 36. . . . . CD44V9 AND CYSTINE-GLUTAMATE TRANSPORTERXCT EMERGE…(2*) 37. . . . . INTESTINE-SPECIFIC DUAL OXIDASE DEFICIENCYLACKS ATP-P2Y-MEDIATED…(2*) 38. . . . . Dendritic Cell - DerivedTGF-β Mediates…(2*) 39. . . . . IMMUNOLOGICAL TOLERANCE TO HELICOBACTERPYLORI INFECTION…(2*) 40. . . . . IMPLANTATION OF AUTOLOGOUS BIOSPHINCTERSIN A…(6*) 41. . . . . EFFECTS OF AGE ANDBODY MASS…(2*) 42. . . . . FUNCTIONAL LUMEN IMAGING PROBE(FLIP) TO…(5*) 43. . . . . â€˜PELVIC FLOOR AKINESIAâ€™ -A HIGHLY…(4*)|(1) 44. . . . . CORTICO-ANORECTAL, SPINO-ANORECTAL AND CORTICO-SPINALNERVE CONDUCTION…(2*) 45. . . . . RELATIONSHIPS BETWEEN ANAL PRESSUREPROFILES DERIVED…(5*) 70. . . . . NARDILYSIN FUNCTIONS AS ATUMOR SUPPRESSOR…(5*) 71. . . . . PATIENT-DERIVED PANCREATIC DUCTAL ORGANOIDSTO STUDY…(2*)


* = Primary Source



72. . . . . A NOVEL PREDICTIVE ORGANOIDCULTURE SYSTEM…(7*)|(4) 73. . . . . PIEZO1, A MECHANICALLY ACTIVATEDION CHANNEL,…(2*) 74. . . . . A NOVEL TRAIL-BASED THERAPYFOR CHRONIC…(2*) 75. . . . . SIRTUIN 3 GENETIC ABLATIONCAUSES MITOCHONDRIAL…(2*) 76. . . . . EGFR INDUCES ILF3 ANDG9A EXPRESSIONS…(4*) 77. . . . . PRDM16-MEDIATED METABOLIC REPROGRAMMING INCOLONIC FIELD…(2*) 78. . . . . MUSCARINIC RECEPTOR-3 MODULATES YAPSIGNALING IN…(5*) 79. . . . . TLR4-DRIVEN TUMORIGENESIS IS ASSOCIATEDWITH AN…(2*) 80. . . . . PAK-1 REGULATES THE INTESTINALSTEM-CELL NICHE…(2*) 81. . . . . TRANSCRIPTION FACTOR ZBP-89 COOPERATESWITH B-CATENIN…(2*) 82. . . . . ASSOCIATION OF FIBER INTAKEWITH COLORECTAL…(2*) 83. . . . . THE RELATIONSHIP BETWEEN DISTALFINDINGS AND…(5*) 84. . . . . COLONOSCOPY IS ASSOCIATED WITHDECREASED COLORECTAL…(2*) 85. . . . . RACIAL AND ETHNIC DIFFERENCESIN HEALTH…(5*) 86. . . . . OUTCOMES AND COST ANALYSISOF A…(6*) 87. . . . . BACTERIAL LPS INHIBITS COLONICBIOTIN (VITAMIN…(2*) 88. . . . . LOSS OF AUTOPHAGY/APOPTOSIS BALANCEIN INTESTINAL…(2*)

89. . . . . C1ORF106 ACTS IN TRAFFICKING,AUTOPHAGY, AND…(2*)|(4) 90. . . . . GOBLET CELL MEDIATED ANTIGENDELIVERY TO…(2*) 91. . . . . THE ER STRESS SENSORIRE1Î’ MODIFIES…(4*)|(2) 92. . . . . EPITHELIAL INTERLEUKIN-15 PROMOTES Î“Î”T CELL…(2*)|(4) 93. . . . . THE FIRST PROSPECTIVE NATIONALEVALUATION OF…(2*) 94. . . . . INDEPENDENT VALIDATION OF ASELF-REPORT VERSION…(3*) Abbvie Canada 95. . . . . VEGETARIAN OR GLUTEN-FREE DIETIN PATIENTS…(2*) 96. . . . . PREDICTORS OF UNPLANNED HEALTHCAREUTILIZATION IN…(5*) 97. . . . . EARLY ANTI-TNF/IMMUNOMODULATOR THERAPY ISASSOCIATED WITH…(5*) 98. . . . . WHAT IS A FLAREOF IBD?:…(2*) 99. . . . . SPECTRUM OF LIVER DISEASEIN HEPATITIS…(2*) 100. . . . . BLOCKING INTERLEUKIN-15 AS ANEW STRATEGY…(3*)| Calypso Biotech SA 101. . . . . SUB-LARYNGEAL ESOPHAGEAL TISSUE DOESNOT RESEMBLE…(4*) 102. . . . . TOPICAL STEROID TREATMENT MODIFIESPATHWAYS ASSOCIATED…(4*) 103. . . . . GENE EXPRESSION-PHENOTYPE ASSOCIATIONS INADULTS WITH…(2*)|(3)| This work was also supported by an investigator-initiated research grant from Miraca Life Sciences. 104. . . . . IN ESOPHAGEAL FIBROBLASTS, TH2CYTOKINES INDUCE…(2*)|(4)

105. . . . . ORAL TYROSINE KINASE 2INHIBITOR AMELIORATES…(3*)| GlaxoSmithKline, Stevenage, UK 106. . . . . ENDOSCOPIC BOWEL INJECTIONS OFMESENCHYMAL STROMAL…(4*) 107. . . . . A NOVEL ROR-GAMMA TINHIBITOR (VPR-254)…(3*)| Subcontract on NIH SBIR grant to Visionary Pharmaceuticals (San Diego, CA). 108. . . . . HELMINTH EXPOSURE PROTECTS INTESTINALEPITHELIUM FROM…(2*) 109. . . . . THE NARROW SPECTRUM KINASEINHIBITOR (NSKI)…(3*)| Topivert Pharma Ltd 110. . . . . THE BIOMARKER PROFILE OFPTG-200, AN…(5*) 121. . . . . TERRY NAILS: A NEWLOOK AT…(5*) 122. . . . . INCREASED RECOGNITION OF HGD/EACAT INDEX…(5*) 123. . . . . CLUSTERING OF ESOPHAGEAL CANCERMORTALITY AMONG…(2*) 124. . . . . ASSOCIATION BETWEEN CIRCULATING LEVELSOF SEX…(2*) 125. . . . . GEOSPATIAL ANALYSES IDENTIFY ACLUSTERING OF…(2*) 126. . . . . A COST-UTILITY ANALYSIS FORGASTRIC CANCER…(5*) 127. . . . . THE EFFECT OF HELICOBACTERPYLORI ERADICATION…(5*) 128. . . . . INCREASED IMMUNOHISTOCHEMICAL/PCR PROVEN PERMEABILITYOF DUODENAL…(4*)| Rashid Hussein Trust, Kuala Lumpur, Malaysia


* = Primary Source



129. . . . . GLUTEN-CHALLENGE YOURSELF: A SELFADMINISTERED BLIND…(1*) Prodeco, Castelfranco (TV), Italy 130. . . . . A BIPHASIC 13C-Î‘-LIMIT DEXTRIN/13C-GLUCOSEBREATH TEST…(4*)|(3)|QOL Medical LLC graciously provided access to some genetic testing. 131. . . . . SEROLOGIC MARKERS OF SYSTEMICIMMUNE ACTIVATION…(2*) 132. . . . . LOW FODMAPS DIET ISSAFE AND…(5*) 133. . . . . THE PREDICTIVE VALUE OFTHE HYDROGEN…(1*) 134. . . . . HIGHER LEVELS OF INFLIXIMABMAY ALLEVIATE…(3*)| Janssen Research & Development, LLC supported this study. 135. . . . . CLINICAL RELEVANCE OF DETECTINGANTI-INFLIXIMAB ANTIBODIES…(5*) 136. . . . . MACHINE LEARNING MODELS ATWEEK 6…(1*) 137. . . . . Integrin α4β7 expression precedingand saturation…(4*) 138. . . . . CORRELATION OF DURABILITY OFRESPONSE, SERUM…(5*) 139. . . . . MRI REMISSION AFTER THERAPEUTICINTERVENTION IS…(5*) 140. . . . . CLOSTRIDIA FROM THE GUTMICROBIOME ARE…(3*)|(4)| Da Nutricia Research) 141. . . . . BRAIN-GUT AXIS AND BARIATRICSURGERY: WEIGHT…(4*) 142. . . . . MICROBIOTA DYSBIOSIS INDUCED BYDEFECT OF…(5*) 143. . . . . COLONIC MUCOSAL MICROBIOME ISASSOCIATED WITH…(2*)

144. . . . . SR-18662: A POTENT COLORECTALCANCER GROWTH…(2*) 145. . . . . TARGETING AURKA EFFECTIVELY SUPPRESSESKRAS-MUTANT TUMORIGENESIS…(2*) 146. . . . . SELECTIVE ERADICATION OF K-RASMUTATED CANCER…(4*) 147. . . . . BLOCKING NUPR1 PROTEIN, ASUCCESSFUL APPROACH…(4*)|(2) 148. . . . . IDO1 IMMUNE CHECKPOINT INHIBITORSYNERGIZES WITH…(2*) 149. . . . . COMBINATION THERAPY WITH AHYPOMETHYLATING DRUG…(2*) 155. . . . . DETERMINATION OF FASTING-STATE BYNON-INVASIVE BREATH…(1*)|(4)|The eNose Company) 156. . . . . DOUBLE BLIND RANDOMIZED CONTROLLEDCROSS-OVER STUDY…(4*)Rashid Hussain trust, Kuala Lumpur/Malaysia) 157. . . . . NOVEL BALLOON MUCOSAL IMPEDANCEFOR DIAGNOSIS…(3*)| Sandhill Scientific provided the equipment tested but they had no input on the study design, analysis or publication details. Vanderbilt and Sandhill are co-patent owners for the balloon MI device 158. . . . . A NEW THERANOSTIC COMBINATIONOF FLUORESCENT…(5*) 159. . . . . OPTICAL MOLECULAR IMAGING OFABERRANT CRYPT…(4*)|(3) 160. . . . . EFFECTS OF COGNITIVE BEHAVIORTHERAPY ON…(5*) 161. . . . . MICROBIAL DNA MARKERS ASSOCIATEDWITH RESPONSE…(5*) 162. . . . . ANTIGLIADIN ANTIBODIES PREDICT THESYMPTOMATIC RESPONSE…(4*) 163. . . . . ORAL Î‘-GALACTOSIDASE IMPROVES

GASTROINTESTINALTOLERANCE TO…(4*) 164. . . . . REDUCE IBS PROJECT: MULTIPLETHERAPY CHOICES…(6*)|(7) 165. . . . . WHAT DETERMINES WHETHER INDIVIDUALSWITH IRRITABLE…(4*) 167. . . . . ALTERATIONS IN MICROBIAL DIVERSITYARE ASSOCIATED…(3*)| Rebiotix Inc., Roseville, MN 167a. . . . . FIDAXOMICIN AND OP1118 INHIBITC. DIFFICILE…(2*)| Supported by a grant from Merck Pharmaceuticals. 168. . . . . UNDERSTANDING THE MECHANISMS OFEFFICACY OF…(4*) 169. . . . . MECHANSIMS UNDERPINNING SUCCESSFUL FAECALMICROBIOTA TRANSPLANTATION…(4*)|(2) 170. . . . . TOXIN-POSITIVE CLOSTRIDIUM DIFFICILE STRAINLEM1 LATENTLY…(2*) 171. . . . . MUTATION OF THE FERRICUPTAKE REGULATOR…(4*) 172. . . . . DETERMINING A CLINICAL OPTIMALDOSE OF…(3*) 173. . . . . NUTRIENT INGESTION LOWERS COLONICSENSORY THRESHOLDS…(1*) 174. . . . . DYSBIOSIS CONTRIBUTES TO CHRONICCONSTIPATION DEVELOPMENT…(2*) 175. . . . . METHANOGENIC FLORA AND ITSEFFECTS ON…(5*) 176. . . . . INFLAMMATORY AND PHENOTYPIC SMOOTHMUSCLE ALTERATIONS…(5*) 177. . . . . SIMULTANEOUS PRESSURE WAVES AREAN ESSENTIAL…(4*)|(2) 178. . . . . EPIC SHORTCOMINGS: MULTICENTER STUDYOF SAFETY…(4*)


* = Primary Source



179. . . . . APPROPRIATENESS OF SURVEILLANCE INTERVALIN NON-DYSPLASTIC…(5*) 180. . . . . ENDOSCOPIC PART-TASK TRAINING BOXIMPROVES PERFORMANCE…(5*) 181. . . . . A VIDEO-BASED ASSESSMENT OFCOLONOSCOPY INSPECTION…(5*) 182. . . . . VARIATION IN COLONOSCOPY QUALITYACROSS PHYSICIANS…(2*) 183. . . . . LIPOPOLYSACCHARIDE INDUCED INCREASE INCACO-2 INTESTINAL…(2*) 184. . . . . CAUDAL-RELATED HOMEOBOX TRANSCRIPTION FACTOR2 (CDX2)…(2*) 185. . . . . UPREGULATION OF PEPT1 ANDBACTERIAL DERIVED…(2*) 186. . . . . TRANSCRIPTIONAL REGULATION OF SLC26A3BY ENTEROPATHOGENIC…(2*) 187. . . . . LONG NONCODING RNA H19INHIBITS TRANSLATION…(2*) 188. . . . . ABSENT IN MELANOMA 2(AIM2) DEFICIENCY…(7*) 189. . . . . IL-27 REGULATES GASTRIC METAPLASIATHROUGH EFFECTS…(2*) 190. . . . . THE INVOLVEMENT OF EPIGENETICREGULATION IN…(2*) 191. . . . . INTESTINE-SPECIFIC HOMEOBOX (ISX) ISAN IMPORTANT…(5*) 192. . . . . LOSS OF TFF1 PROMOTESCELL PROLIFERATION…(2*) 193. . . . . IDENTIFICATION, DEVELOPMENT AND VALIDATIONOF A…(2*) 194. . . . . A PRIMARY HUMAN MACROPHAGE-ENTEROIDCO-CULTURE MODEL…(2*)

195. . . . . IN VITRO MODELING OFHUMAN ENTEROHEPATIC…(2*) 196. . . . . HUMAN-DERIVED GASTRIC CANCER ORGANOIDSSECRETE TUMOR…(2*) 197. . . . . ENTEROTOXIGENIC E. COLI (ETEC)PATHOGENESIS MODELED…(2*) 198. . . . . HUMAN PLURIPOTENT STEM CELL-DERIVEDINTESTINAL ORGANOID…(2*) 199. . . . . INTESTINE-CHIP: A NEW MODELTO UNDERSTAND…(4*) 200. . . . . THE BENEFIT OF COMBINATIONTHERAPY DEPENDS…(6*) 201. . . . . PATTERNS OF ANTI-TNF USEAND ASSOCIATED…(5*) 202. . . . . LOWER SUSTAINED PERTUSSIS CONCENTRATIONSIN PATIENTS…(4*) 203. . . . . IMPROVED ANTIBODY RESPONSE TOTHREE ADDITIONAL…(4*) 204. . . . . PREDIAGNOSTIC SERUM VITAMIN DLEVELS AND…(3*)|(2)| This work was supported by an unrestricted research grant from Dr. Falk Pharma. 205. . . . . GENETIC POLYMORPHISMS IN FATTYACID METABOLISM…(5*) 234. . . . . TREATMENT OF FAMILIAL ADENOMATOUSPOLYPOSIS PATIENTS…(6*) 235. . . . . MUTATIONAL AND EPIGENETIC SPECTRUMOF COLORECTAL…(6*)|(2) 236. . . . . POLYMORPHISMS IN HIGH ORDERCHROMATIN REMODELER…(5*) 237. . . . . EFFECT OF ERADICATION OFHELICOBACTER PYLORI…(5*) 238. . . . . THE RISK OF HEPATOBILIARYCANCER WITH…(4*)

239. . . . . LOW-DOSE ASPIRIN CAN REDUCECOLORECTAL CANCER…(5*) 240. . . . . A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLEDMULTICENTER 26-WEEK…(3*)| Sponsored by Takeda Development Center Americas, Inc., Deerfield, IL, USA 241. . . . . TIMELY MEDICAL OR SURGICALANTI-REFLUX TREATMENT…(5*) 242. . . . . RATES, RISK AND PREDICTORSOF BARRETT'S…(2*) 243. . . . . DIAPHRAGMATIC BREATHING EXERCISES ISEFFICACIOUS IN…(4*) 244. . . . . EFFICACY OF VONOPRAZAN, ANOVEL POTASSIUM-COMPETITIVE…(5*) 245. . . . . ADVERSE EVENTS RELATED TOENDOSCOPIC ERADICATION…(7*) 246. . . . . EARLY ANTI-TNF IS EFFECTIVEIN PREVENTING…(6*) 247. . . . . REDUCED MORTALITY RATES WITHANTI-TUMOR NECROSIS…(2*) 248. . . . . PHASE III RANDOMIZED, DOUBLE-BLIND,CONTROLLED TRIAL…(3*) 249. . . . . BIOSIMILAR INFLIXIMAB (CT-P13) ISNOT INFERIOR…(2*)|(5) 250. . . . . UNCHANGED INFLIXIMAB SERUM CONCENTRATIONSAFTER SWITCHING…(3*)| Mundipharma 251. . . . . COMPARATIVE ACCURACY OF USVERSUS MRI…(1*)|(5) 252. . . . . DECREASED EXPRESSION OF SLC26A3PROTEIN IN…(2*) 253. . . . . HEPATOCYTE NUCLEAR FACTOR 1Î’UPREGULATES P-GLYCOPROTEIN…(2*)


* = Primary Source



254. . . . . CHOLERA TOXIN DESTABILIZES RETROMERTO INHIBIT…(2*) 255. . . . . ALDOSTERONE DOWN-REGULATES COLONIC CL-SECRETION MEDIATED…(2*) 256. . . . . CK2 PHOSPHORYLATION OF NHE3-S719REGULATES NHE3…(2*) 257. . . . . CHRONIC HIGH-PHOSPHATE DIET UPREGULATESBASAL INTESTINAL…(4*) 258. . . . . PREVALENCE AND PREDICTORS OFâ€œIBS-LIKEâ€� SYMPTOMS…(3*)The National GI Survey was funded by Ironwood Pharmaceuticals.) 259. . . . . HEALTH CARE UTILIZATION FORROME IV…(4*) 260. . . . . SERUM CYTOKINES ARE ELEVATEDIN PATIENTS…(2*)|(3)|Primary Source: NIH Additional Source 1: Takeda) 261. . . . . ALTERED COLONIC PERMEABILITY ANDEPITHELIAL SECRETION…(2*)|(4) 262. . . . . TRYPTOPHAN HYDROXLASE 1 (TPH1)PROMOTER GENOTYPE…(4*)|(3)|Prometheus Laboratories Inc 263. . . . . INTESTINAL, NON-INTESTINAL, AND EXTRA-DIGESTIVERESPONSE TO…(3*)| Allergan plc. 264. . . . . MAGNETIC RESONANCE ELASTOGRAPHY VSTRANSIENT ELASTOGRAPHY…(2*) 283. . . . . REACTIVITY TO NEOEPITOPES OFDGP-TTG COMPLEXES…(5*) 284. . . . . NUTRITIONAL WHEAT AMYLASE TRYPSININHIBITORS EXACERBATE…(2*) 285. . . . . CIRCULATING EXTRACELLULAR VESICLES, ANOVEL MECHANISM…(2*)

286. . . . . ACTIVATION OF INNATE IMMUNEPATHWAYS BY…(2*)|(4) 287. . . . . MICROBIAL MODULATION OF INTESTINALINNATE ACTIVATION…(4*) 288. . . . . RECURRENT ACUTE PANCREATITIS WITHOUTUNDERLYING OVERT…(5*) 289. . . . . COMPARISON OF NORMAL SALINEVERSUS LACTATED…(4*) 290. . . . . MULTIPLE GENE INTERACTION INCREASESTHE RISK…(4*) 291. . . . . ACUTE PANCREATITIS: TRENDS INOUTCOMES AND…(5*) 292. . . . . PATIENTS WITH PRIMARY SCLEROSINGCHOLANGITIS UNDERGOING…(5*) 293. . . . . A RANDOMIZED CONTROLLED TRIALOF PROTON…(5*) 294. . . . . THE EFFECT OF NATIONWIDECOLORECTAL CANCER…(2*)No) 295. . . . . PREDICTORS OF TIMELY COLONOSCOPYAFTER A…(2*) 296. . . . . REDUCTION IN WAIT-TIMES TOCOLONOSCOPY AFTER…(2*) 297. . . . . MAILED FIT TO IMPROVECOLORECTAL CANCER…(2*) 298. . . . . PROSPECTIVE COST-ACCOUNTING OF ANOUTREACH PROGRAM…(2*) 299. . . . . HIGH RATE OF ADVANCEDNEOPLASIA AFTER…(5*)| There are no industry/commercial sources related to our study 300. . . . . SERRATED EPITHELIAL CHANGE INULCERATIVE.COLITIS PATIENTS…(5*) 301. . . . . ZERO DIAGNOSTIC YIELD OFDYSPLASIA IN…(5*)

302. . . . . RISK OF MYOCARDIAL INFARCTIONAND CONGESTIVE…(5*) 303. . . . . BIOLOGIC THERAPY AND IMMUNODULATORSARE ASSOCIATED…(5*) 304. . . . . EFFECT OF VEDOLIZUMAB DOSEESCALATION ON…(5*) 305. . . . . HIF1Î‘ REGULATES FOXP3 EPIGENETICCOMPLEXES IMPLICATED…(6*) 306. . . . . POPULATION-OPTIMIZED SNP ARRAY REVEALSRAP1A AS…(2*) 307. . . . . GENOME-WIDE SEARCH IDENTIFIED GENETICVARIANTS THAT…(4*)|(6) 308. . . . . THE EPIGENETIC COMPLEX PRC-1MAINTAINS T…(2*) 309. . . . . AUTOPHAGY GENE VMP1, IMPLICATEDIN IBD…(2*) 310. . . . . MOLECULAR PROFILING OF EARLYCROHN'S DISEASE…(2*)|(4)|AbbVie, MSD and Takeda 311. . . . . THE SIMPLE PEDIATRIC ACTIVITYULTRASOUND SCORE…(4*) 312. . . . . ASSESSING DISEASE ACTIVITY INCROHN'S DISEASE…(2*)|(4) 313. . . . . NOVEL APPROACH FOR DYSPLASIAEVALUATION IN…(5*) 314. . . . . SUPER-REDUCED-LAXATIVE VOLUME FOR CTCOLONOGRAPHY USING…(3*)|(4)|EA Farma 315. . . . . DEVELOPMENT OF COMPUTER-ASSISTED REALTIME HISTOLOGY…(2*) 316. . . . . USEFULNESS OF LINKED COLORIMAGING SYSTEM…(4*)|(3)


* = Primary Source



317. . . . . CGRP SIGNIFICANTLY REGULATES APPETITE,ENERGY INTAKE…(2*) 318. . . . . IMPACT OF NUTRIENT EXCESSON INSULIN…(2*)|(4) 319. . . . . A DOUBLE-BLIND RANDOMIZED CROSS-OVERSTUDY TO…(3*)|(5)| This study was subsidized by Top Institute of Food and Nutrition.TI Food and Nutrition is a public private partnership of science, industry and government conducting strategic research in food and nutrition. 320. . . . . OBESOGENIC DRUGS AND THEIREFFECTS ON…(4*)|(2) 321. . . . . EFFECT OF LIRAGLUTIDE ONGASTRIC EMPTYING…(2*) 322. . . . . ASSOCIATION OF PHYSICAL ACTIVITYWITH FOOD…(2*) 323. . . . . MECHANICALLY INDUCED ENTEROGENESIS OFHUMAN INTESTINAL…(7*)|(2) 324. . . . . HUMAN FETAL DERIVED ENTEROSPHERESPROVIDE NEW…(2*) 325. . . . . A NOVEL ENTEROID MODELOF CONGENITAL…(2*) 326. . . . . GENERATION OF HUMAN GUTORGANOIDS-DERIVED MONOLAYERS…(2*) 357. . . . . REGULATION OF CD44 EXPRESSIONBY BONE…(2*) 358. . . . . SUBSTANCE P-REGULATED MICRORNA-31-3P SILENCINGENHANCES MUCOSAL…(2*)|(6) 359. . . . . MESENTERIC ADIPOSE TISSUE DERIVEDSTROMAL CELLS…(2*)|(6) 360. . . . . GATA4 REGULATES DEVELOPMENT OFTHE SQUAMOCOLUMNAR…(2*)|(4) 361. . . . . CD44V9-XCT SYSTEM IS REQUIREDFOR CHIEF…(2*)

362. . . . . ENDOGLIN AS AN IMPORTANTREGULATOR OF…(6*)|(4)|TRC105 was a generous gift from Tracon Pharmaceuticals, San Diego, USA.) 363. . . . . VAGAL DYSREGULATION IN THEFIRST WEEK…(2*) 364. . . . . BRAIN MORPHOMETRY DISTINGUISHES TWODISTINCT IBS…(4*)| Institutional Grant Numbers: (2 Total) P50 DK064539 R01 DK048351 365. . . . . DIETARY SERINE PREVENTS THEDEVELOPMENT OF…(2*) 366. . . . . INTERPLAY OF SPINAL ANDVAGAL PATHWAYS…(2*) 367. . . . . EFFECT OF SLOW DEEPBREATHING AND…(2*)|(5) 368. . . . . CENTRAL NERVOUS SYSTEM (CNS)MECHANISMS OF…(4*) 369. . . . . IL-1α neutralization markedly amelioratesCrohn’s Disease…(2*)|(6) 370. . . . . PTPN2 controls intestinal inflammationand promotes…(2*)|(4) 371. . . . . IL-28-DEPENDENT ACTIVATION OF EPITHELIALSTAT1 DRIVES…(2*)|(4) 372. . . . . TARGETING THE NUCLEAR RECEPTORLRH-1 TO…(2*) 373. . . . . A TWO-STEP MODEL -INVOLVING TRANSCRIPTION…(2*) 374. . . . . MITOCHONDRIAL DNA IS ADAMAGE-ASSOCIATED MOLECULAR…(2*)|(6) 393. . . . . IMPROVING THE QUALITY OFINPATIENT ULCERATIVE.COLITIS… (POSTER PRESENTATION)… (5*)

394. . . . . IMPLEMENTATION OF A STANDARDIZEDSEDATION CLASSIFICATION… (POSTER PRESENTATION)… (5*) 395. . . . . TRAINEE COLONOSCOPY WITHDRAWAL TIMEIS INFLUENCED… (POSTER PRESENTATION)… (5*) 396. . . . . MOVIPREP IMPROVES RATES OFSUCCESSFUL COLONOSCOPY… (POSTER PRESENTATION)… (5*) 397. . . . . INAPPROPRIATE ACUTE HEPATITIS TESTING:WHEN A… (POSTER PRESENTATION)… (5*) 398. . . . . TUBE FEED APP: ANOVEL SMART… (POSTER PRESENTATION)… (4*) 399. . . . . CREATING A PERSONALIZED SMOKINGCESSATION PHARMACOTHERAPY… (POSTER PRESENTATION)… (4*) 400. . . . . EFFECT OF STANDARDIZED CONSENTVERSUS STANDARDIZED… (POSTER PRESENTATION)… (4*) 401. . . . . CONTENT OF CONSENT FORCOLONOSCOPY: COMPARISON… (POSTER PRESENTATION)… (4*) 402. . . . . TIMELINESS TO ANTIBIOTICS INPEDIATRIC SHORT… (POSTER PRESENTATION)… (5*) 403. . . . . COLONOSCOPY-NAÃ�VE RATERS CAN ACCURATELYASSESS COLONOSCOPY… (POSTER PRESENTATION)… (5*) 404. . . . . PREDICTORS OF NO-SHOW RATEIN THE… (POSTER PRESENTATION)… (5*) 405. . . . . TOWARDS IDENTIFYING ENDOSCOPIST OPHTHALMICPARAMETERS THAT… (POSTER PRESENTATION)… (4*) 406. . . . . ASSESSING THE SUCCESS OFA MULTIDISCIPLINARY… (POSTER PRESENTATION)… (5*)


* = Primary Source



407. . . . . ASSESSING THE QUALITY OFEND OF… (POSTER PRESENTATION)… (5*) 408. . . . . IMPROVING COUNSELING AND INTERVENTIONSTO REDUCE… (POSTER PRESENTATION)… (5*) 409. . . . . SAME ADMISSION CHOLECYSTECTOMY (SAC)COMPARED TO… (POSTER PRESENTATION)… (5*) 410. . . . . IMPACT OF TRAINEE EXPERIENCEON THE… (POSTER PRESENTATION)… (5*) 411. . . . . VOICE-OF-THE-VETERAN ANALYSIS: IMPLEMENTATION OFA REVISED… (POSTER PRESENTATION)… (5*) 412. . . . . BARRIERS TO POST-SURGICAL BIOLOGICTHERAPY IN… (POSTER PRESENTATION)… (4*)|(5) 413. . . . . THE BOSTON BOWEL PREPARATIONSCALE: INTRODUCTION… (POSTER PRESENTATION)… 5*) 414. . . . . A GOOD BOWEL PREP,CAN WE… (POSTER PRESENTATION)… 5*) 415. . . . . ADHERENCE TO THE AMERICANASSOCIATION FOR… (POSTER PRESENTATION)… 5*) 416. . . . . INCREASED EMERGENCY DEPARTMENT UTILIZATIONFOLLOWING COLONOSCOPY… (POSTER PRESENTATION)… 5*) 417. . . . . CELIAC DISEASE TESTING INTYPE I…(POSTER PRESENTATION)… (5*) 430. . . . . FECAL MICROBIOTA TRANSPLANTATION INIRRITABLE BOWEL…(5*) 431. . . . . IL-1 β / IL-1RSignaling in…(2*) 432. . . . . M2 MACROPHAGES ARE LINKEDWITH PYLORIC…(5*)

433. . . . . OPTOGENETIC INDUCTION OF PROPAGATINGCOLONIC MOTOR…(2*)|(4) 434. . . . . EVIDENCE FOR TRP CHANNELSENSITIZATION IN…(2*) 435. . . . . SUBSTANCE P-INDUCED COLONIC EPITHELIALCELL-SECRETED EXOSOMES…(2*) 436. . . . . GENETIC EDITING OF COLONICORGANOIDS PROVIDES…(2*)|(4) 437. . . . . ROTAVIRUS INFECTION INDUCES LGR5INTESTINAL STEM…(2*) 438. . . . . BIFIDOBACTERIUM DENTIUM UPREGULATES INTESTINALSERT VIA…(2*) 439. . . . . TRIM21 NEGATIVELY REGULATES INTESTINALMUCOSAL INFLAMMATION…(2*) 440. . . . . A LACTOBACILLUS RHAMNOSUS GG(LGG)-DERIVED PROTEIN…(2*)|(6) 441. . . . . COMBINED ESOPHACAP CYTOLOGY WITHMUC2 IMMUNOHISTOCHEMISTRY…(2*) 442. . . . . BARRETT'S ESOPHAGUS IS ASSOCIATEDWITH AN…(5*) 443. . . . . ASPIRIN USE IS ASSOCIATEDWITH LOWER…(2*)| UM1 CA186107 (NIH), R01DK088782 (NIH), CAHP (Council on Aspirin for Health and Prevention). No industry or commercial sources funded this research. 444. . . . . NON-ENDOSCOPIC DETECTION OF BARRETT'SESOPHAGUS (BE)…(2*)|(4) 445. . . . . SHALLOW WHOLE GENOME SEQUENCINGCAN DETECT…(2*)|(4) 446. . . . . INSULIN-LIKE GROWTH FACTOR 2MRNA BINDING…(2*)|(6)

447. . . . . PATIENT-DERIVED IN VITRO ANDIN VIVO…(2*)|(4) 448. . . . . KRÃœPPEL-LIKE FACTOR 5 ISREQUIRED FOR…(4*)|(2) 449. . . . . INFILTRATING MACROPHAGES SHOW EVIDENCEOF IMPAIRED…(4*) 450. . . . . TH17 CELLS INDUCE EPITHELIAL-MESENCHYMALTRANSITION VIA…(2*) 451. . . . . BUTYRATE REGULATES TRANSCRIPTION FACTORZBP-89 AND…(2*) 452. . . . . HIGH INFLIXIMAB LEVELS ARENOT ASSOCIATED…(5*) 453. . . . . A PROLONGED FOLLOW-UP ONTHE EFFICACY…(5*) 454. . . . . EFFECT OF VEDOLIZUMAB ANDTACROLIMUS ON…(5*) 455. . . . . COMPARISONS OF PREMEDICATION STRATEGIESFOR PREVENTING…(5*) 456. . . . . INFLIXIMAB IS NOT ASSOCIATEDWITH EXCESS…(4*) 457. . . . . VEDOLIZUMAB DOES NOT INCREASETHE RISK…(6*) 458. . . . . A COORDINATED CARE APPROACHTO COMPLEX…(5*) 459. . . . . PROTON PUMP INHIBITORS WORSENHOSPITALIZATION RISK…(2*) 460. . . . . A 12 WEEK MAINTENANCETHERAPY WITH…(3*)| ITC Farma srl (Pomezia, Italy) provided all the entire drug supply used in this study. 461. . . . . UNIQUE GROWTH CHARACTERISTICS OFE. COLI…(2*) 462. . . . . A ROLE FOR BACTERIALUREASE IN…(2*)|(6)


* = Primary Source



463. . . . . CROHN'S DISEASE, OBESITY, ANDHIGH CROHN'S…(6*) 464. . . . . DEVELOPMENT OF A REDUCTIONISTMODEL TO…(2*)|(6) 465. . . . . CD8+ T CELL-SPECIFIC TUMORNECROSIS FACTOR…(6*)|(2) 466. . . . . RISK FACTORS FOR REBLEEDINGAND THROMBOEMBOLISM…(5*) 467. . . . . POOR ADHERENCE TO RECOMMENDATIONSTO PREVENT…(3*)| Blue Cross Blue Shield of Michingan 468. . . . . WHICH PPI, HOW MUCH,HOW OFTEN?…(4*) 469. . . . . CHARACTERISTICS ASSOCIATED WITH DECREASEDRELAPSE AFTER…(5*) 470. . . . . AN AMBULATORY PROGRAM TOREDUCE PPI…(5*) 497. . . . . THE OROPHARYNX RATHER THANTHE STOMACH…(2*) 498. . . . . A SYNBIOTIC PARTIAL WHEYHYDROLYSATE WITH…(5*) 511. . . . . VIRTUAL REALITY REDUCES ABDOMINALPAIN IN…(5*) 512. . . . . THE PREVALENCE AND IMPACTOF OVERLAPPING…(4*) 513. . . . . PATIENT ENGAGEMENT IS ASSOCIATEDWITH HEALTH…(2*) 514. . . . . DEFINING RESPONSE TO THEPAC-SYM QUESTIONNAIRE…(3*)Shire International GmbH) 515. . . . . HOW COST AFFECTS THETREATMENT CHOICE…(5*)

516. . . . . AT WHAT PRICE ANDACCURACY ARE…(3*)This study was funded by Commonwealth Diagnostics International, Inc. 517. . . . . LONG NONCODING RNA UC-173ENHANCES GUT…(2*) 518. . . . . ROLE OF AUTOPHAGY RELATEDPROTEIN ATG6/BECLIN…(2*) 519. . . . . LOSS OF INTESTINAL EPITHELIALDESMOGLEIN 2…(4*) 520. . . . . DELETION OF TRPV6 CHANNELIN MICE…(2*) 521. . . . . PP2A-ASSOCIATED PROTEIN Î‘4 ISESSENTIAL FOR…(2*) 522. . . . . SOLUBLE PROTEIN P40 PRODUCEDBY LACTOBACILLUS…(2*) 523. . . . . A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDCLINICAL TRIAL…(1*) 524. . . . . AUTONOMIC FUNCTION IN GASTROPARESIS:RELATIONSHIP WITH…(2*) 525. . . . . RELATIONSHIP OF SYMPTOMS OFGASTROPARESIS TO…(2*) 526. . . . . REDUCTION IN SYMPTOMS DURINGPROVOCATIVE MEAL…(2*) 527. . . . . GASTRIC PER ORAL ENDOSCOPICMYOTOMY (G-POEM)…(5*) 528. . . . . WHAT IS THE DIAGNOSTICUTILITY OF…(5*) 529. . . . . A BEHAVIORAL INTERVENTION INCREASESMEDICATION ADHERENCE…(4*) 530. . . . . A SURVEY OF WORKPLACEACCOMMODATIONS AMONG…(3*)| Abbvie Canada

531. . . . . INVESTING IN WORKABILITY OFPATIENTS WITH…(3*)| Abbvie provided a budget to finance the operational aspects of the project. 532. . . . . ONE-DAY BEHAVIORAL INTERVENTION FORPATIENTS WITH…(5*) 533. . . . . FATIGUE IN QUIESCENT INFLAMMATORYBOWEL DISEASE…(5*) 534. . . . . LONGITUDINAL ASSESSMENT OF THEEFFECTS OF…(6*) 577. . . . . HIGH FAT DIET ACCELERATESESOPHAGEAL CARCINOGENESIS…(6*)|(2) 578. . . . . INFLAMMATION AND NOTCH ACTIVATIONIN STEM…(6*)|(2) 579. . . . . REMODELING BARRETT'S METAPLASIA INA NOVEL…(4*) 580. . . . . Epithelial-Mesenchymal Transition in Barrett’sEsophagus: The…(2*) 581. . . . . ANALYSIS OF STRUCTURAL VARIANTSIN ESOPHAGEAL…(2*)|(4) 582. . . . . CXCR4 LABELS IMMUNE CELLSIN ESOPHAGEAL…(6*)|(2) 583. . . . . PRSS1 MUTATIONS AND FAMILYHISTORY OF…(2*)|(7) 584. . . . . RITUXIMAB MAINTENANCE THERAPY DECREASESRELAPSE RATE…(5*) 585. . . . . CORRELATION BETWEEN PANCREATIC SECRETIONOF BICARBONATE…(2*) 586. . . . . CLINICAL PROFILE OF EARLYAND LATE…(2*) 587. . . . . PANCREATIC EXOCRINE INSUFFICIENCY (PEI)AND CARDIOVASCULAR…(2*)


* = Primary Source



588. . . . . ACUTE PANCREATITIS (AP) ISTHE INITIAL…(5*) 589. . . . . STROMAL DCLK1 EXPRESSION LABELSMULTI-POTENTIAL NEURAL…(2*)|(4) 590. . . . . NOVEL ROLE FOR GLI1AS A…(2*) 591. . . . . NOVEL MUTATIONS IN NEUROGENICCHRONIC INTESTINAL…(4*)|(7) 592. . . . . PATHOGENESIS OF COLON MOTILITYDYSFUNCTION AFTER…(2*)|(4) 593. . . . . SUCCINATE ACCUMULATION EPIGENETICALLY REPRESSESKIT EXPRESSION,…(2*)|(4) 594. . . . . LIPID RAFT DISRUPTION PREVENTSENTERIC NEURODEGENERATION…(2*) 595. . . . . THE UPPER ESOPHAGEAL SPHINCTERASSIST DEVICE…(2*) 596. . . . . DO ALL PATIENTS WITHSUSPECTED EXTRAESOPHAGEAL…(4*) 597. . . . . MEAN NOCTURNAL BASELINE IMPEDANCEON MULTICHANNEL…(5*) 598. . . . . THE INFLUENCE OF ACIDREFLUX ON…(5*) 599. . . . . PHYSIOLOGICAL CHARACTERISTICS OF ISOLATEDLARYNGOPHARYNGEAL REFLUX…(4*) 600. . . . . PANCREATIC DUCT SIZE INTHE ELDERLY.…(5*) 601. . . . . A COST-EFFECTIVENESS ANALYSIS COMPARINGLUMEN APPOSING…(5*) 602. . . . . NEEDLE-BASED CONFOCAL LASER ENDOMICROSCOPY(NCLE) FOR…(3*)

603. . . . . MORPHOMICS-BASED RISK STRATIFICATION MODELPREDICTS COMPLICATIONS…(7*) 604. . . . . VARIATIONS IN USE OFADVANCED ENDOSCOPY…(5*) 605. . . . . INHIBITION OF P-GLYCOPROTEIN/MDR1 TRANSPORTERSUPPRESSES TH17…(2*)|(6) 606. . . . . WISKOTT-ALDRICH SYNDROME PROTEIN (WASP)IS CRITICAL…(6*)|(2) 607. . . . . COMMD10 IS A NEGATIVEREGULATOR OF…(6*) 608. . . . . 3D CO-CULTURE SYSTEM OFINTESTINAL ORGANOIDS…(5*) 609. . . . . GPBAR1 (TGR5) LIGATION PROTECTSAGAINST COLITIS…(4*) 610. . . . . A NEW BARIATRIC BALLOONCAPSULE THERAPY…(5*) 611. . . . . IS RE-IMPLANTATION OF THEDUODENAL-JEJUNAL BYPASS…(5*) 612. . . . . SPATZ3Â® ADJUSTABLE INTRAGASTRIC BALLOONTREATMENT: TWENTY…(5*) 613. . . . . TRANSORAL OUTLET REDUCTION UTILIZINGA PURSESTRING…(4*) 614. . . . . BARIATRIC SURGERY IS SAFEIN OBESE…(5*) 615. . . . . EARLY INITIATION OF ANTI-TNFTHERAPY IS…(2*)|(4) 616. . . . . LONG-TERM SAFETY OF ADALIMUMABIN PATIENTS…(3*)AbbVie 617. . . . . DEFINING PATIENT-CENTERED OUTCOMES FORIBD AND…(4*) 618. . . . . SEXUAL DYSFUNCTION IS FREQUENTAMONG INFLAMMATORY…(7*)|(6)

619. . . . . A RANDOMISED CONTROLLED TRIALOF ACCEPTANCE…(3*)| Tillotts Pharma Ltd. 620. . . . . IL-33 INDIRECTLY INDUCES GOBLETCELL HYPERPLASIA…(2*)|(6) 637. . . . . PERORAL ENDOSCOPIC MYOTOMY (POEM)VERSUS PNEUMATIC…(6*)|(7) 638. . . . . RELAMORELIN IN PATIENTS WITHDIABETIC GASTROPARESIS:…(3*)| This study was supported by Motus Therapeutics, Inc. 639. . . . . EFFECT OF COX ANDEGFR INHIBITION…(2*)|(4) 648. . . . . REPURPOSING PENFLURIDOL: AN OLDANTIPSYCHOTIC DRUG…(2*)|(4) 649. . . . . IMMUNE CHECK POINT INHIBITORTREATMENT FOR…(4*) 650. . . . . PREDIAGNOSIS ASPIRIN USE ANDINCIDENT PANCREATIC…(4*) 651. . . . . LONG-TERM USE OF LOW-DOSEASPIRIN CAN…(5*) 652. . . . . A NOVEL DERIVATIVE OFEICOSAPENTAENOIC ACID…(3*)| The studies described in this abstract were funded by Thetis Pharmaceuticals LLC. 653. . . . . DIETARY PATTERNS AND RISKOF COLORECTAL…(2*) 654. . . . . CHROMOFUNGIN TREATMENT PROMOTES ALTERNATIVELYACTIVATED MACROPHAGES,…(2*)|(6) 655. . . . . HEDGEHOG PATHWAY ACTIVATION PROTECTSTHE COLON…(2*)|(4) 656. . . . . INTESTINAL EP4 RECEPTOR ISREQUIRED FOR…(5*) 657. . . . . LONG NON-CODING RNA (LNCRNA)PROFILING REVEALS…(2*)|(6)


* = Primary Source



658. . . . . A DOWN REGULATION OFSEMAPHORIN3E (SEMA3E)…(2*)|(4) 659. . . . . GENE EXPRESSION PROFILING IDENTIFIESCDKN2B-AS1 AS…(4*) 660. . . . . REVERSAL OF A VIRTUALLESION IN…(5*) 661. . . . . EFFECT OF AGING ONUES PRESSURE…(2*) 662. . . . . STRENGTH TRAINING USING ANOVEL SWALLOW…(2*) 663. . . . . REGIONAL PHARYNGEAL MOTILITY FUNCTIONSARE DISTINCT…(2*) 664. . . . . EFFECT OF ONO-8539, APROSTANOID EP1…(5*) 665. . . . . CHOLECYSTOKININ INDUCES ESOPHAGEAL LONGITUDINALMUSLCE CONTRACTION…(4*) 666. . . . . A MULTICENTER, VALIDATION STUDYOF CYST…(5*) 667. . . . . NATURAL HISTORY OF PANCREATICCYSTIC LESIONS:MID-TERM…(5*) 668. . . . . PANCREATIC CANCER INCIDENCE ISLOW IN…(5*) 669. . . . . NOVEL DNA METHYLATION MARKERSASSAYED FROM…(3*)|(4)| Exact Sciences 670. . . . . TARGETED PROTEOMIC ANALYSIS OFPANCREATIC CYST…(4*)|(6) 671. . . . . THE INCIDENCE AND RISKFACTOR FOR…(5*) 672. . . . . A DOUBLE-BLIND, RANDOMIZED TRIALOF MISOPROSTOL…(2*) 673. . . . . THE INTERNATIONAL BLEEDING RISKSCORE: A…(5*)

674. . . . . PREDICTORS FOR IN-HOSPITAL MORTALITYAND 30-DAY…(5*) 675. . . . . EFFECT OF VONOPRAZAN ONTHE ANTI-PLATELET…(4*)|(2)| The First Department of Medicine and the Center for Clinical Research at Hamamatsu University School of Medicine have received grants from Takeda Pharmaceutical Co., Ltd., AstraZeneca KK, Eisai Co., Ltd. and Daiichi-Sankyo Co. Ltd. 676. . . . . POTASSIUM-COMPETITIVE ACID BLOCKER VERSUSPROTON PUMP…(5*) 677. . . . . INFLUENCE OF CYP3A4/5 GENOTYPESTATUS FOR…(5*) 700. . . . . USE OF THE MICROBIOMEAS A…(3*)|(1)Metabiomics Corporation 701. . . . . MICROBIOME AND METABOLOME RESPONSESTO FECAL…(4*) 708. . . . . PLASMA LEVELS OF PIRNASAS BIOMARKERS…(2*) 709. . . . . THE BET-DEPENDENT EXPRESSION OFNSD1 DEFINES…(4*)|(2) 710. . . . . A NOVEL MIRNA-BASED, NON-INVASIVE,DIAGNOSTIC PANEL…(2*) 711. . . . . Ring Finger Protein 6Exerts an…(4*) 712. . . . . CLONAL INTERACTIONS AS MECHANISMSOF POLYCLONALITY…(4*) 713. . . . . CIGARETTE SMOKING TRIGGERS PANETHCELL DEFECT…(6*) 714. . . . . OBESITY IS ASSOCIATED WITHINFERIOR RESPONSE…(7*) 715. . . . . PEPT1-KNOCK OUT MICE HARBORA PROTECTIVE…(2*)|(6) 716. . . . . MATERNAL IMMUNOMODULATOR OR BIOLOGICUSE DOES…(6*)

717. . . . . The α4β1 homing pathwayis essential…(2*)|(3)| Takeda 718. . . . . SUPERIOR ENDOSCOPIC AND DEEPREMISSION OUTCOMES…(3*) AbbVie Inc. 719. . . . . CORTICOTROPIN-RELEASING HORMONE RECEPTOR 2(CRHR2) MEDIATES…(2*) 720. . . . . SEMAPHORIN 3A AND PLEXINA4 SIGNALING…(2*) 721. . . . . MECHANOSENSITIVITY OF THE BACTERIALVOLTAGE GATED…(2*) 722. . . . . BITTER TASTE RECEPTORS, T2R138AND T2R16,…(2*) 723. . . . . EXTRACELLULAR CGMP REDUCES THEEXCITABILITY OF…(3*)| Supported by Ironwood Pharmaceuticals Inc, and Allergan 724. . . . . FFAR1 BUT NOT FFAR4REGULATES FATTY…(2*) 725. . . . . RISK OF CLOSTRIDIUM DIFFICILEINFECTION IN…(2*) 726. . . . . ANNUAL INCIDENCE AND IN-HOSPITALMORTALITY TRENDS…(5*) 727. . . . . FACTORS ASSOCIATED WITH VILLUSATROPHY IN…(3*)| Alvine Pharmaceuticals, Inc., San Carlos, CA, USA 728. . . . . LOWER QUALITY OF LIFEAND ENERGY…(4*)|(2) 729. . . . . UNDIAGNOSED CELIAC DISEASE ASSOCIATEDWITH DECREASED…(5*) 730. . . . . PREDICTORS FOR POSITIVE FINDINGSON EGD,…(5*) 731. . . . . DIET-MICROBIOTA INTERACTIONS UNDERLIE SYMPTOMS'GENERATION IN…(2*)|(7)


* = Primary Source



732. . . . . FECAL TRANSPLANTATION AND MYCOBIOMEANALYSIS SHOWING…(4*)|(6) 733. . . . . SERUM 7C4 LEVELS DECREASEAFTER LOW…(4*)|(3)| Prometheus Laboratories, Inc. 734. . . . . THE PRESENCE OF TWOBACTERIAL GENERA…(4*) 735. . . . . EXPRESSION OF TLR-2, 4AND 5…(2*) 736. . . . . MAST CELLS MEDIATE STAPHYLOCOCCALENTEROTOXIN B-TRIGGERED…(4*) 742. . . . . A PROSPECTIVE, NON-INFERIOITY, MULTI-CENTER,RANDOMIZED TRIAL…(2*) 743. . . . . ALTERED PHAGE DIVERSITY ANDINCREASED GROWTH…(2*) 758. . . . . DETECTION OF BARRETT'S ESOPHAGUSVIA ELECTRONIC-NOSE…(4*)|(3)|The eNose company. 760. . . . . DEVELOPMENT OF A NEWDIAGNOSTIC TEST…(5*) 762. . . . . INHIBITION OF EPIDERMAL GROWTHFACTOR RECEPTOR…(2*) 764. . . . . ABNORMAL BOLUS EXPOSURE ONMULTICHANNEL INTRALUMINAL…(5*) 766. . . . . GASTROINTESTINAL EVENTS IN ARTHRITISPATIENTS AT…(3*)Funded by Pfizer) 767. . . . . A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALWITH BACLOFEN…(2*)| FWO - Research Foundation Flanders (Belgium) personal grant to Dr. Ans Pauwels 768. . . . . THE FECAL MICROBIOME ASA TOOL…(3*)| Janssen Research & Development, LLC provided support for this study.

769. . . . . GASTRIC ELECTRICAL STIMULATION (GES)FOR REFRACTORY…(2*) 770. . . . . GUT MICROBIOME FUNCTION PREDICTSRESPONSE TO…(2*) 771. . . . . ASSOCIATION BETWEEN LUMINAL BILESALT CONTENT…(5*) 772. . . . . CHRONIC PSYCHOLOGICAL STRESS DISRUPTEDTHE COMPOSITION…(3*)| This work was funded by the Yakult Honsha Co.,Ltd (http://institute.yakult.co.jp/). The funder provided support in the form of salaries for all authors. 773. . . . . DUODENAL LOW-GRADE INFLAMMATION ANDTIGHT JUNCTION…(5*) 774. . . . . ENDOSPORE-FORMING BACTERIA ARE ASSOCIATEDWITH MAINTENANCE…(2*) 775. . . . . CHOLECYSTECTOMY IS SIGNIFICANTLY ASSOCIATEDWITH DEVELOPMENT…(5*) 776. . . . . INFANTS BORN TO MOTHERSWITH INFLAMMATORY…(6*) 777. . . . . ENDOSCOPY-GUIDED EVALUATION OF DUODENALMUCOSAL PERMEABILITY…(5*) 778. . . . . MICROBIAL COMPOSITION IN IBDMAY INFLUENCE…(2*) 779. . . . . THE EFFICACY OF ORALZHIZHU KUANZHONG,…(5*) 780. . . . . CIRCULATING NEUROENDOCRINE TUMOR (NET)TRANSCRIPTS ARE…(6*) 781. . . . . IMMUNE HEALTH AND RISKOF IPILIMUMAB…(4*) 782. . . . . LINEAGE TRACING REVEALS CONTRIBUTIONOF ATOH1+…(2*)

783. . . . . GASTROINTESTINAL IMMUNE RELATED ADVERSEEVENTS ASSOCIATED…(5*) 784. . . . . 3D ORGANOIDS REVEAL THEAUTOPHAGY-CD44 CELL…(2*) 785. . . . . REGIONAL PATTERNS OF OLMESARTANPRESCRIPTION AND…(5*) 786. . . . . TFF1 ANTAGONIZES TIMP-1 MEDIATEDNEOPLASTIC PROLIFERATIVE…(4*) 787. . . . . MEDICATION EXPOSURE AND THERISK OF…(5*) 788. . . . . CELLULAR ORIGINS OF SQUAMOUSMETAPLASIA IN…(2*)|(6) 789. . . . . IS MICROSCOPIC COLITIS LARGELYIATROGENIC? …(5*) 790. . . . . UP-REGULATION OF MIR-222 EXPRESSIONDOWNSTREAM OF…(2*) 791. . . . . A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLEDTRIAL OF…(3*)| Adare Pharmaceuticals, Inc. (former Aptalis Pharma). 792. . . . . GENETIC POLYMORPHISMS PREDICT SYMPTOMBURDEN IN…(2*) 793. . . . . WEIGHT LOSS IN ACHALASIAIS DETERMINED…(5*) 794. . . . . INTESTINAL CRYPT FISSION ANDEXPRESSION OF…(5*) 795. . . . . ABDOMINAL COMPRESSION BY WAISTBELT AGGRAVATES…(4*) 796. . . . . DOES CONTINUED MEDICAL MANAGEMENTPREVENT THE…(4*) 797. . . . . OBESE ACHALASIA PATIENTS AREAT SIGNIFICANT…(5*) 798. . . . . HYPERBARIC OXYGEN THERAPY ISSAFE AND…(7*)| Broad Medical Research Program at the Crohn's and Colitis Foundation of America, Foundation for Clinical Research in IBD


* = Primary Source



800. . . . . CORRELATION OF CLINICAL ANDENDOSCOPIC OUTCOMES…(3*)This study was sponsored by Celgene Corporation. 802. . . . . EFFICACY AND SAFETY OFABRILUMAB IN…(3*)|Amgen and AstraZeneca/MedImmune sponsored this study. 804. . . . . SHORT DURATION, LOW INTENSITY,POOLED FECAL…(2*)|(6) 806. . . . . NEW TREATMENT OPTIONS FORPROCTITIS. A…(3*) 808. . . . . EFFICACY AND SAFETY OFORAL TOFACITINIB…(3*)Pfizer Inc. 809. . . . . MICROBIOTA METABOLITE SHORT CHAINFATTY ACID…(2*) 811. . . . . ENTEROPATHOGENIC ESCHERICHIA COLI (EPEC)EFFECTOR NLEH1…(2*) 813. . . . . SALMONELLA ENTERITIDIS EFFECTOR PROTEINAVRA INHIBITS…(2*) 815. . . . . CITROBACTER RODENTIUM-SECRETING SHIGA TOXIN-2ORAL INOCULATE…(4*) 817. . . . . LACTOBACILLUS RHAMNOSUS GG STIMULATESCOX-2-DERIVED PGE2…(2*) 819. . . . . LACTOBACILLUS PLANTARUM PREVENTS ANDMITIGATES ETHANOL-INDUCED…(2*) 821. . . . . RAPID LPS TRANSPORT DURINGLONG-CHAIN FATTY…(2*)| Shire Pharmaceuticals) 822. . . . . SUBOPTIMAL EARLY OUTCOMES FOLLOWINGSTANDARDIZED INDUCTION…(2*) 824. . . . . INCREASED BIOLOGIC USE ANDLOWER SURGICAL…(3*) Celgene Corporation

826. . . . . PREDICTING NON-RESPONSE TO INTRAVENOUSCORTICOSTEROID INDUCTION…(2*) 828. . . . . EXCLUSIVE ENTERAL NUTRITION THERAPYIN PEDIATRIC…(2*) 830. . . . . CHARACTERIZATION OF DISEASE SEVERITYIN PATIENTS…(2*) 832. . . . . IRRITABLE BOWEL SYNDROME (IBS)LIKE SYMPTOMS…(5*) 843. . . . . ENTERIC CHOLINERGIC NEURONS STIMULATEMUSCARINIC RECEPTORS…(2*) 845. . . . . STRETCH-INDUCED BDNF IN COLONSMOOTH MUSCLE…(2*) 847. . . . . TARGETING THE RECEPTOR KINASERET FOR…(3*) 849. . . . . PSYCHOLOGICAL STRESS-DIET ANTIGEN INTERACTIONINCREASES NOCICEPTIVE…(4*) 851. . . . . CHRONIC ORAL ADMINISTRATION OFLINACLOTIDE INHIBITS…(3*)| Supported by Ironwood Pharmaceuticals Inc, and Allergan 853. . . . . CHRONIC STRESS-ASSOCIATED ABDOMINAL PAIN:GLUCOCORTICOID RECEPTOR…(2*) 875. . . . . SUCCESSFUL TRANSPLANTATION OF ATISSUE ENGINEERED…(4*) 876. . . . . THE DISTAL DUODENAL BRAKEREVEALED BY…(5*) 877. . . . . MEASUREMENT OF HYDROGEN SULFIDEDURING BREATH…(4*) 878. . . . . GASTROINTESTINAL MOTILITY AND LUMINALPH INFLUENCE…(2*)

879. . . . . INTERACTION BETWEEN THE HERBALPREPARATION STW…(3*)| Steigerwald Arzneimittelwerk GmbH, Bayer consumer Health, Darmstadt, Germany. 880. . . . . DO CHRONIC CLINICAL SYMPTOMSPREDICT THE…(1*) 893. . . . . BUDESONIDE ORODISPERSIBLE TABLETS AREHIGHLY EFFECTIVE…(3*)| This study was sponsored by Dr. Falk Pharma GmbH, Freiburg, Germany. 894. . . . . STEP-UP EMPIRIC ELIMINATION DIETFOR PEDIATRIC…(5*) 895. . . . . THE CYTOSPONGE IS ASAFE AND…(6*)|(3)|Covidien/Medtronic provided some of the sponges used in this study. 896. . . . . CHANGES IN ESOPHAGEAL DISTENSIBILITYASSOCIATED WITH…(5*) 897. . . . . DEVELOPMENT AND EVALUATION OFA THERAPEUTIC…(5*) 899. . . . . CORRELATION BETWEEN ENDOSCOPIC ANDHISTOLOGICAL ACTIVITY…(5*) 901. . . . . FECAL IMMUNOCHEMICAL TEST PREDICTSHISTOLOGICAL HEALING…(5*) 903. . . . . AGREEMENT BETWEEN CROHN'S DISEASEENDOSCOPY SEVERITY…(5*) 905. . . . . WHAT IS THE BESTDEFINITION OF…(5*) 907. . . . . OVEREXPRESSION AND HYPOGLYCOSYLATION OFMUC1 IS…(5*) 909. . . . . MAGNETIC RESONANCE INDEX OFACTIVITY (MARIA)…(5*) 911. . . . . POST-INFLAMMATORY VISCERAL HYPERSENSITIVITY: ANIMPORTANT ROLE…(4*)


* = Primary Source



913. . . . . MRGPRC11 EXPRESSION AND FUNCTIONIN VAGAL…(2*)|(4) 915. . . . . ROLE OF MU ANDDELTA OPIOID…(2*) 917. . . . . NGF AND BDNF REGULATESENSORY ACTIVITY…(2*) 919. . . . . OLFR78, A SHORT CHAINFATTY ACID…(2*) 921. . . . . PGE2 PRODUCED BY MASTCELLS IS…(2*) 922. . . . . LACK OF ASSOCIATION BETWEENPROTON PUMP…(4*)|(6) 923. . . . . RACE PREDICTS SVR 12AMONG PATIENTS…(5*) 924. . . . . REMODELING GUT MICROBIOTA BYLACTOBACILLUS REUTERI…(2*)|(3) BioGaia AB (Sweden) 925. . . . . (CAN'T GET NO) PATIENTSATISFACTION: THE…(2*) 926. . . . . CROHN'S DISEASE EXCLUSION DIETAND PARTIAL…(3*)|(4)| Nestle Future Leaders in IBD Canada (Janssen). 927. . . . . DERIVATION AND INTERNAL VALIDATIONOF A…(5*) 928. . . . . DIFFERENCES IN THE STOOLAND SKIN…(4*)|(6) 929. . . . . ARE PATHOLOGISTS MISSING ADENOMAS?NOVEL POLYP…(5*) 930. . . . . GUT DYSBIOSIS FEATURED BYABUNDANT RUMINOCOCCUS…(2*) 931. . . . . COST-EFFECTIVENESS OF WAIVING ALLCOPAYMENTS FOR…(2*) 932. . . . . EXCLUSIVE ENTERAL NUTRITION MODULATESTHE MICROBIOTA…(6*)

933. . . . . COMPARISON OF PROTON MAGNETICRESONANCE SPECTROSCOPY…(5*) 934. . . . . FIRST GENOTYPE-PHENOTYPE STUDY INACHALASIA IMPLIES…(5*) 935. . . . . THE ROLE OF NONINVASIVEBREATH TESTS…(5*) 936. . . . . ACTIVATED EOSINOPHILS IN THEMUSCLE LAYER…(5*) 937. . . . . EVALUATION OF INTRAPARENCHYMAL ANDPORTAL BLOOD…(5*) 938. . . . . IMPACT OF A COMPROMISEDESOPHAGOGASTRIC JUNCTION…(5*) 940. . . . . CORRELATION OF NOVEL 3D-HRMMETRICS OF…(5*) 942. . . . . CHARACTERIZATION AND MECHANISMS OFINITIATION OF…(2*) 944. . . . . FUNCTIONAL MORPHOLOGY OF THELOWER ESOPHAGEAL…(2*) 946. . . . . LONG-TERM IMPACT OF COLORECTALCANCER SCREENING…(2*) 948. . . . . ROUTINE MOLECULAR ANALYSIS FORLYNCH SYNDROME…(5*) 950. . . . . ENHANCING THE IDENTIFICATION OFLYNCH SYNDROME…(5*) 952. . . . . THE EFFECT OF ADENOMASURVEILLANCE ON…(2*) 954. . . . . RATES AND CHARACTERISTICS OFPOST-COLONOSCOPY COLORECTAL…(1*) 956. . . . . LONG TERM RISK OFCOLORECTAL CANCER…(5*) 957. . . . . UTP IS A POTENTIALPHYSIOLOGICAL REGULATOR…(2*)

959. . . . . EFFECTS OF L-DOPA/BENSERAZIDE CO-TREATMENTON COLONIC…(5*) 961. . . . . COLONIC DYSMOTILITY ASSOCIATED WITHHIGH FAT…(4*) 963. . . . . MECHANOSENSITIVE ION CHANNEL PIEZO2DISTRIBUTION IN…(5*) 965. . . . . ROLE OF TRPV4 INTHE MECHANOSENSITIVITY…(2*) 967. . . . . A NOVEL PERIPHERALLY RESTRICTEDGABA-A POSITIVE…(2*) 969. . . . . DYNAMICS OF ACUTE H.PYLORI INFECTION…(3*) 970. . . . . THE GLOBAL PREVALENCE OFHELICOBACTER PYLORI:…(5*) 971. . . . . AGE OF HELICOBACTER PYLORIERADICATION AND…(4*) 972. . . . . EFFICACY OF HIGH-DOSE DUALTHERAPY VERSUS…(4*) 973. . . . . A RANDOMIZED CONTROLLED STUDYCOMPARING 14-DAY…(5*) 974. . . . . AUTOPHAGY PROTEIN ATG16L1 CONFERSTOLERANCE TO…(2*) 975. . . . . IL-22 CONTROLS HEME-DEPENDENT NUTRITIONALIMMUNITY AGAINST…(2*)|(4) 976. . . . . THE HOST ENGULFMENT PATHWAY:A NEW…(2*)|(4) 977. . . . . EPITHELIAL NA+/H+ EXCHANGE PROMOTESHOMEOSTASIS IN…(2*) 978. . . . . BILE ACIDS REGULATE INTESTINALPANETH CELL…(2*) 979. . . . . MITOTEMPO PREVENTS INTESTINAL EPITHELIALCELL MITOCHONDRIAL…(6*)|(2)


* = Primary Source



980. . . . . COST-EFFECTIVENESS OF LAPAROSCOPIC ILEOCECALRESECTION VERSUS…(2*) 981. . . . . FISTULA HEALING IN PIVOTALSTUDIES OF…(3*)| Janssen Research & Development, LLC supported this study. 982. . . . . TELEMEDICINE ENABLES A SAFESHIFT FROM…(4*)|(3)| This work was supported by an academic incentive fund of the MUMC+ and Ferring BV. 983. . . . . HIGHLY PURIFIED EICOSAPENTAENOIC ACID,AS FREE…(5*)| SLA Pharma AG supplied EPA-FFA and placebo capsules. 984. . . . . SUBMUCOSAL INJECTION OF THEOLIGONUCLEOTIDE STNM01…(3*)| Stelic Institute & Co., Inc. 985. . . . . CX601, ALLOGENEIC EXPANDED ADIPOSE-DERIVEDMESENCHYMAL STEM…(3*)| TiGenix 986. . . . . DEFICITS IN ENTEROCYTE APICALTRANSPORTERS ASSOCIATED…(2*) 987. . . . . EGFR-ACTIVATED NOTCH SIGNALING CONTRIBUTESTO PATHOGENESIS…(4*) 988. . . . . ZONULIN TRANSGENIC MOUSE MODELSHOWS ALTERED…(2*) 989. . . . . AN INDUCIBLE DOMINANT NEGATIVEALLELE OF…(2*) 990. . . . . STIMULATION OF CYP450-MEDIATED Î©-3DOCOSAHEXAENOIC ACID…(2*)|(4) 991. . . . . NOD2 DEFICIENCY IMPAIRS PERI-OPERATIVEOUTCOME AND…(4*) 992. . . . . DETECTION OF PANCREATIC CANCERBY ASSAY…(3*)|(4)| Exact Sciences 993. . . . . EFFECTIVENESS OF PD-L1 INHIBITIONAS A…(5*)

994. . . . . A UNIQUE SET OFTHREE CIRCULATING…(2*) 995. . . . . CRITICAL ROLES OF PYRUVATEKINASE MUSCLE…(2*) 996. . . . . PANCREATIC CANCER CELLS INDUCEPROFIBROGENIC ACTIVITIES…(2*) 997. . . . . MICRORNA-196B IS A DIAGNOSTICBIOMARKER AND…(2*)

AGA Poster Presentations


* = Primary Source



Sa1000. . . . . PERFORMANCE OF A MULTIDISCIPLINARYTEAM IN…(5*) Sa1001. . . . . THE REFLUX IMPROVEMENT ANDMONITORING PROGRAM…(2*) Sa1002. . . . . PHYSICIAN CHARACTERISTICS ASSOCIATED WITHHIGHER ADENOMA…(2*) Sa1003. . . . . ENDOSCOPY-RELATED MUSCULOSKELETAL INJURY INAGA GASTROENTEROLOGISTS…(4*)|(7) Sa1004. . . . . ADENOMA DETECTION RATE AMONGCOLONOSCOPY FOR…(5*) Sa1005. . . . . PATIENTS CARED FOR INAN INTEGRATED…(5*) Sa1006. . . . . A STRUCTURED CARE PATHWAYIMPROVES QUALITY…(5*) Sa1007. . . . . DEVELOPMENT AND VALIDATION OFA NOVEL,…(5*) Sa1008. . . . . EARLY USE OF THERAPEUTICDRUG MONITORING…(4*) Sa1009. . . . . A NEW RISK SCOREAIMED AT…(5*) Sa1010. . . . . GASTROINTESTINAL BLEEDING IN INPATIENTSADMITTED FOR…(5*) Sa1011. . . . . CHANGES IN TRANSFUSION PRACTICESIN PATIENTS…(5*) Sa1012. . . . . REDUCING PPI AND H2RAPRESCRIPTIONS IN…(5*) Sa1013. . . . . FACTORS AFFECTING OPTIMAL ANDACCURATE ASSESSMENT…(1*) Sa1014. . . . . TITLE: IMPLEMENTING AN ELECTRONICTREATMENT ALGORITHM…(5*) Sa1015. . . . . UTILIZATION OF QUALITY IMPROVEMENTSTRATEGIES IN…(5*)

Sa1016. . . . . THE RIGHT IDEA INTHE WRONG…(5*) Sa1017. . . . . CAN THE USE OFCOMPUTER DECISION…(1*)|(4) Sa1018. . . . . LEVELS OF INAPPROPRIATE FECALIMMUNOHISTOCHEMISTRY TEST…(2*) Sa1019. . . . . SIX SIGMA APPROACH TOIMPROVE SUCCESS…(5*) Sa1020. . . . . VALIDATION OF ONTARIO HEALTHADMINISTRATIVE DATA…(2*) Sa1021. . . . . LABORATORY TESTING FOR CELIACDISEASE AT…(4*) Sa1022. . . . . CHRONIC PROTON PUMP INHIBITORUSE IN…(5*) Sa1023. . . . . DO THE RISKS OUTWEIGHTHE BENEFITS…(5*) Sa1024. . . . . ABDOMINAL COMPRESSION ADMINISTERED EARLYBY THE…(5*) Sa1025. . . . . CURRENT UTILIZATION AND DIAGNOSTICYIELD OF…(5*) Sa1026. . . . . REAL-TIME COMMUNICATION OF ACLINICAL PATHWAY…(1*) Sa1027. . . . . SAFETY OF GASTROINTESTINAL ENDOSCOPYPERFORMED WITH…(5*) Sa1028. . . . . PATIENTS ARE WILLING TOREPEAT COLONOSCOPY…(4*) Sa1029. . . . . EFFECT OF A DEDICATEDGI HOSPITALIST…(5*) Sa1030. . . . . SCREENING AND EVALUATION OFSEXUAL DYSFUNCTION…(5*) Sa1123. . . . . PERCEPTIONS OF THE INPATIENTTRAINING EXPERIENCE:…(5*)

Sa1124. . . . . WHAT MAKES A GOODENDOSCOPIC TEACHER:…(5*) Sa1125. . . . . INTRODUCING GASTROENTEROLOGY FELLOWS TORESEARCH UTILIZING…(5*) Sa1126. . . . . IMPACT OF LEVEL OFFELLOWSHIP TRAINING…(5*) Sa1127. . . . . THE GASTROENTEROLOGY FELLOWSHIP MATCH:A DECADE…(5*) Sa1128. . . . . MUSCULOSKELETAL INJURIES ARE FREQUENTLYREPORTED AMONG…(5*) Sa1129. . . . . EQUAL OPPORTUNITY: THE TRENDIN WOMEN…(4*) Sa1130. . . . . IMPROVING PHYSICIANS' AND PATIENTS'KNOWLEDGE OF…(3*)| Supported by an independent medical education grant from NPS Pharmaceuticals, a subsidiary of Shire. Sa1131. . . . . HOW IS OIC DIAGNOSEDAND MANAGED?…(3*)| |Supported by an independent educational grant from Valeant. Sa1132. . . . . CAN CONTINUING MEDICAL EDUCATIONIMPROVE EFFECTIVE…(3*)| Supported by an independent educational grant from Allergan. Sa1133. . . . . INTERACTIVE ONLINE LIVER MODULESINCREASE KNOWLEDGE…(4*) Sa1134. . . . . INCREASED TIME SPENT ONINTERACTIVE ONLINE…(4*) Sa1135. . . . . HOW ACADEMIC IS MYGASTROENTEROLOGY (GI)…(5*) Sa1136. . . . . SOCIAL MEDIA IN GITRAINING PROGRAMS:…(5*) Sa1137. . . . . TRENDS IN SOCIAL MEDIAREACH AND…(5*) Sa1138. . . . . NOVEL INTERACTIVE FLASHCARD EDUCATIONIMPROVES COLONOSCOPY…(5*)


* = Primary Source



Sa1139. . . . . IDENTIFICATION OF GENOMIC REGIONSASSOCIATED WITH…(2*) Sa1140. . . . . Aspirin Prevents NF-κB Activationand CDX2…(2*) Sa1141. . . . . IDENTIFICATION OF MYELOID DERIVEDSUPPRESSOR CELLS…(2*) Sa1142. . . . . SOX2 AND Î”NP63 INCREASESQUAMOUS CYTOKERATIN…(2*) Sa1143. . . . . IN VITRO ASSESSMENT OFMICE LARYNGEAL…(2*) Sa1144. . . . . ROLE OF TRPV1 RECEPTORSIN ACID…(2*) Sa1145. . . . . NRF2 PROTECTS BARRETT'S ESOPHAGEALCELLS FROM…(2*) Sa1146. . . . . CLINICAL CHARACTERISTICS MAY DISTINGUISHPATIENTS WITH…(5*) Sa1147. . . . . PATHOGENESIS OF POTASSIUM-COMPETITIVE ACIDBLOCKER (P-CAB)-RESISTANT…(5*) Sa1148. . . . . THE EFFECT OF THEACID POCKET…(5*) Sa1149. . . . . PATHOGENESIS OF DOUBLE-DOSE PROTONPUMP INHIBITOR-RESISTANT…(5*) Sa1150. . . . . INNERVATION PATTERN OF THEDISTAL MUCOSAL…(4*) Sa1151. . . . . THE EFFECT OF SLEEVEGASTRECTOMY ON…(5*) Sa1152. . . . . GENDER DIFFERENCES OF CLINICALPARAMETERS FOR…(4*) Sa1153. . . . . A NEW FUNCTION OFAPE1 IN…(2*) Sa1154. . . . . EXPRESSION OF GENES ASSOCIATEDWITH INFLAMMATION…(4*)

Sa1155. . . . . INFLUENCE OF ACUTE TRYPTOPHANDEPLETION ON…(5*) Sa1156. . . . . ROLES OF METABOLIC SYNDROME-RELATEDFACTORS IN…(5*) Sa1157. . . . . ESOPHAGEAL EPITHELIAL INTEGRITY AFTERBUT NOT…(4*) Sa1158. . . . . ACID AND BILE INDUCEDTGFB1 AND…(4*)|(6) Sa1159. . . . . DYSPLASIA ASSOCIATED MICROENVIRONMENT CHANGESIN BARRETT'S…(5*) Sa1160. . . . . HOW DOES ESOPHAGEAL REFLUXINDUCE DNA…(2*)|(4) Sa1161. . . . . GLANDULAR METAPLASIA AND DYSPLASIAAT THE…(2*) Sa1162. . . . . PROSPECTIVE 3-MONTH EVALUATION OFTHE UPPER…(3*)| |Somna Therapeutics) Sa1163. . . . . A COHORT STUDY TOASSESS THE…(4*) Sa1164. . . . . DOES THE NOVEL POTASSIUM-COMPETITIVEACID BLOCKER…(5*) Sa1165. . . . . QUALITATIVE EVALUATION OF THECOMPOSITION OF…(1*) Sa1166. . . . . INTRALUMINAL PHARYNGEAL IMPEDANCE AFTERACID EXPOSURE…(2*) Sa1167. . . . . PHARYNGOLARYNGEAL GERD SYMPTOMS AREASSOCIATED WITH…(2*) Sa1168. . . . . PHARYNGEAL BASELINE IMPEDANCE INPATIENTS WITH…(4*) Sa1169. . . . . ASSOCIATION BETWEEN INCREASED UPPERESOPHAGEAL SPHINCTER…(5*) Sa1170. . . . . NATIONWIDE INPATIENT TRENDS INHOSPITALIZATION, DEMOGRAPHIC…(5*)

Sa1171. . . . . DIFFERENCES IN MOTILITY ANDREFLUX PROFILES…(5*) Sa1172. . . . . EFFECT OF PROTON PUMPINHIBITION ON…(5*) Sa1173. . . . . FEMALE GENDER IS THEONLY SIGNIFICANT…(5*) Sa1174. . . . . TEMPORAL TRENDS IN HELICOBACTERPYLORI ERADICATION…(5*) Sa1175. . . . . INCREASED HELICOBACTER PYLORI UREASEACTIVITY IS…(5*) Sa1176. . . . . MULTI-CENTER PROSPECTIVE, TEST ANDTREAT�: STUDY…(2*)| Fund for the promotion of comprehensive cancer control project, Department of Health and Welfare, Kyoto Prefecture Sa1177. . . . . IS HELICOBACTER PYLORI CHRONICINFECTION ASSOCIATED…(5*) Sa1178. . . . . EFFICACY OF VONOPRAZAN FUMARATEFOR HELICOBACTER…(1*) Sa1179. . . . . INTERACTION OF ETHNICITY ANDH. PYLORI…(5*) Sa1180. . . . . UNEXPECTED HIGH PREVALENCE OFGASTRIC NON-HELICOBACTER…(4*) Sa1181. . . . . PATIENTS WITH AUTOIMMUNE GASTRITISARE SOMETIMES…(4*) Sa1182. . . . . MAKING HELICOBACTER PYLORI (HP)STATUS WITH…(5*) Sa1183. . . . . PEPTIC ULCER DISEASE ANDNON-ULCER DYSPEPSIA:…(5*) Sa1184. . . . . INTRAGASTRIC ACID SUPPRESSION ANDSYMPTOMATIC IMPROVEMENT…(3*)| Sanfer supported this study) Sa1185. . . . . EVALUATION OF THE EFFICACYAND SAFETY…(5*)


* = Primary Source



Sa1186. . . . . PROTON PUMP INHIBITOR-BISMUTH-TETRACYCLINE-LEVOFLOXACIN QUADRUPLETHERAPY ACHIEVES…(5*) Sa1187. . . . . EFFECTS OF DOSING STRATEGYOF AMOXICILLIN…(5*) Sa1188. . . . . A LARGE-SCALE STUDY TOCOMPARE SUCCESS…(5*) Sa1189. . . . . HELICOBACTER PYLORI ERADICATION INOBESE PATIENTS…(5*) Sa1190. . . . . OPEN-LABEL RANDOMIZED CONTROLLED TRIALOF VONOPRAZAN…(1*) Sa1191. . . . . VONOPRAZAN INDUCES PARIETAL CELLDAMAGE IN…(4*) Sa1192. . . . . EFFICACY OF 7-DAY BISMUTH-BASEDQUADRUPLE THERAPY…(5*) Sa1193. . . . . VONOPRAZAN-BASED TRIPLE THERAPY ASFIRST LINE…(5*) Sa1194. . . . . THE EVALUATION OF CLARITHROMYCIN,LEVOFLOXACIN RESISTANCE…(5*) Sa1195. . . . . POLAPREZINC COMBINED WITH TRIPLETHERAPY FOR…(3*)| This study was partially sponsored by Broadwell Pharmaceutical Co., Ltd.) Sa1196. . . . . COMPARISON OF AOC ANDAOM TRIPLE,…(5*) Sa1197. . . . . THE EFFICACY OF PCR-BASEDTAILORED ERADICATION…(5*) Sa1198. . . . . EFFICACY AND SAFETY OFVONOPRAZAN-BASED TRIPLE…(1*)|(4) Sa1199. . . . . EFFECTIVENESS OF 7-DAY AND14-DAY MOXIFLOXACIN-DEXLANSOPRAZOLE…(4*) Sa1200. . . . . RANDOMIZED PLACEBO-CONTROLLED PHASE IIISTUDY TO…(3*)| RedHill Biopharma Ltd. was the study sponsor.

Sa1201. . . . . A MULTICENTER, OPEN-LABEL, RANDOMIZEDTRIAL OF…(5*) Sa1202. . . . . EFFICACY AND TOLERABILITY OFTWO QUADRUPLE…(2*) Sa1203. . . . . HIGH DOSE CAM WITHVONOPRAZAN (P-CAB)…(5*) Sa1204. . . . . ESOMEPRAZOLE BASED TRIPLE THERAPYREGIMENS ON…(5*) Sa1237. . . . . CONDITIONAL EXPRESSION OF MNEURODINDUCES ENTEROENDOCRINE…(2*) Sa1238. . . . . EZRIN-ACAP4 INTERACTION REGULATES GASTRICPARIETAL CELL…(2*)|(4) Sa1239. . . . . MESENCHYMAL STEM CELL TRANSITIONTO INFLAMMATORY…(2*) Sa1240. . . . . INTESTINAL TREFOIL FACTOR (ITF)PLAYS CRITICAL…(5*) Sa1241. . . . . HIGH-FAT FEEDING ENHANCES STEMNESSOF INTESTINAL…(2*) Sa1242. . . . . FIBROBLAST GROWTH FACTOR 21DEPLETION ATTENUATES…(2*) Sa1243. . . . . DIFFERENTIAL ROLE OF SIRT2PROTEIN IN…(2*) Sa1244. . . . . ROLE AND REGULATION OFINSULIN-LIKE GROWTH…(2*) Sa1245. . . . . IDENTIFICATION OF SPECIFIC SUBPOPULATIONSOF TUMOR…(2*) Sa1246. . . . . FERRICHROME, A TUMOR SUPPRESSIVEMOLECULE DERIVED…(2*) Sa1247. . . . . INFLUENCE OF LABORATORY ANDCLINICAL FACTORS…(5*) Sa1248. . . . . NON INVASIVE DIAGNOSIS OFUPPER GI…(5*)

Sa1249. . . . . ADVANTAGE OF POTASSIUM-COMPETITIVE ACIDBLOCKER TO…(5*) Sa1250. . . . . NEXT-GENERATION SEQUENCING OF INITIALEARLY GASTRIC…(4*) Sa1251. . . . . DIFFERENTIAL CANCER-RELATED PATHWAY PROFILESOF INITIAL…(5*) Sa1252. . . . . POPDC1/BVES AND POPDC3 AREDOWNREGULATED IN…(4*) Sa1253. . . . . COMPARING THE RISK FACTORSINFLUENCING DIAGNOSTIC…(5*) Sa1254. . . . . GASTRIC INTESTINAL METAPLASIA ANDSURVEILLANCE RECOMMENDATIONS…(5*) Sa1255. . . . . HELICOBACTER PYLORI ERADICATION AFTERENDOSCOPIC RESECTION…(5*) Sa1256. . . . . CROHN'S DISEASE SUSCEPTIBILITY POLYMORPHISMATG16L1 T300A…(6*) Sa1257. . . . . CIRCULATION MICRORNA-22-3P COULD PREDICTGASTRIC PRECANCEROUS…(4*) Sa1258. . . . . LONG-TERM EFFICACY AND SAFETYOF TC-325…(4*) Sa1259. . . . . SERUM VITAMIN D LEVELAND ITS…(5*) Sa1260. . . . . EFFECTIVENESS OF A VONOPRAZANON PREVENTION…(5*) Sa1261. . . . . FACTORS ASSOCIATED WITH THEEFFICACY OF…(5*) Sa1262. . . . . COMPARISON OF METACHRONOUS TUMORSAFTER ENDOSCOPIC…(5*) Sa1263. . . . . SCORING SYSTEM ACCORDING TOTHE KYOTO…(5*)


* = Primary Source



Sa1264. . . . . LOCATION FEATURES OF EARLYGASTRIC CANCER…(5*) Sa1265. . . . . PREDICTIVE FACTORS OF BEYONDEXPANDED INDICATION…(5*) Sa1266. . . . . PREVALENCE OF INTESTINAL METAPLASIAIN PATIENTS…(5*) Sa1267. . . . . YIELD OF CLINICAL ANDIMAGING FACTORS…(5*) Sa1268. . . . . ANALYSIS OF POTENTIAL SOMATICMUTATIONS OF…(5*) Sa1269. . . . . CLINICOPATHOLOGIC PREDICTORS FOR LYMPHNODE METASTASIS…(5*) Sa1270. . . . . PREVALENCE OF BONE MARROWINVOLVEMENT IN…(4*) Sa1271. . . . . HEMATOLOGISTS SHOULD ORDER ENDOSCOPICEXAMINATION TO…(5*) Sa1272. . . . . CLINICAL AND PATHOLOGICAL CHARACTERISTICSOF GASTRIC…(5*) Sa1273. . . . . RATIO OF NEUTROPHIL TOLYMPHOCYTES IS…(5*) Sa1274. . . . . IS THE NEUTROPHIL/LYMPHOCYTE RATIOAN INDEPENDENT…(5*) Sa1275. . . . . NON-H. PYLORI HELICOBACTERS (NHPH)COULD CAUSE…(5*) Sa1276. . . . . CLINICAL TRENDS AND BURDENOF DEATH…(5*) Sa1277. . . . . THE DIFFERENCE BETWEEN THETHAI AND…(5*) Sa1278. . . . . PREVALENCE OF ADRENAL INCIDENTALOMAIN GASTRIC…(5*) Sa1279. . . . . THE BEST INDICATIONS FORA DUODENAL…(5*)

Sa1280. . . . . OPTIMAL BIOPSY STRATEGIES FORTHE DIAGNOSIS…(5*) Sa1281. . . . . HISTOMORPHOMETRICAL CHARACTERISTICS OF SERONEGATIVECELIAC-TYPE DUODENAL…(5*) Sa1282. . . . . CULTURE OF CELIAC GASTRICBIOPSIES: NEW…(4*) Sa1283. . . . . THE PERFORMANCE OF TISSUETRANSGLUTAMINASE ANTIBODIES…(5*) Sa1284. . . . . HISTOLOGIC FINDINGS IN GASTRICBIOPSIES AT…(5*) Sa1285. . . . . NON-INVASIVE BIOMARKERS FOR ASSESSMENTOF VILLOUS…(2*) Sa1286. . . . . DO WE PROPERLY DIAGNOSEOUR CELIAC…(5*) Sa1287. . . . . ROLE OF HLA TYPINGIN PATIENTS…(5*) Sa1288. . . . . EFFECT OF A GLUTENFREE DIET…(2*) Sa1289. . . . . PSYCHOTROPIC MEDICATION USE AMONGPATIENTS WITH…(5*) Sa1290. . . . . PERSISTENT ECONOMIC BURDEN OFTHE GLUTEN…(5*) Sa1291. . . . . SELF-REPORTED DIETARY ADHERENCE, DISEASE-SPECIFICSYMPTOMS, AND…(6*) Sa1292. . . . . THE COMBINATION OF SERUMI-FABP AND…(5*) Sa1293. . . . . LONG-TERM IMPROVEMENT OF IMPAIREDBONE MICROARCHITECTURE…(5*) Sa1294. . . . . FACTORS ASSOCIATED WITH THEPERSISTENCE OF…(5*) Sa1295. . . . . DETERMINANTS OF FOLLOW-UP CAREFOR PATIENTS…(5*)

Sa1296. . . . . PERSISTENT VILLOUS ATROPHY ISCOMMON IN…(5*) Sa1297. . . . . TWO FOR ONE. ISTHERE A…(4*) Sa1298. . . . . PREDICTORS FOR POOR RESPONSEIN GASTROINTESTINAL…(5*) Sa1299. . . . . DEPRESSION MODIFIES THE ASSOCIATIONBETWEEN GLUTEN-FREE…(5*) Sa1301. . . . . CREATION OF CELIAC BENCHMARKS'THE FIRST…(1*) Sa1302. . . . . OVERWEIGHT STATUS AT DIAGNOSISOF CELIAC…(2*) Sa1303. . . . . INTESTINAL FAILURE: A RAREBUT SIGNIFICANT…(5*) Sa1304. . . . . INTESTINAL-FAILURE ASSOCIATED LIVER DISEASE:INCIDENCE AND…(5*) Sa1305. . . . . NHE3 EXPRESSION IS NEGATIVELYREGULATED BY…(2*) Sa1306. . . . . INTESTINAL SEROTONIN TRANSPORTER UNTRANSLATEDREGIONS INFLUENCE…(2*) Sa1307. . . . . UNIQUE REGULATION OF NA:HEXCHANGE (NHE3)…(2*) Sa1308. . . . . PHYSIOLOGICAL STIMULATION OF CONSTITUTIVENITRIC OXIDE…(2*) Sa1309. . . . . DIFFERENTIAL-EXPRESSION OF VITAMIN CTRANSPORTERS (SVCT-1…(2*) Sa1310. . . . . MECHANISM OF REGULATION OFNA-GLUCOSE CO-TRANSPORT…(2*) Sa1311. . . . . REGULATION OF NA/K-ATPASE DURINGDIFFERENTIATION OF…(2*)


* = Primary Source



Sa1312. . . . . INCREASED RISK OF NEPHROLITHIASISIN PATIENTS…(5*) Sa1313. . . . . UNIQUE MECHANISM OF PARADOXICALINHIBITION OF…(7*)|(2) Sa1314. . . . . IDENTIFICATION OF A CIRCULATINGMIRNA DIAGNOSTIC…(2*) Sa1315. . . . . DEFERASIROX (DFX), A NEWLYORAL IRON…(5*) Sa1316. . . . . PREDICTORS OF NEOPLASTIC PROGRESSIONIN HIGH-RISK…(2*)|(6) Sa1317. . . . . A CLINICAL PREDICTION MODELTO ASSESS…(2*)|(6) Sa1318. . . . . DIFFERENTIAL P120CTN ISOFORM REGULATIONOF PANCREATIC…(2*) Sa1319. . . . . DETECTION OF PANCREAS SITE-SPECIFICMETHYLATION FROM…(4*) Sa1320. . . . . CDX2 IS A BIOMARKEROF BETTER…(5*) Sa1321. . . . . SBI-0143183 IS A QSOX1INHIBITOR WITH…(2*)|(4) Sa1322. . . . . REGULATION OF ENHANCER OFZESTE HOMOLOG…(4*) Sa1323. . . . . CLINICAL SIGNIFICANCE OF SERUMWISTERIA FLORIBUNDA…(5*) Sa1324. . . . . SURGICAL OUTCOMES IN PATIENTSWITH BORDERLINE…(5*) Sa1325. . . . . PANCREATIC CANCER SCREENING INHIGH RISK…(2*) Sa1326. . . . . INITIAL EXPERIENCE OF IRREVERSIBLEELECTROPORATION IN…(5*) Sa1327. . . . . STATINS USE AND OVERALLSURVIVAL IN…(5*)

Sa1328. . . . . ENDOSCOPIC ULTRASONOGRAPHY (EUS) FORTHE DIAGNOSIS…(5*) Sa1329. . . . . METASTATIC SIGNET-RING CELL CARCINOMAPRESENTING AS…(5*) Sa1330. . . . . ARE INTERLEUKINS USEFUL INPREDICTING THE…(5*) Sa1331. . . . . CLINICAL IMPLICATION OF REFEEDINGSYNDROME BASED…(5*) Sa1332. . . . . THROMBOSIS OF SPLANCHNIC VEINSDURING A…(5*) Sa1333. . . . . DOES CONCURRENT DIABETIC ACIDOSISAFFECT CLINICAL…(5*) Sa1334. . . . . QUICK SOFA: AN ACCURATEPREDICTOR OF…(5*) Sa1335. . . . . READMISSION RATES AFTER ACUTEPANCREATITIS IN…(5*) Sa1336. . . . . IMPACT OF PREGNANCY ONTHE OUTCOME…(5*) Sa1337. . . . . GUIDELINES VERSUS DIRECTED IVFLUID THERAPY…(4*) Sa1338. . . . . EFFECT OF SERUM TRIGLYCERIDELEVELS ON…(5*) Sa1339. . . . . NATIONAL TRENDS IN ACUTEPANCREATITIS IN…(5*) Sa1340. . . . . OUTCOMES OF WEEKEND VERSUSWEEKDAY ADMISSION…(5*) Sa1341. . . . . DIFFERENT DEMOGRAPHIC, CLINICAL ANDSEVERITY PROFILE…(5*) Sa1342. . . . . PRE-EXISTING DIABETES IS ANINDEPENDENT RISK…(5*) Sa1343. . . . . FREQUENCY AND CLINICAL PREDICTORSOF PAIN…(5*) Sa1344. . . . . HOSPITAL ACQUIRED CONDITIONS INPATIENTS WITH…(5*)

Sa1345. . . . . EXTRAPANCREATIC BACTERIAL INFECTIONS ARECOMMON IN…(2*)|(1) Sa1346. . . . . NATIONAL TRENDS FOR SAME-ADMISSIONCHOLECYSTECTOMY IN…(5*) Sa1347. . . . . AN INTERNATIONAL MULTICENTER STUDYOF MORTALITY…(5*) Sa1348. . . . . ANALYSIS AND PREDICTIVE FACTORSOF SPLANCHNIC…(5*) Sa1349. . . . . TARGETED EARLY AGGRESSIVE FLUIDRESUSCITATION IN…(5*) Sa1350. . . . . SIMILAR OUTCOMES FOR ACUTENECROTIC COLLECTIONS…(5*) Sa1351. . . . . MANAGEMENT OF MILD ACUTEPANCREATITIS THROUGH…(5*) Sa1352. . . . . IATROGENIC EVENTS IN ICUPATIENTS HOSPITALIZED…(5*) Sa1353. . . . . ROLE OF THROMBOPHILIA INSPLANCHNIC VENOUS…(5*) Sa1354. . . . . MARKED DIFFERENCES IN FASTINGTIME AND…(5*) Sa1355. . . . . ERCP ACCESS IMPACTS MORTALITYIN BILIARY…(5*) Sa1356. . . . . ASSESSING ROLE OF HIGHERDOSE OF…(4*) Sa1357. . . . . THE BURDEN OF ACUTEPANCREATITIS IN…(2*) Sa1358. . . . . FACTORS AFFECTING OPIOID USEIN HOSPITALIZED…(5*) Sa1359. . . . . SHORT AND LONG-TERM OUTCOMESIN PATIENTS…(5*) Sa1360. . . . . CAN MESALAZINE AFFECT THEPROGNOSIS OF…(5*)


* = Primary Source



Sa1361. . . . . IMPACT OF BODY MASSINDEX AND…(5*) Sa1362. . . . . RISK FACTORS FOR CHRONICAND RECURRENT…(5*) Sa1363. . . . . A NOVEL CHARACTERIZATION OFLONG-TERM PROGNOSIS…(5*) Sa1364. . . . . INCIDENCE AND OUTCOMES OFSEVERE ACUTE…(2*) Sa1365. . . . . REDUCTION IN INTRA-ABDOMINAL PRESSUREAFTER PERCUTANEOUS…(5*) Sa1366. . . . . THE COST OF OBESITYIN THE…(4*) Sa1367. . . . . GENETIC MUTATION TESTING ANDSMOKING ARE…(5*) Sa1368. . . . . PERCUTANEOUS CATHETER DRAINAGE FOLLOWEDBY ENDOSCOPIC…(5*) Sa1369. . . . . THE EFFECT OF CANNABISCONSUMPTION ON…(5*) Sa1370. . . . . ACUTE PANCREATITIS PATIENT REGISTRYTO EXAMINE…(5*) Sa1451. . . . . MALNOURISHED HCC PATIENTS ASSOCIATEDWITH HIGHEST…(5*) Sa1452. . . . . POSTOPERATIVE PROGNOSTIC PREDICTORS OFBILE DUCT…(5*) Sa1453. . . . . INCIDENCE AND PREDICTORS OFLYMPH NODAL…(5*) Sa1454. . . . . DUAL ORGAN INVASION ISBETTER PREDICTOR…(4*)|(5) Sa1455. . . . . COMPARISON BETWEEN RADIO FREQUENCYABLATION THERAPY…(5*) Sa1456. . . . . THE ANTI-TUMOR EFFECT OFPACLITAXEL, GEMCITABINE…(5*)

Sa1528. . . . . DISCOVERY OF BAR704, APOTENT AND…(4*)| |BAR Pharmaceuticals) Sa1529. . . . . IMPORTANCE OF SCREENING FORESOPHAGOGASTRIC VARICES…(5*) Sa1530. . . . . CANCER RISK AFTER LIVERTRANSPLANTATION FOR…(5*) Sa1531. . . . . NEXT-GENERATION SEQUENCING IMPROVES THEDETECTION OF…(5*) Sa1532. . . . . MODULATING HEPATOCELLULAR CARCINOMA BIOLOGYWITH AMNIOTIC…(5*) Sa1533. . . . . DIAGNOSIS VALUE OF SERUMMUC3A IN…(4*) Sa1534. . . . . WHICH THERAPEUTIC METHOD SHOULDBE SELECTED…(5*) Sa1535. . . . . DNA METHYLATION ALTERATIONS INBILE OF…(5*) Sa1536. . . . . RECEIPT AND SURVIVAL OUTCOMESOF CURATIVE…(5*) Sa1537. . . . . COMPARISON OF ACCURACY OFSIMULTANEOUS CHOLANGIOSCOPIC…(5*) Sa1538. . . . . ALPHA FETOPROTEIN AND AUSEFUL TOOL…(5*) Sa1539. . . . . A NATIONAL STUDY OFCANCER DIAGNOSES…(5*) Sa1540. . . . . SERUM MONOMERIC LAMININ-Î“2 ASA NOVEL…(5*) Sa1541. . . . . HEPATIC DELIVERY OF THERAPEUTICAGENTS USING…(5*) Sa1542. . . . . PROGNOSTIC IMPACT OF HEPATITISB OR…(5*) Sa1543. . . . . NATURAL HISTORY OF SMALLSPORADIC NONFUNCTIONING…(5*)

Sa1544. . . . . THE DEVELOPMENT OF NON-INVASIVEMETHOD FOR…(5*) Sa1545. . . . . PROPOSAL OF HIGH RISKGROUP FOR…(5*) Sa1546. . . . . ASSOCIATION BETWEEN BODY MASSINDEX AND…(5*) Sa1547. . . . . HEPATOCELLULAR CARCINOMA IS NOWTHE LEADING…(5*) Sa1548. . . . . VALIDATION AND MODIFYING OFJAPANESE GRADING…(5*) Sa1550. . . . . EPA-ENRICHED NUTRITION AS ACOMBINED MODALITY…(5*) Sa1552. . . . . PROPHYLACTIC PERCUTANEOUS ENDOSCOPIC GASTROSTOMYFOR HEAD…(5*) Sa1554. . . . . OBESITY DOES NOT AFFECTADVERSE EVENT…(5*) Sa1556. . . . . DOES PRIOR ABDOMINAL SURGERYINCREASE THE…(5*) Sa1558. . . . . IMPACT AND OUTCOMES OFNUTRITIONAL SUPPORT…(5*) Sa1560. . . . . INPATIENT TREND ANALYSIS OFMECHANICAL COMPLICATION…(5*) Sa1572. . . . . FOOD-GRADE TIO2 PIGMENT INITIATESPRENEOPLASTIC LESIONS…(2*)|(4) Sa1574. . . . . INTER-ETHNIC DIFFERENCES IN COLONICRESPONSE OF…(4*) Sa1576. . . . . FATTY ACIDS IN AHIGH-FAT DIET…(4*) Sa1578. . . . . OBESITY MAY PLACE YOUNGMINORITIES AT…(5*) Sa1580. . . . . LONG NON-CODING RNAS: POTENTIALPREDICTORS OF…(2*)


* = Primary Source



Sa1582. . . . . ALTERATIONS IN GUT MICROBIOMECOULD PARTLY…(2*) Sa1583. . . . . ROLE OF SA1 POLYMORPHISMSIN METABOLIC…(5*) Sa1585. . . . . VITAMIN D DEFICIENCY INGASTROPARESIS AND…(2*) Sa1587. . . . . INCREASED DIETARY CARBOHYDRATE ISASSOCIATED WITH…(2*)|(6) Sa1589. . . . . A POTENTIAL MECHANISM FORDEVELOPING THIAMINE…(5*) Sa1643. . . . . INITIAL EXPERIENCE OF THEEVALUATION OF…(5*) Sa1644. . . . . ACOTIAMIDE IN COMBINATION WITHA STANDARD…(5*) Sa1645. . . . . SUSTAINED SYMPTOM RELIEF AFTERREVASCULARIZATION OF…(5*) Sa1646. . . . . THE IMPORTANCE OF HYPOCHONDRIASISIN DYSPEPTIC…(5*) Sa1647. . . . . TRANS-RADIAL ACCESS FOR ENDOVASCULARABDOMINAL INTERVENTIONS:…(5*) Sa1648. . . . . INFLUENCE OF GLUTEN INTAKEON FUNCTIONAL…(4*) Sa1649. . . . . VALIDATION OF A SCORECHART TO…(5*) Sa1650. . . . . HELICOBACTER PYLORI ERADICATION ALLEVIATESFD SYMPTOMS:…(5*) Sa1651. . . . . FLUORINE-LABELED BILE ACID LIVE-ANIMALMAGNETIC RESONANCE…(2*) Sa1652. . . . . SIMILARITIES IN PATIENTS WITHGASTROPARESIS AND…(5*) Sa1653. . . . . MEASUREMENT OF GUT PERMEABILITYUSING FLUORESCENT…(6*)|(3)| MediBeacon Inc.

Sa1654. . . . . FOOD AND FUNCTIONAL DYSPEPSIA:A SYSTEMATIC…(5*) Sa1655. . . . . FIRST DEFECATION TIME AFTERINGESTION OF…(5*) Sa1656. . . . . ERADICATION OF HELICOBACTER PYLORIALLEVIATES FUNCTIONAL…(5*) Sa1657. . . . . COMPARISON OF EFFICACY ANDSAFETY BETWEEN…(5*) Sa1658. . . . . THE MECHANISM OF GENDERDIFFERENCE IN…(3*)| |Tsumura & Co.) Sa1659. . . . . DETECTION OF INADEQUATE BOWELPREPARATIONS PRIOR…(1*)|(3)| Owlstone Medical Ltd. Sa1660. . . . . DUODENAL EOSINOPHILIA AND GASTROPARESIS:IS THERE…(4*) Sa1661. . . . . A NOVEL CAPSULE TECHNOLOGYPLATFORM FOR…(4*) Sa1662. . . . . THE IMPACT OF ROMEIV CRITERIA…(5*) Sa1663. . . . . THE UTILITY OF ENDOSCOPICULTRASONOGRAPHY IN…(4*) Sa1664. . . . . ANALYSIS OF POSTPRANDIAL SYMPTOMPATTERNS IN…(5*) Sa1665. . . . . COMPUTATIONAL MODELING OF DUCTALPRESSURE IN…(5*) Sa1666. . . . . IMPAIRED GASTRIC DISTRIBUTION OFA MEAL…(5*) Sa1667. . . . . EVALUATION OF AN IRREVERSIBLEELECTROPORATION ABLATIONS…(5*) Sa1668. . . . . DUODENAL EOSINOPHILIA IS ASSOCIATEDWITH EARLY…(4*) Sa1669. . . . . PIEZOELECTRIC SMALL VOLUME PRINTINGINTO

PLANAR…(2*)|(3)| Zcube (Zambon Research Ventures Sa1670. . . . . ASSESSMENT OF GASTROINTESTINAL MOTORFUNCTION WITH…(5*) Sa1671. . . . . ARE STATINS ASSOCIATED WITHUPPER GASTROINTESTINAL…(5*) Sa1672. . . . . JIANPILIQI FORMULA UPREGULATES NA+/HCO3-CO-TRANSPORTER 1…(2*) Sa1673. . . . . OBESITY IS QUITE PREVALENTIN PATIENTS…(5*) Sa1674. . . . . RANDOMIZED CONTROLLED TRIAL TOASSESS THE…(3*)|IM HealthScience Sa1675. . . . . EFFICACY OF CARAWAY OIL/L-MENTHOLPLUS USUAL…(3*)| IM HealthScience Sa1676. . . . . A CARAWAY OIL/MENTHOL COMBINATIONIMPROVES FUNCTIONAL…(3*)| IM HealthScience Sa1677. . . . . NOVEL DIAGNOSTIC APPROACH FORFUNCTIONAL HEARTBURN…(1*) Sa1678. . . . . MULTITARGET THERAPY BY STW5- THE…(3*)|(4)| The study received research funds from the Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health Care. Sa1679. . . . . DIRECT OBSERVATION OF MUCOSALSURFACES AND…(2*) Sa1680. . . . . SEX DIFFERENCES IN FECALINCONTINENCE: RESULTS…(3*)| |Ironwood) Sa1681. . . . . CLINICAL AND ECONOMIC IMPACTOF A…(1*) Sa1682. . . . . IDENTIFICATION OF A NOVELPATTERN OF…(5*) Sa1683. . . . . BASELINE SEVERITY PREDICTS OUTCOMEOF INSTRUMENTED…(5*)


* = Primary Source



Sa1684. . . . . BALLOON EXPULSION TESTING INA LARGE…(5*) Sa1685. . . . . ENDORECTAL BALLOON (ERB) DURINGIMAGE GUIDED…(4*) Sa1686. . . . . SHELF LIFE OF ENGINEEREDAUTOLOGOUS BIOSPHINCTERS…(2*) Sa1687. . . . . ANORECTAL PHYSIOLOGY TESTING INâ€˜ASYMPTOMATICâ€™ OBSTETRIC…(5*) Sa1688. . . . . LONG TERM RESULTS OFSACRAL NERVE…(5*) Sa1689. . . . . ANAL SPHINCTER FUNCTION EVALUATEDBY 3D…(5*) Sa1690. . . . . RISK FACTORS FOR FECALINCONTINENCE IN…(5*) Sa1691. . . . . RECTAL ENDOSCOPIC MUCOSAL RESECTIONIS SUPERIOR…(4*) Sa1692. . . . . HIGH FREQUENCY ULTRASOUND IMAGINGOF THE…(2*) Sa1693. . . . . IMPAIRED RECTAL EVACUATION ANDRECTAL STRUCTURAL…(5*) Sa1694. . . . . PICTOGRAMS ARE USEFUL FORTHE IDENTIFICATION…(5*) Sa1695. . . . . A SYSTEMATIC REVIEW ANDMETA-ANALYSIS TO…(5*) Sa1696. . . . . HISTORY OF DISORDERED EATINGWITH RESTRICTIVE…(5*) Sa1697. . . . . HIGH DEFINITION ANORECTAL MANOMETRYVERSUS HIGH…(5*) Sa1698. . . . . IS THERE DIAGNOSTIC GAINOR LOSS…(5*) Sa1699. . . . . USEFULNESS OF BIOFEEDBACK TRAININGWITH NOVEL…(2*)|(3)| InControl Medical Company, WI, USA

Sa1700. . . . . FECOBIONICS: A NOVEL BIONICTEST OF…(4*) Sa1701. . . . . EFFECT OF RECTAL DISTENTIONON ANAL…(5*) Sa1702. . . . . EVALUATION OF ANORECTAL FUNCTIONBY HIGH…(5*) Sa1703. . . . . PHENOTYPE IDENTIFICATION OF PATIENTSWITH DEFECATORY…(5*) Sa1704. . . . . SEX DIFFERENCES IN ANORECTALPRESSURES AND…(2*) Sa1705. . . . . A PRACTICE AUDIT ONTHE EFFECTIVENESS…(5*) Sa1706. . . . . INTERMODALITY AGREEMENT BETWEEN CONTRAST-ENHANCEDULTRASONOGRAPHY AND…(5*) Sa1707. . . . . MECHANISMS OF REPETITIVE, RETROGRADECONTRACTIONS: A…(2*) Sa1708. . . . . NARROW BAND IMAGING GUIDEDBIOPSY IMPROVES…(5*) Sa1709. . . . . LONG-TERM SYMPTOMATIC OUTCOMES AMONGPATIENTS WITH…(2*) Sa1710. . . . . MEASUREMENT OF PANCREATIC SIZEIN A…(2*) Sa1711. . . . . LOWER ESOPHAGEAL SPHINCTER (LES)RECEPTIVE RELAXATION…(5*) Sa1712. . . . . THE ASSOCIATION OF RADIOGRAPHICAND HIGH-RESOLUTION…(2*) Sa1713. . . . . ALTERED ESOPHAGEAL MECHANOSENSITIVITY OFSECONDARY PERISTALSIS…(4*) Sa1714. . . . . INFLUENCE OF GABAB AGONISTBACLOFEN ON…(4*)

Sa1715. . . . . BODY MASS INDEX, ESOPHAGEALDYSMOTILITY, AND…(5*) Sa1716. . . . . ESOPHAGOGASTRIC JUNCTION OUTFLOW OBSTRUCTIONIS DISCRIMINATED…(2*) Sa1717. . . . . ACHALASIA DESPITE NORMAL INTEGRATEDRELAXATION PRESSURE…(5*) Sa1718. . . . . THE TIMED BARIUM ESOPHAGRAMSURFACE AREA…(5*) Sa1719. . . . . AN INCREASED PREVALENCE OFNEURODEGENERATIVE/DEMYELINATING PROCESSES…(4*) Sa1720. . . . . JACKHAMMER ESOPHAGUS: CLINICAL, FUNCTIONALAND THERAPEUTIC…(1*) Sa1721. . . . . ASSESSMENT FOR SYSTEMIC SCLEROSISAND CONNECTIVE…(5*) Sa1722. . . . . IN INEFFECTIVE ESOPHAGEAL MOTILITY,FAILED SWALLOWS…(5*) Sa1723. . . . . UPPER ESOPHAGEAL SPHINCTER (UES)METRICS ON…(5*) Sa1724. . . . . HIGH RESOLUTION MANOMETRY WITHA STANDARDIZED…(5*) Sa1725. . . . . SAFETY AND TOLERABILITY OFHIGH-RESOLUTION ESOPHAGEAL…(5*) Sa1726. . . . . IN PATIENTS WITH ACHALASIA,THE IRP…(4*) Sa1727. . . . . EGJ OUTFLOW OBSTRUCTION ISOFTEN ASSOCIATED…(5*) Sa1728. . . . . MANOMETRIC SUBTYPES OF INEFFECTIVEESOPHAGEAL MOTILITY…(5*) Sa1729. . . . . LOWER ESOPHAGEAL SPHINCTER PRESSURESIN ADULT…(5*)


* = Primary Source



Sa1730. . . . . MICROSCOPIC ASSESSMENT OF THELOWER ESOPHAGEAL…(2*) Sa1731. . . . . RELATIONSHIP BETWEEN ESOPHAGEAL MOTILITYABNORMALITIES AND…(5*) Sa1732. . . . . COMBINATION ASSESSMENT OF ESOPHAGO-GASTRICJUNCTION MORPHOLOGY…(5*) Sa1733. . . . . INCREASED EX-VIVO PRODUCTION OFPRO-INFLAMMATORY CYTOKINES…(6*)| Anemgi Onlus Sa1734. . . . . RAPID DRINK CHALLENGE (RDC)DURING ESOPHAGEAL…(5*) Sa1735. . . . . LOW BASELINE IMPEDANCE INPROXIMAL ESOPHAGUS…(4*) Sa1736. . . . . THE EFFECT OF BODYPOSTURE ON…(5*) Sa1737. . . . . 24-H ESOPHAGEAL PH/IMPEDANCE MONITORINGPROFILES IN…(5*) Sa1738. . . . . BOLUS CLEARANCE AND SEVERITYOF SYMPTOMS…(5*) Sa1739. . . . . LOSS OF PERISTALTIC RESERVEIS THE…(5*) Sa1740. . . . . ESOPHAGEAL SYMPTOMS ARE COMMONAND RELATED…(2*) Sa1741. . . . . FUNCTIONAL AND ANATOMICAL MORPHOLOGYOF THE…(2*) Sa1742. . . . . THE CLINICAL VALUE OFPSYCHOLOGICAL INTERVENTIONS…(5*) Sa1743. . . . . PNEUMATIC DILATION IS ADURABLE NON-SURGICAL…(5*) Sa1744. . . . . CORRELATION BETWEEN THE COMPUTERGENERATED HIGH-RESOLUTION…(5*)

Sa1745. . . . . DISRUPTION OF RESTING BRAINFUNCTIONAL CONNECTIVITY…(4*) Sa1746. . . . . PERORAL CHOLANGIOPANCREATOSCOPY WITH SPYGLASS®SYSTEM: A…(5*) Sa1747. . . . . SYNCHRONIZED VIDEORADIOGRAPHY, S-EMG ANDMANOMETRY. A…(4*)|(1) Sa1748. . . . . EUS-GUIDED ENTERO-ENTEROSTOMY USING LUMEN-APPOSINGMETAL STENTS…(5*) Sa1749. . . . . FEASIBILITY AND TESTING OFGROUP HRM…(2*) Sa1750. . . . . PHARYNGEAL PERISTALTIC PRESSURE VARIABILITY,OPERATIONAL RANGE…(2*) Sa1751. . . . . REVERSAL OF PHARYNGEAL CONSTRICTORSARCOPENIA BY…(2*) Sa1752. . . . . EFFECT OF A NOVELSTRENGTH TRAINING…(2*) Sa1753. . . . . PERILS AND PROMISES OFPHARYNGEAL AND…(2*) Sa1754. . . . . ESOPHAGEAL DYSPHAGIA SCREENING: IMPROVINGTHE DIAGNOSTIC…(5*) Sa1755. . . . . AGE RELATED DIFFERENCES INTHE EFFECT…(2*) Sa1756. . . . . METFORMIN DOES NOT REDUCETHE RISK…(5*) Sa1757. . . . . ENDOSCOPIC SCORE MAY HELPDIFFERENTIATE PPI-REE…(5*) Sa1758. . . . . IMPACT OF THE WEEKENDEFFECT ON…(5*) Sa1759. . . . . EVALUATION OF DISEASE SEVERITYAND QUALITY…(2*)

Sa1760. . . . . EFFECTIVENESS OF SECOND-LINE HELICOBACTERPYLORI ERADICATION:…(2*)|(4) Sa1761. . . . . THE EPIDEMIOLOGY OF EOSINOPHILICESOPHAGITIS IN…(5*) Sa1762. . . . . ANTIBIOTICS VERSUS NO ANTIBIOTICSFOR UNCOMPLICATED…(5*) Sa1763. . . . . ENDOSCOPIC FINDINGS IN CHILDRENWHO ARE…(5*) Sa1764. . . . . SESSILE SERRATED POLYP (SSP)DETECTION RATES…(5*) Sa1765. . . . . HIGH BURDEN OF PERSISTENTGASTROINTESTINAL SYMPTOMS…(2*) Sa1766. . . . . A SYSTEMATIC REVIEW OF THE SF-36®…(3*)| |Pfizer Inc Sa1767. . . . . ETHNIC DISPARITIES IN PHENOTYPEAND HISTOPATHOLOGY…(5*) Sa1768. . . . . REAL WORLD EFFECTIVENESS OFVEDOLIZUMAB OVER…(3*)| This meta-analysis was sponsored by Takeda Pharmaceuticals Company Ltd. Sa1769. . . . . ESOPHAGEAL DISTENSIBILITY AS APREDICTOR OF…(5*) Sa1770. . . . . THE SF-36® HEALTH SURVEYDISTINGUISHES DISEASE…(3*)| |Pfizer Inc) Sa1771. . . . . SLEEP PATTERNS IN PEDIATRICCROHN'S DISEASE…(2*) Sa1772. . . . . IS PERORAL ENDOSCOPIC MYOTOMY(POEM) SAFER…(5*) Sa1773. . . . . THE FIRST REPORTED PEDIATRICCASE OF…(5*) Sa1774. . . . . BONE HEALTH IN CHILDRENWITH INTESTINAL…(5*)


* = Primary Source



Sa1775. . . . . MANAGEMENT OF UNCOMPLICATED ESOPHAGEALFOOD IMPACTION…(2*) Sa1776. . . . . CONUNDRUMS WITH REFLUX-TYPE OFSYMPTOMS IN…(2*) Sa1777. . . . . ALBUMINURIA IN CHILDREN WITHUNTREATED CELIAC…(4*) Sa1778. . . . . ASSESSING THE NEED FORSMALL BOWEL…(5*) Sa1779. . . . . SERUM AMYLASE AND LIPASEPATTERNS IN…(4*) Sa1780. . . . . IMPROVING SCREENING OF VITAMIND STATUS…(5*) Sa1781. . . . . IMPROVEMENT IN ECKARDT SCOREWITH PERORAL…(5*) Sa1782. . . . . THE USE OF ACOMPUTERIZED PROVIDER…(2*) Sa1783. . . . . ADRENAL INSUFFICIENCY IN CHILDRENWITH EOSINOPHILIC…(5*) Sa1784. . . . . NOVEL WEB-BASED PILOT PEDIATRICGI FELLOWSHIP…(5*) Sa1785. . . . . UPPER GASTROINTESTINAL INVOLVEMENT INCHILDREN WITH…(5*) Sa1786. . . . . INTUSSUSCEPTIONS ALONG GASTROJEJUNOSTOMY TUBES:KNOWN COMPLICATION…(5*) Sa1787. . . . . ENVIRONMENTAL ENTEROPATHY IN PAKISTANICHILDREN: CLINICAL…(6*)|(2) Sa1873. . . . . CLOSTRIDIUM DIFFICILE FECAL TOXINLEVEL IS…(5*) Sa1874. . . . . CHANGE IN MORTALITY TRENDOF HOSPITALIZED…(5*) Sa1875. . . . . CHARACTERISTICS AND OUTCOMES INPATIENTS WITH…(3*)| Merck & Co., Inc., Ke worth, NJ, USA

Sa1876. . . . . RISING INCIDENCE OF MULTIPLY-RECURRENTCLOSTRIDIUM DIFFICILE…(2*) Sa1877. . . . . FECAL MICROBIOTA TRANSPLANT FORC DIFFICILE…(5*) Sa1878. . . . . SUCCESSFUL THERAPY OF CLOSTRIDIUMDIFFICILE INFECTION…(5*) Sa1879. . . . . PREVALENCE AND RECURRENCE OFCLOSTRIDIUM DIFFICILE…(5*) Sa1880. . . . . THE RELATIONSHIP BETWEEN CHOLECYSTECTOMYAND THE…(5*) Sa1881. . . . . OUTCOMES OF FECAL MICROBIOTATRANSPLANTATION FOR…(5*) Sa1882. . . . . PREVALENCE OF EARLY ANTIBIOTICUSE POST-FECAL…(5*) Sa1883. . . . . EFFICACY OF BEZLOTOXUMAB INPATIENTS WITH…(3*)| Merck & Co., Inc. Sa1884. . . . . TREATMENT OF RECURRENT CLOSTRIDIUMDIFFICILE INFECTION…(5*) Sa1885. . . . . SUCCESSFUL RESOLUTION OF RECURRENTCLOSTRIDIUM DIFFICILE…(4*)|(2)| CIPAC Limited Sa1886. . . . . CLOSTRIDIUM DIFFICILE INFECTIONS ANDASSOCIATED TRANSPLANT…(5*) Sa1887. . . . . HIGH PREVALENCE OF SUBCLASS-SPECIFICBINDING AND…(4*) Sa1888. . . . . DETECTING OUTCOMES FROM CLOSTRIDIUMDIFFICILE SCREENING…(5*) Sa1889. . . . . USE OF PROPHYLACTIC SACCHAROMYCESBOULARDI I…(4*) Sa1890. . . . . SPECIFIC HOSPITAL ROOMS AREASSOCIATED WITH…(7*)

Sa1891. . . . . DO STATINS DECREASE THESEVERITY OF…(5*) Sa1892. . . . . OUTCOMES AND MANAGEMENT OFPATIENTS WITH…(5*) Sa1893. . . . . EFFICACY AND SAFETY OFORAL, CAPSULIZED,…(5*) Sa1894. . . . . ADVERSE EFFECTS OF LIQUIDVS. ENCAPSULATED…(1*) Sa1895. . . . . READMISSIONS AFTER HOSPITALIZATION FORCLOSTRIDIUM DIFFICILE…(5*) Sa1896. . . . . ZINC DEFICIENCY PREDICTS FECALMICROBIOTA TRANSPLANT…(4*) Sa1897. . . . . OPIOIDS IN CLOSTRIDIUM DIFFICILEINFECTIONS: DECREASING…(5*) Sa1898. . . . . ORALLY ACTIVE CATHELICIDIN MIMICCERAGENIN CSA13…(2*) Sa1899. . . . . PROPHYLACTIC FECAL MICROBIAL TRANSPLANTRESTORES CLOSTRIDIUM…(2*)|(4) Sa1900. . . . . CURRENT OR PAST CLOSTRIDIUMDIFFICILE INFECTION…(5*) Sa1901. . . . . OUTCOMES IN PATIENTS WITHRECURRENT CLOSTRIDIUM…(4*) Sa1902. . . . . A PROSPECTIVE STUDY ONTHE INCIDENCE,…(3*)| Astellas Sa1903. . . . . DO SPECIFIC BACTERIA DRIVECLINICAL CURE…(6*) Sa1905. . . . . BMI1 MARKS ACTIVELY CYCLINGGASTRIC STEM…(5*) Sa1906. . . . . LYSOPHOSPHATIDIC ACID RECEPTOR 5IS ESSENTIAL…(4*)|(2) Sa1907. . . . . CLONING COLONIC STEM CELLSOF ULCERATIVE.COLITIS…(7*)|(4)


* = Primary Source



Sa1908. . . . . STROMAL-EPITHELIAL CROSS-TALK IN THEINTESTINAL STEM…(2*) Sa1909. . . . . ISOLATION OF STEM-LIKE CELLSFROM DEEP…(2*) Sa1910. . . . . DEVELOPMENT OF A NOVELHYBRID TREATMENT…(5*) Sa1911. . . . . CHARACTERIZATION OF NOVEL METAPLASTICORGANOIDS DRIVEN…(2*) Sa1912. . . . . USING FUNCTIONAL ASSAYS INPATIENT-DERIVED ENTEROIDS…(2*)|(4) Sa1913. . . . . GROWTH OF MINIGUTS ISOLATEDFROM ALTERED…(6*)|(4) Sa1914. . . . . EFFECT OF CYTOKINES ONTHE GROWTH…(6*)|(4) Sa1915. . . . . MORPHOLOGY OF VARIOUS CANCERCELLS USING…(5*) Sa1916. . . . . NOVEL IMMUNOMODULATORY ROLE OFASPARTATE AND…(2*) Sa1917. . . . . OPTIMIZING THE DEVELOPMENT ANDCHARACTERIZATION OF…(4*) Sa1918. . . . . UPREGULATED CLAUDIN-1 EXPRESSION IMPEDESRECOVERY FROM…(2*)|(4) Sa1919. . . . . IMMUNE PROFILE OF THETUMOR MICROENVIRONMENT…(2*) Sa1920. . . . . OVEREXPRESSION OF DARPP-32 PROMOTESACTIVATION OF…(2*) Sa1921. . . . . FAECALIBACTERIUM PRAUSNITZII PREVENTS TUMORIGENESISIN A…(5*) Sa1922. . . . . PROSTAGLANDIN E2 ACTIVATES YAPAND A…(2*)|(4)

Sa1923. . . . . ALMOREXANT: A NEW PROMISINGMOLECULE IN…(6*) Sa1924. . . . . MSI-L/EMAST, A POOR OUTCOMEBIOMARKER FOR…(2*)|(4) Sa1925. . . . . THE ETHNIC DISTRIBUTION OFSESSILE SERRATED…(5*) Sa1926. . . . . UTILITY OF IMMUNOSTAINING INTHE DIAGNOSIS…(5*) Sa1927. . . . . DUODENAL BIOPSIES DIAGNOSE WALDENSTRÃ–MMACROGLOBULINEMIA …(5*) Sa1928. . . . . MUCOSAL INFLAMMATION, NOT MICROBIOME,DRIVES THE…(2*) Sa1929. . . . . DNA VARIANTS IN HELICOBACTERPYLORI INFECTED…(4*) Sa1930. . . . . VARIATIONS IN THERAPY FORINFLAMMATORY BOWEL…(6*)|(2) Sa1931. . . . . INCREASED SERO-REACTIVITY TO ANTIGENSOF FIRMICUTES…(3*)| Support for this study was provided by Janssen Pharmaceuticals and Prometheus Laboratories under a Cooperative Research andDevelopment Agreement entitled ‘Antimicrobial antibodies as predictors of inflammatory bowel diseases’ NCRADA number NMR-11-3920. Sa1932. . . . . CHANGES IN MORTALITY INPATIENTS WITH…(5*) Sa1933. . . . . AN UPDATE ON THENATURAL COURSE…(5*) Sa1934. . . . . GENETIC ASSOCIATIONS WITH VISCERALFAT DEPOSITION…(2*)|(4) Sa1935. . . . . PERIANAL DISEASE: FAR BEYONDA SIMPLE…(5*) Sa1936. . . . . OUTCOMES IN PATIENTS WITHCROHN'S DISEASE:…(5*)

Sa1937. . . . . COMPLICATIONS OF NEWLY DIAGNOSEDCROHN'S DISEASE…(6*) Sa1938. . . . . INCIDENCE OF CLINICAL FLARE-UPIN PATIENTS…(5*) Sa1940. . . . . THE PREVALENCE AND PREDICTORSOF ANTI-TNF…(3*)| |Janssen Canada) Sa1941. . . . . INFLAMMATORY BOWEL DISEASE ISASSOCIATED WITH…(5*) Sa1942. . . . . SUPERFICIAL CROHN'S DISEASE ANDAN OBSERVATIONAL…(5*) Sa1943. . . . . PERIPHERAL EOSINOPHILIA AS APREDICTOR OF…(5*) Sa1944. . . . . SEROLOGIC AND GENETIC MARKERSMAY HELP…(5*) Sa1945. . . . . ANTI-TNFS MORE FREQUENTLY STOPPEDDUE TO…(6*) Sa1946. . . . . SURGICAL OUTCOMES AMONG INFLAMMATORYBOWEL DISEASE…(5*) Sa1947. . . . . ROLE OF ASSISTED REPRODUCTIVETECHNOLOGIES IN…(6*) Sa1948. . . . . ROLE OF PATHOGENIC BACTERIAIN DISEASE…(5*) Sa1949. . . . . PREFERENCES FOR CARE FORACTIVE SYMPTOMS…(3*)| Abbvie Canada Sa1950. . . . . A SURVEY OF PATIENTVIEWS OF…(2*) Sa1951. . . . . POOR CONSUMPTION OF FIBER,NOT FAT,…(5*) Sa1952. . . . . PHENOTYPIC PREDICTORS OF ENDOSCOPICRECURRENCE AFTER…(2*) Sa1953. . . . . HYPERTROPHIC AND CONSTRICTIVE ILEALSTRICTURES IN…(6*)|(7)


* = Primary Source



Sa1954. . . . . DE-NOVO INFLAMMATORY BOWEL DISEASEAFTER BARIATRIC…(5*) Sa1955. . . . . IMPACT OF BARIATRIC SURGERYON THE…(5*) Sa1956. . . . . PHENOTYPIC CHARACTERISATION OF ELDERLYAND ONSET…(5*) Sa1957. . . . . VARIATIONS IN PHENOTYPE ANDHEALTHCARE UTILIZATION…(4*) Sa1958. . . . . THE NOVEL ISOFORMS 1AND 4…(1*)|(2) Sa1959. . . . . FACTORS ASSOCIATED WITH STEROID-FREECLINICAL REMISSION…(5*) Sa1960. . . . . STRUCTURED TRANSITION ENHANCES CLINICALOUTCOME WITHOUT…(3*) Sa1961. . . . . DISEASE PROGRESSION IN PUERTORICANS WITH…(5*) Sa1962. . . . . THE IMPACT OF CLOSTRIDIUMDIFFICILE INFECTION…(5*) Sa1963. . . . . PREGNANT WOMEN WITH INFLAMMATORYBOWEL DISEASE…(5*) Sa1964. . . . . HIGH RISK OF POUCHDYSPLASIA IN…(5*) Sa1965. . . . . PREDICTORS OF CLINICAL ANDENDOSCOPIC RESPONSE…(4*)|(3)| Statistical analyses were conducted at the University of California, San Diego and funded in part by Takeda Pharmaceuticals Sa1966. . . . . INTERNATIONAL DIFFERENCES IN GASTROENTEROLOGISTS'PERSPECTIVE ON…(2*) Sa1967. . . . . REAL-WORLD TREATMENT PATHWAY VISUALIZATIONSSHOW LOW…(3*)| This study was sponsored by Celgene Corporation.

Sa1968. . . . . IS HIGH GLOBULIN FRACTIONA BIOMARKER…(5*) Sa1969. . . . . PREDICTORS OF LONG-TERM OUTCOMESIN PATIENTS…(5*) Sa1970. . . . . RACIAL DISPARITIES IN READMISSIONRATES, PROCEDURES…(5*) Sa1971. . . . . 5-AMINOSALICYLIC ACID AND STATINUSE ARE…(5*)| The Hong Kong IBD Registry was supported by unrestricted educational grant from Abbvie pharmaceuticals, Hong Kong. Sa1972. . . . . PROXIMAL DISEASE EXTENSION INPATIENTS WITH…(5*) Sa1973. . . . . THE IMPACT OF HEPATITISC ON…(5*) Sa1974. . . . . OPTIMIZING SURVEILLANCE COLONOSCOPY FORULCERATIVE.COLITIS-ASSOCIATED COLORECTAL…(2*)| Research Group for Intractable Inflammatory Bowel Disease of the Ministry of Health, Labour and Welfare of Japan) Sa1975. . . . . HISTOLOGICAL CHARACTERISTICS OF IBD-ASSOCIATEDDYSPLASIA IN…(6*) Sa1976. . . . . INTRA-ABDOMINAL ABSCESS SIZE ANDTHE USE…(2*) Sa1977. . . . . ASSOCIATION BETWEEN IBD DISABILITYAND REDUCED…(3*)| Abbvie Canada Sa1978. . . . . PERSISTENT INTESTINAL INFLAMMATION LEADSTO SURGERY…(5*) Sa1979. . . . . RACIAL DIFFERENCES IN DISEASEPROGRESSION AND…(2*) Sa1980. . . . . THE MODIFIED POSTOPERATIVE ENDOSCOPICRECURRENCE SCORE…(5*) Sa1982. . . . . WHAT ARE THE MOSTCOMMON SYMPTOMS…(2*)

Sa1983. . . . . CURRENT PRACTICES IN ILEALPOUCH SURVEILLANCE…(5*) Sa1984. . . . . A PROSPECTIVE STUDY TOPREDICT A…(3*)| Ferring Arzneimittel GmbH Sa1985. . . . . ASSOCIATION OF OBESITY WITHIBD DISEASE…(5*) Sa1986. . . . . NATURAL HISTORY AND PHENOTYPEOF INFLAMMATORY…(1*) Sa1987. . . . . A NOVEL USER-FRIENDLY MODELTO IDENTIFY…(5*) Sa1988. . . . . CLINICAL PREDICTORS OF DISEASEEXTENSION IN…(2*) Sa1989. . . . . HISTOLOGICAL FEATURES IN PAIREDILEAL RESECTIONS…(6*)|(7) Sa1990. . . . . SEVERELY ACTIVE ULCERATIVE COLITISIS ASSOCIATED…(5*) Sa1991. . . . . RECENT ANTI-TNF EXPOSURE PREDICTSLOWER VEDOLIZUMAB…(5*) Sa1992. . . . . UBE2L3, ANCA, ASCA, ANDCBIR1 ARE…(2*) Sa1993. . . . . PROACTIVE COMPARED TO REACTIVETHERAPEUTIC DRUG…(5*) Sa1994. . . . . LONG-TERM OUTCOMES OF PROACTIVEVERSUS REACTIVE…(5*) Sa1995. . . . . INFLIXIMAB CONCENTRATION THRESHOLDS DURINGMAINTENANCE THERAPY…(5*) Sa1996. . . . . ANTIBODIES TOWARDS VEDOLIZUMAB APPEARFROM WEEK…(5*) Sa1997. . . . . APPLICATION OF DRIED BLOODSPOTS FOR…(3*)| IIS#55038 from MSD Belgium Sa1998. . . . . HYDROCORTISONE PREMEDICATION WITHDRAWAL INPATIENTS ON…(5*)


* = Primary Source



Sa1999. . . . . EARLY SUPPRESSION OF THESEROLOGICAL MACROPHAGE…(4*) Sa2000. . . . . SEROLOGICAL BIOMARKERS OF TISSUETURNOVER CAN…(4*) Sa2001. . . . . RAPID DETECTION OF ANTI-INFLIXIMABANTIBODIES IN…(5*) Sa2002. . . . . SWITCHING FROM INFLIXIMAB ORIGINATORTO CT-P13…(5*) Sa2003. . . . . DEFINITION OF THERAPEUTIC RESPONSECRITERIA USING…(5*) Sa2004. . . . . HIGHER VEDOLIZUMAB TROUGH LEVELSASSOCIATED WITH…(3*) Sa2005. . . . . SERUM INTERLEUKIN-6 LEVEL PREDICTSSHORT-TERM CLINICAL…(5*) Sa2006. . . . . A NOVEL APPROACH TOTHE IMPLEMENTATION…(5*) Sa2007. . . . . ENDOSCOPIC RESPONSE TO INDUCTIONTHERAPY WITH…(5*) Sa2008. . . . . PREDICTORS OF TISSUE HEALINGIN ULCERATIVE.COLITIS…(5*) Sa2009. . . . . RELATIONSHIP BETWEEN SEVERE ENDOSCOPICLESIONS AND…(5*) Sa2010. . . . . IDENTIFICATION OF GENETIC SIGNATURESAND IMMUNE…(5*) Sa2011. . . . . ANTIBODIES TO INFLIXIMAB INPATIENTS TREATED…(5*) Sa2012. . . . . FREQUENT CONVERSION OF TUBERCULOSISSCREENING TEST…(2*)| Unrestricted educational grant from Janssen Pharmaceuticals. Sa2013. . . . . FINAL RESULTS ON IMMUNOGENICITYPROFILE AND…(2*)

Sa2014. . . . . ADALIMUMAB MAINTENANCE CONCENTRATION THRESHOLDSDIFFER DEPENDING…(5*) Sa2015. . . . . A NOVEL AND SIMPLEREGIMEN FOR…(5*) Sa2016. . . . . TROUGH LEVELS AND ANTIBODIESTO USTEKINUMAB…(5*) Sa2017. . . . . A TARGET 6-THIOGUANINE NUCLEOTIDELEVEL â‰¥…(5*) Sa2018. . . . . UNDERESTIMATION OF FECAL LOSSOF INFLIXIMAB…(5*) Sa2019. . . . . HIGHER VEDOLIZUMAB LEVELS AREASSOCIATED WITH…(4*)|(3)| Promtheus Laboratories Sa2020. . . . . VARIATIONS IN INTERPRETATION OFTHERAPEUTIC DRUG…(4*) Sa2021. . . . . POTENTIAL OUT-OF-POCKET COSTS NEGATIVELYINFLUENCE THE…(5*)|(2) Sa2022. . . . . LONG-TERM OUTCOMES OF ANTI-TNFTHERAPY DISCONTINUATION…(5*) Sa2023. . . . . ATTITUDE AND BARRIERS TOWARDSTHE IMPLEMENTATION…(5*) Sa2024. . . . . TROUGH LEVELS AT INDUCTION:IMPACT ON…(5*) Sa2025. . . . . RAPID POINT-OF-CARE MONITORING OFANTI-INFLIXIMAB ANTIBODIES…(5*) Sa2026. . . . . THIOPURINES TREATMENT IN CHILDRENWITH INFLAMMATORY…(5*) Sa2027. . . . . PROACTIVE MONITORING OF INFLIXIMAB(IFX) AND…(5*) Sa2028. . . . . FACTORS INFLUENCING CLEARANCE OFADALIMUMAB IN…(5*) Sa2029. . . . . ANTI-INFLIXIMAB ANTIBODY CONCENTRATIONS

GUIDETHERAPEUTIC DECISION-MAKING…(2*)| This study was financially supported in part by TBM grant T003716N of the Research Foundation – Flanders (FWO), Belgium. Sa2030. . . . . ANTI-TNF FOR POST-OPERATIVE PREVENTIONIN CROHN'S…(6*)|(2) Sa2031. . . . . SERUM ADALIMUMAB TROUGH LEVELSREQUIRED FOR…(2*)|(1) Sa2032. . . . . FINAL RESULTS ON EFFICACYAND SAFETY…(2*) Sa2033. . . . . THE INTRODUCTION OF INFLIXIMABTHERAPEUTIC DRUG…(5*) Sa2034. . . . . ASSESSMENT OF THE USEOF THERAPEUTIC…(5*) Sa2035. . . . . MONOCYTOSIS AS A BIOMARKERTO PREDICT…(5*) Sa2036. . . . . SERUM ADALIMUMAB LEVELS PREDICTSUCCESSFUL REMISSION…(2*) Sa2037. . . . . BIOMARKERS CALPROTECTIN AND C-REACTIVEPROTEIN CUT-OFF…(4*)|(5) Sa2038. . . . . INVESTIGATION OF THE INVITRO STABILITY…(3*)| IDKmonitor® Golimumab ELISA kits supplied free of charge by Biohit healthcare. Sa2039. . . . . IMPACT OF THE DURATIONOF COMBINATION…(1*) Sa2041. . . . . EFFICACY OF VEDOLIZUMAB ONEXTRAINTESTINAL MANIFESTATION…(5*) Sa2042. . . . . THERE IS NO DIFFERENCEIN SHORT-TERM…(5*) Sa2043. . . . . EFFECTIVENESS AND SAFETY OFCT-P13 UNDER…(3*)


* = Primary Source



Sa2044. . . . . DISCONTINUATION OF CORTICOSTEROIDS AMONGULCERATIVE COLITIS…(3*)| The study was funded by Takeda Development Centre Europe Ltd. No medical writing assistance was provided. Sa2045. . . . . DISCONTINUATION OF CORTICOSTEROIDS AMONGCROHN'S DISEASE…(3*)| The study was funded by Takeda Development Centre Europe Ltd. Sa2046. . . . . USTEKINUMAB FOR THE TREATMENTOF CROHN…(5*) Sa2047. . . . . COMBINATION THERAPY OF VEDOLIZUMABAND A…(5*) Sa2048. . . . . EVALUATION OF TREATMENT PERSISTENCEOF VEDOLIZUMAB…(3*)| This study was funded by Takeda Oy. Sa2049. . . . . BIOSIMILAR INFLIXIMAB IN ANTI-TNFNAIVE IBD…(5*) Sa2050. . . . . INTENSIFIED INFLIXIMAB RESCUE THERAPYFOR ACUTE…(5*) Sa2051. . . . . EXCLUSIVE ENTERAL NUTRITION INADULTS WITH…(5*) Sa2052. . . . . NO INCREASE IN IMMUNOMODULATORUSE IN…(5*) Sa2053. . . . . INFLIXIMAB RE-INTRODUCTION AFTER TEMPORARYDISCONTINUATION: A…(5*) Sa2054. . . . . ULCERATIVE.COLITIS PATIENTS ON VEDOLIZUMABLACKING RESPONSE…(5*) Sa2055. . . . . COMBINATION THERAPY WITH ADALIMUMABAND IMMUNOMODULATORS…(5*) Sa2056. . . . . EFFICACY AND TOLERABILITY OFTHE AUTOIMMUNE…(4*) Sa2057. . . . . EFFICACY AND SAFETY OFSWITCHING FROM…(5*)

Sa2058. . . . . INFLIXIMAB (IFX) IN MODERATETO SEVERE…(5*) Sa2059. . . . . EFFICACY OF VEDOLIZUMAB INREDUCING BILIARY…(1*) Sa2060. . . . . MACHINE LEARNING MODELS ATWEEK 6…(1*) Sa2061. . . . . ENDOSCOPIC NEEDLE KNIFE THERAPYIN THE…(5*) Sa2062. . . . . PILOT STUDY: SELECTIVE DEGLYCOSYLATIONOF TERMINAL…(2*) Sa2063. . . . . EFFICACY OF CALCINEURIN INHIBITORSDURING INDUCTION…(5*) Sa2064. . . . . VEDOLIZUMAB IS SAFE ANDEFFECTIVE FOR…(4*) Sa2065. . . . . MUCOSAL HEALING RATES INPATIENTS WITH…(5*) Sa2066. . . . . AN ELEVATED BODY MASSINDEX IS…(4*) Sa2067. . . . . VEDOLIZUMAB PERSISTENCE AND TOLERABILITYIN SPECIAL…(2*) Sa2068. . . . . EFFECTIVENESS AND SAFETY INCROHN'S DISEASE…(3*)| |Celltrion, Inc.) Sa2069. . . . . SUCCESSFUL DOSE DE-ESCALATION TOADALIMUMAB 40MG…(5*) Sa2070. . . . . IMMUNOSUPPRESSANT USE IN CHRONIC,ACTIVE MICROSCOPIC…(5*) Sa2071. . . . . USTEKINUMAB FOR THE TREATMENTOF PERIANAL…(4*) Sa2072. . . . . EFFECT OF SERUM ALBUMINLEVELS ON…(5*) Sa2073. . . . . PATIENTS WITH ULCERATIVE.COLITIS TAKINGASACOL HAVE…(4*)|(5)

Sa2074. . . . . SHORT-TERM OUTCOMES OF ADALIMUMABFOR PATIENTS…(5*) Sa2075. . . . . LOW-DOSE AZATHIOPRINE IMPROVES LONG-TERMEFFICACY OF…(5*) Sa2076. . . . . COLECTOMY RATE TWO YEARSAFTER SEQUENTIAL…(5*) Sa2077. . . . . MAINTENANCE THERAPY WITH LOWERDOSE 5-AMINOSALICYLATE…(5*) Sa2078. . . . . COULD THE HYPERBARIC OXYGENTHERAPY BE…(5*) Sa2079. . . . . RAPID IMPROVEMENT IN SYMPTOMSAND QUALITY…(4*) Sa2080. . . . . ARE ANTI-TUMOR NECROSIS FACTORSASSOCIATED WITH…(5*) Sa2081. . . . . USTEKINUMAB IS EFFECTIVE FORINDUCING CLINICAL,…(7*)| The Canadian Association of Gastroenterology Sa2082. . . . . DOES STATIN USE REDUCETHE RISK…(5*) Sa2083. . . . . ANTI-TNF THERAPY IN REFRACTORYPOUCHITIS AND…(5*) Sa2084. . . . . INTESTINAL ORGANOIDS DERIVED FROMINFLAMED TISSUES…(4*)|(2) Sa2085. . . . .REDUCED MITOCHONDRIAL FUNCTION IN THE INFLAMED…(2*)|(4) Sa2086. . . . . LACK OF INTESTINAL VDRREGULATION LEADS…(2*) Sa2087. . . . . RESVERATROL COUNTERACTS TNF-ALPHA-INDUCED INHIBITIONOF INTESTINAL…(2*) Sa2088. . . . . ENDOSCOPICALLY ASSISTED GLUCOSE BREATHTEST (EAGBT):…(5*)


* = Primary Source



Sa2089. . . . . COLIFORM AND UPPER RESPIRATORYTRACT BACTERIAL…(5*) Sa2090. . . . . TH-RELATED CYTOKINES PROMOTE FIBROSISTHROUGH HUMAN…(5*) Sa2091. . . . . COUNTERACTION OF ISCHEMIC COLITISLESION IN…(2*) Sa2092. . . . . MECHANISMS UNDERLYING THE NON-ANTICOAGULANTEFFECTS OF…(5*) Sa2093. . . . . ENTERIC PROTECTIVE EFFECTS OFTHE COMBINATION…(5*) Sa2094. . . . . IT DOESN'T TAKE ALOT OF…(5*) Sa2095. . . . . ARGON PLASMA COAGULATION ALONEOR IN…(5*) Sa2096. . . . . ELEVATED NO PRODUCTION ISPROTECTIVE AGAINST…(4*) Sa2097. . . . . ENDOSCOPIC FINDINGS ARE SIGNIFICANTFACTOR ASSOCIATED…(5*) Su1000. . . . . AFRICAN AMERICAN PATIENTS ARELESS LIKELY…(5*) Su1001. . . . . INSURANCE STATUS IMPACTS TREATMENTFOR HEPATOCELLULAR…(5*) Su1002. . . . . DISPARITIES IN THE TREATMENTOF HEPATOCELLULAR…(5*) Su1003. . . . . COLORECTAL CANCER AT ANURBAN VETERANS'…(5*) Su1004. . . . . EFFECT OF RACE ANDGENDER ON…(5*) Su1005. . . . . LOCATION OF HEALTHCARE DELIVERY(COUNTY VS…(5*) Su1006. . . . . PATHOLOGY AND DISTRIBUTION OFCOLONIC POLYPS…(5*)

Su1007. . . . . A COMPARISON OF HOSPITALIZATIONSOF AFRICAN-AMERICAN…(5*) Su1008. . . . . DISPARITIES IN CLINICAL OUTCOMESIN AFRICAN…(5*) Su1009. . . . . THE ASSOCIATION BETWEEN RACEAND THE…(5*) Su1010. . . . . CLINICAL FACTORS ASSOCIATED WITHHIGH-RISK PATIENTS…(5*) Su1011. . . . . TRENDS IN STATIN PRESCRIPTIONSAMONG PATIENTS…(5*) Su1012. . . . . UNINSURED PATIENTS WITH CIRRHOSISAND ASCITES…(5*) Su1013. . . . . IDENTIFYING GENDER BARRIERS FORENDOSCOPY ACCESS:…(5*) Su1014. . . . . RESOURCE UTILIZATION AND COLORECTALCANCER SCREENING…(6*) Su1015. . . . . LOW INCOME, AFRICAN AMERICANRACE AND…(5*) Su1016. . . . . FREQUENCY OF GASTROINTESTINAL SYMPTOMSOF DENGUE…(5*) Su1017. . . . . INCREASING ECONOMIC BURDEN OFINPATIENT IBD…(5*) Su1018. . . . . FACTORS THAT DELAY DISCHARGEAFTER ADMISSION…(1*) Su1019. . . . . ACUTE PANCREATITIS REGIONAL ANDDIVISIONAL COST…(4*) Su1021. . . . . A SUCCESSFUL PHARMACIST BASEDQUALITY INITIATIVE…(5*) Su1022. . . . . THE TRUE COST OFULCERATIVE COLITIS…(3*)| Allergan funded the release the acquisition of HES data

Su1023. . . . . IN-PATIENT HEALTHCARE UTILIZATION ASSOCIATEDWITH OBESITY:…(4*) Su1024. . . . . COST-EFFECTIVENESS OF MELANOMA SCREENINGIN INFLAMMATORY…(5*) Su1025. . . . . COST-EFFECTIVENESS OF INFLIXIMAB'S BIOSIMILARCT-P13 COMPARED…(2*)|(4) Su1026. . . . . 30-DAY UNPLANNED READMISSION RATES,COST AND…(5*) Su1027. . . . . DIRECT HEALTHCARE COSTS ASSOCIATEDWITH OSTEOPOROSIS…(3*)| Gilead Sciences, Inc. Su1028. . . . . THE TOTAL DIRECT COSTOF HEALTHCARE…(3*)| |Celgene) Su1029. . . . . COST-EFFECTIVENESS ANALYSIS OF HELICOBACTERPYLORI DIAGNOSTIC…(4*) Su1032. . . . . INTEROBSERVER AGREEMENT AFTER ADDITIONOF P53…(5*) Su1033. . . . . ADHERENCE TO QUALITY INDICATORSFOR THE…(5*) Su1034. . . . . RISK OF PROGRESSION AFTERA DIAGNOSIS…(2*)|(4) Su1035. . . . . META-ANALYSIS OF MISSED HIGHGRADE DYSPLASIA…(2*) Su1036. . . . . THE IMPACT OF BARRETT'SESOPHAGUS ON…(5*) Su1037. . . . . THE IMPACT OF SURVEILLANCEENDOSCOPY ON…(5*) Su1038. . . . . PREVALENCE AND PREDICTORS OFMISSED DYSPLASIA…(5*) Su1039. . . . . IMPACT OF SURVEILLANCE INBARRETT'S ESOPHAGUS…(2*)


* = Primary Source



Su1040. . . . . CANNABINOID RECEPTOR 1 ANDEPIDERMAL GROWTH…(5*) Su1041. . . . . YOUNGER AGE OF ONSETOF BARRETT'S…(5*) Su1042. . . . . ADHERENCE TO BARRETT'S ESOPHAGUSSURVEILLANCE GUIDELINES:…(5*) Su1043. . . . . EXTERNAL VALIDATION OF THEMICHIGAN BARRETT'S…(5*) Su1044. . . . . PROPORTION OF GASTROESOPHAGEAL REFLUXDISEASE AND…(5*) Su1045. . . . . TEN YEARS OF RADIOFREQUENCYABLATION (RFA)…(5*) Su1046. . . . . CASE-CONTROL STUDY OF THEPREVALENCE OF…(5*) Su1047. . . . . LOW RISK OF SUSPECTEDLONG SEGMENT…(4*) Su1048. . . . . BARRETT'S ESOPHAGUS SCREENING ANDSURVEILLANCE IS…(5*) Su1049. . . . . MUTATION STATUS OF BARRETT'SESOPHAGUS BIOPSIES…(4*) Su1050. . . . . RISK FACTORS FOR PROGRESSIONOF BARRETT'S…(5*) Su1051. . . . . USE OF MOLECULAR ANALYSISTO INFORM…(4*) Su1052. . . . . GENOMIC TESTING OF ENDOSCOPICBIOPSIES AID…(2*) Su1053. . . . . NEOPLASTIC PROGRESSION IN PATIENTSWITH SHORT…(5*) Su1054. . . . . INFLUENCE OF PERSISTENT LGDON PROGRESSION…(5*) Su1055. . . . . ACCEPTABILITY OF TISSUE COLLECTIONBY CYTOSPONGE…(2*)|(4)|Covidien LP/Medtronic

Su1056. . . . . SLEEVE GASTRECTOMY IS ARISK FACTOR…(5*) Su1057. . . . . VOLUMETRIC LASER ENDOMICROSCOPY FINDINGSCAN RISK…(3*)| NinePoint Medical, Inc. Su1058. . . . . DISTAL ESOPHAGEAL IMPEDANCE MEASUREMENTSDURING HIGH…(5*) Su1059. . . . . HISTOLOGIC PROGRESSION DURING TREATMENTWITH RADIOFREQUENCY…(2*)|(4) Su1060. . . . . ACID INHIBITION ATTAINED BYCONCOMITANT ADMINISTRATION…(4*)|(2)||The First Department of Medicine and the Center for Clinical Research at Hamamatsu University School of Medicine have received grants from Takeda Pharmaceutical Co., Ltd., AstraZeneca KK, Eisai Co., Ltd. and Daiichi-Sankyo Co. Ltd. Su1061. . . . . THE EFFICACY AND SAFETYOF RABEPRAZOLE…(3*) Su1062. . . . . PREDICTORS OF NON-RESPONSE TOACID SUPPRESSION…(5*) Su1063. . . . . EFFECT OF CJ-12420, ANOVEL POTASSIUM-COMPETITIVE…(3*) Su1064. . . . . TOPICAL PROTECTION OF HUMANOESOPHAGEAL MUCOSAL…(2*) Su1065. . . . . EFFECTIVENESS OF MANAGEMENT ONHEALTH-RELATED AND…(5*) Su1066. . . . . EFFECTIVENESS OF ON-DEMAND THERAPYUSING 20-MG…(5*) Su1067. . . . . A SLEEP POSITIONING DEVICEFOR REFRACTORY…(2*) Su1068. . . . . PREDICTORS OF PERSISTENT GASTROESOPHAGEALREFLUX SYMPTOMS…(5*) Su1069. . . . . FACTORS ASSOCIATED WITH NEEDFOR RE-DO…(5*)

Su1070. . . . . PRE-OPERATIVE ESOPHAGEAL MOTILITY DISORDERSARE NOT…(5*) Su1071. . . . . EFFICACY OF A POTASSIUM-COMPETITIVEACID BLOCKER…(5*) Su1072. . . . . PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITYOF DWP14012,…(3*)| Daewoong Pharmaceutical Co., Ltd., Korea Su1073. . . . . OMEGA-CUFF: A NOVEL IMPLANTTO AUGMENT…(2*) Su1074. . . . . AN ASSESSMENT OF THERELATIONSHIP BETWEEN…(3*)| The studies were funded by AstraZeneca, which entered into an agreement with Pfizer for the over-the-counter (OTC) rights for NEXIUM® (esomeprazole magnesium). Medical writing support was provided by Dennis Stancavish of Peloton Advantage, LLC. Su1075. . . . . LAPAROSCOPIC NISSEN AGAINST ANTERIORPARTIAL FUNDOPLICATION…(5*) Su1076. . . . . EFFECT OF COGNITIVE BEHAVIOURALTHERAPY ON…(4*)|(3)|Sandhill Sci, (Denver, USA) Su1077. . . . . TREATMENT OF MILD GASTROESOPHAGEALREFLUX DISEASE…(5*) Su1078. . . . . A PILOT, PHASE IV,RANDOMIZED, DOUBLE-BLIND,…(3*)| Medical writing support was provided by Dennis Stancavish of Peloton Advantage, LLC, and was funded by Pfizer Inc.) Su1079. . . . . AN ANALYSIS OF THEPERCENTAGE OF…(3*)| The studies were funded by AstraZeneca, which entered into an agreement with Pfizer for the over-the-counter (OTC) rights for NEXIUM® (esomeprazole magnesium). Medical writing support was provided by Dennis Stancavish of Peloton Advantage, LLC, Su1080. . . . . VISIBLE LESIONS IN BARRETT'SESOPHAGUS: CLINICAL…(5*)


* = Primary Source



Su1081. . . . . THE OPTIMAL TIMING TOMODIFY THE…(7*) Su1082. . . . . THE INFLUENCE OF DEPRESSIONAND ANXIETY…(7*) Su1083. . . . . DEVELOPMENT AND VALIDATION OFA SIMPLE…(7*) Su1084. . . . . GASTRIN ELEVATION FOLLOWING PROTONPUMP INHIBITOR…(5*) Su1085. . . . . WIRELESS ELECTRICAL STIMULATION FORMANAGING GASTROESOPHAGEAL…(5*) Su1086. . . . . A SYSTEMATIC REVIEW ANDNETWORK META-ANALYSIS…(3*)| Takeda Pharmaceutical Company Limited Su1087. . . . . A SYSTEMATIC REVIEW ANDNETWORK META-ANALYSIS…(3*)| |Takeda Pharmaceutical Company Limited Su1088. . . . . TO COMPARE THE EFFICACYAND SAFETY…(5*) Su1089. . . . . GERD PREVALENCE AND TREATMENTIN PRIMARY…(5*) Su1090. . . . . PRELIMINARY RESULTS OF APROSPECTIVE MULTICENTER…(3*)| EndoStim BV Su1091. . . . . ELECTRICAL STIMULATION THERAPY (EST)OF THE…(3*)| EndoStim BV Su1108. . . . . SPORADIC FUNDIC GLAND POLYPSAND LEVEL…(5*) Su1109. . . . . EFFICACY OF PPI +ASA REGIMEN…(5*) Su1110. . . . . INDIVIDUAL ASSESSMENT OF GASTRICACID PRODUCTION…(5*) Su1111. . . . . RECOVERY OF GASTRIC FUNCTIONIN CHRONIC…(5*)

Su1112. . . . . AGGRESSIVE AND ADVANCED NON-CARDIAGASTRIC CANCER…(5*) Su1113. . . . . THE CURRENT TRENDS OFGASTRIC POLYPS…(5*) Su1114. . . . . FOLLOW-UP RESULT OF SUBEPITHELIALLESIONS DIAGNOSED…(5*) Su1115. . . . . THE STAGING OF GASTRITISWITH THE…(5*) Su1116. . . . . GASTRIC INTESTINAL METAPLASIA TYPEIII AND…(2*) Su1117. . . . . AUTOPHAGIC PROTEINS AS MARKERSOF DYSPLASTIC…(5*) Su1118. . . . . VALIDATION OF SERUM MARKERSIN MONGOLIA…(2*) Su1119. . . . . WHERE IS THE BLEEDINGSITE IN…(4*)|(2) Su1120. . . . . IS HEMOSTASIS WITH DOPPLERENDOSCOPIC PROBE…(4*)|(2) Su1121. . . . . SMALL BOWEL AND OTHERGI LESIONS…(4*) Su1122. . . . . UPPER GASTROINTESTINAL MUCOSAL INJURYAND SYMPTOMS…(5*) Su1123. . . . . TURNING OFF THE DRIP:A SINGLE…(5*) Su1124. . . . . PREVALENCE AND RISK FACTORSFOR GASTROINTESTINAL…(4*) Su1125. . . . . INFECTION IS ASSOCIATED WITHGASTROINTESTINAL BLEEDING…(5*) Su1126. . . . . SOMATOSTATIN ANALOGUES ARE HIGHLYEFFECTIVE IN…(5*) Su1127. . . . . A MULTICENTRE OBSERVATIONAL STUDYON STRESS…(3*)| |This study was funded by AstraZeneca.)

Su1128. . . . . INCIDENCE, ADMISSION RATES ANDECONOMIC BURDEN…(5*) Su1129. . . . . INCIDENCE AND PREDICTORS OFALL-CAUSE 30-DAY…(5*) Su1130. . . . . INCIDENCE, ADMISSION RATES ANDECONOMIC BURDEN…(5*) Su1131. . . . . INCIDENCE, ADMISSION RATES ANDECONOMIC BURDEN…(5*) Su1132. . . . . HYPERPARATHYROIDISM IS ASSOCIATED WITHA LOWER…(5*) Su1133. . . . . ATTITUDES REGARDING FOOD ANDVACCINE SAFETY…(5*) Su1134. . . . . CELIAC DISEASE PATIENTS PRACTICINGA GLUTEN-FREE…(3*)| ImmunongenX Su1135. . . . . PREVALENCE, CAUSES AND CHARACTERISTICSOF NONRESPONSIVE…(5*) Su1136. . . . . NO DETRIMENTAL EFFECT OFOATS ON…(5*) Su1137. . . . . ASPERGILLUS NIGER-DERIVED ENZYME DEGRADESGLUTEN IN…(5*) Su1138. . . . . GENDER-BASED DIFFERENCES IN UNDIAGNOSEDCELIAC DISEASE:…(4*) Su1139. . . . . REGIONAL AND NATIONAL VARIATIONSIN REASONS…(5*) Su1140. . . . . DEPRESSION AND INSOMNIA AMONGINDIVIDUALS WITH…(5*) Su1141. . . . . INCREASED RISK OF HERPESZOSTER IN…(2*) Su1142. . . . . THE RISE AND FALLOF CELIAC…(5*) Su1143. . . . . CO-EXISTENCE OF CELIAC DISEASEAND OTHER…(4*)


* = Primary Source



Su1144. . . . . PATTERN OF THYROID DISEASEPRESENTATION IN…(4*) Su1145. . . . . CONCERNS REGARDING GLUTEN PRESENCEIN MEDICINES…(2*)|The US Food and Drug Administration awarded Beyond Celiac a grant to conduct a research study in gluten in medicine (#4288). Su1146. . . . . A POPULATION-BASED ANALYSIS OFTHE CONTRIBUTION…(5*) Su1147. . . . . ETHNIC AND GENDER VARIATIONOF ANTI-TISSUE…(5*) Su1240. . . . . A NATIONWIDE TREND ANALYSISOF PATIENTS…(4*) Su1241. . . . . IN-HOSPITAL MORTALITY AND ANDRESOURCE UTILIZATION…(4*) Su1242. . . . . THE IMPACT OF PORTALVEIN THROMBOSIS…(4*) Su1243. . . . . PERITONEAL CAVITY DIAMETER ISASSOCIATED WITH…(4*) Su1244. . . . . FREQUENCY AND PROGNOSIS OFACUTE PANCREATITIS…(5*) Su1245. . . . . ACUTE PANCREATITIS (AP) ANDTHE WEEKEND…(1*) Su1246. . . . . THE CHANGING UTILIZATION OFIMAGING MODALITIES…(5*) Su1247. . . . . ASSOCIATION OF DIETARY HABITSWITH SEVERE…(5*) Su1248. . . . . THE SYSTEMIC INFLAMMATORY RESPONSESYNDROME (SIRS)…(5*) Su1249. . . . . IMPACT OF EARLY FLUIDTHERAPY ON…(5*) Su1250. . . . . INCIDENCE, ETIOLOGY, AND OUTCOMEOF ACUTE…(5*) Su1251. . . . . THE IMPACT OF METFORMININ OVERALL…(5*)

Su1252. . . . . SUITABLE LIQUID BIOPSY SAMPLESFOR DETECTING…(5*) Su1253. . . . . HISTOLOGY CORE OBTAINED WITHA NOVEL…(5*) Su1254. . . . . ALTERED EXPRESSION OF TIGHTJUNCTION (TJ)…(2*) Su1255. . . . . PARANEOPLASTIC WEIGHT LOSS ANDRISE IN…(4*)|(5) Su1256. . . . . A MULTICENTER, OPEN-LABEL, RANDOMIZEDCONTROLLED TRIAL…(4*)|(5) Su1257. . . . . SUBOPTIMAL INTEROBSERVER AGREEMENT (IOA)AMONGT CYTOPATHOLOGISTS…(4*)| Supported by the Department of Medicine Outstanding Early Scholars Program Su1258. . . . . QUANTITATIVE DETECTION OF SPARCGENE PROMOTER…(2*) Su1259. . . . . THE EFFICACY AND SAFETYOF PANCREATIC…(1*) Su1260. . . . . FATTY PANCREAS IS ASSOCIATEDWITH PANCREATIC…(5*) Su1261. . . . . IMPLEMENTING A MULTIDISCIPLINARY CONFERENCEIMPROVES PATIENT…(5*) Su1262. . . . . SERUM LEVELS OF INSULIN-LIKEGROWTH FACTOR…(5*) Su1263. . . . . AUTOPHAGY FAILS TO SUSTAINPROLIFERATION OF…(2*) Su1264. . . . . CHARACTERIZATION OF MIRNAS INCHRONIC PANCREATITIS…(2*) Su1265. . . . . CURATIVE INTENT SURGERY INBORDERLINE RESECTABLE…(5*) Su1266. . . . . FASTING HUMAN PANCREATIC POLYPEPTIDE(HPP) LEVEL…(4*)

Su1267. . . . . THE BURDEN OF PANCREATICCANCER IN…(2*) Su1268. . . . . THE INFLUENCE OF PROTONPUMP INHIBITORS…(2*)| The work was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000003. Su1269. . . . . PREOPERATIVE SARCOPENIA AND ACCELERATEDMUSCLE LOSS…(5*) Su1270. . . . . PROGNOSTIC ROLE OF HEDGEHOGSIGNALING PATHWAY…(4*)|(2) Su1271. . . . . PARANEOPLASTIC DIFFERENTIAL ADIPOSE TISSUELOSS IMPACTS…(5*) Su1272. . . . . National Pancreas Foundation’s (NPF)Patient Education…(5*) Su1273. . . . . ENDOSCOPIC ULTRASOUND FINDING INPATIENTS WITH…(1*) Su1274. . . . . HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)THERAPY FOR…(5*) Su1276. . . . . THE USE OF PHOTODYNAMICTHERAPY IN…(4*)| Pinnacle Biologics Su1277. . . . . ENDOSCOPIC ULTRASOUND AS APREDICTOR AND…(5*) Su1278. . . . . PREDICTORS OF SHORT-TERM ANDLONG-TERM RESOLUTION…(5*) Su1390. . . . . CHOLANGIOPATHIC PATTERNS DETECTED BYMAGNETIC RESONANCE…(2*) Su1391. . . . . RESET CUT-OFF VALUE OFELEVATED ALKALINE…(5*) Su1392. . . . . EVALUATION OF A PROPOSEDSCORING SYSTEM…(5*)


* = Primary Source



Su1393. . . . . EFFICACY OF ENDOSCOPIC BILIARYSTENTS IN…(5*) Su1394. . . . . PREVALENCE OF PRE-OPERATIVE HYPERBILIRUBINEMIAAND PREDICTORS…(5*) Su1395. . . . . RISK FACTORS FOR REFRACTORYBACTERIA IN…(5*) Su1396. . . . . THE ASSOCIATION OF GALLSTONEAND CHOLECYSTECTOMY…(5*) Su1397. . . . . A STUDY TO INVESTIGATERISK FACTOR…(5*) Su1398. . . . . PREDICTORS OF BILE TREEPATHOLOGY IN…(5*) Su1399. . . . . EFFICACY AND SAFETY OFNON-FLUOROSCOPIC ENDOSCOPIC…(5*) Su1400. . . . . RELAPSING FACTORS AFTER PERCUTANEOUSCHOLECYSTOSTOMY FOR…(5*) Su1401. . . . . IS ANTIMICROBIAL RESISTANCE TOINITIAL ANTIBIOTIC…(5*) Su1402. . . . . ELEVATED CONCENTRATION OF BILEACIDS AND…(5*) Su1403. . . . . ASYMPTOMATIC COMMON BILE DUCTDILATION AND…(5*) Su1404. . . . . COMPARISON BETWEEN DIRECT DIGITALCHOLANGIOSCOPY AND…(5*) Su1406. . . . . CLINICAL CHARACTERISTICS OF CLONORCHISSINENSIS ASSOCIATED…(1*) Su1407. . . . . ERCP GUIDED BILE ASPIRATECULTURE CAN…(5*) Su1408. . . . . CAUSATIVE PATHOGENS PATTERN ANDCLINICAL OUTCOMES…(5*)

Su1409. . . . . TIMING OF ERCP ANDINPATIENT MORTALITY…(5*) Su1508. . . . . 13C MANNITOL IS SUPERIORTO 12C…(2*)|(4) Su1509. . . . . INVOLVEMENT OF GLIADIN, ACOMPONENT OF…(5*) Su1510. . . . . COLONIC LOAD DIFFERENTIATES ORGANIZATIONOF MUCUS…(2*) Su1511. . . . . LEPTIN ALLEVIATES INTESTINAL MUCOSALBARRIER INJURY…(5*) Su1512. . . . . PPI AGGRAVATED LEAKY GUTSYNDROME, WHILE…(5*) Su1513. . . . . GLP-2 ACUTELY AMELIORATES LPS-RELATEDINTESTINAL PERMEABILITY…(2*)|Shire Pharmaceuticals) Su1514. . . . . ZONULIN TRANSGENIC MOUSE MODELSHOWS ALTERED…(4*) Su1515. . . . . PLECANATIDE AND DOLCANATIDE, GUANYLATECYCLASE-C AGONISTS,…(3*)|Funding for these trials and editorial support were provided by Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals Inc. also provided the plecanatide and placebo used for the study. Writing and editorial support provided by The Medicine Group. Su1516. . . . . HYDROXY-Î‘-SANSHOOL INDUCED NNOS-MEDIATED LONGDISTANCE CONTRACTION…(3*)| Tsumura & Co. Su1517. . . . . EFFICACY AND SAFETY OFPLECANATIDE IN…(3*)| Funding for these trials and editorial support were provided by Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals Inc. also provided the plecanatide and placebo used for the study. Writing and editorial support provided by The Medicine Group. Su1518. . . . . PLECANATIDE FOR THE TREATMENTOF CHRONIC…(3*)|Funding for these trials and editorial support were provided by Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals Inc. also provided the plecanatide and placebo

used for the study. Writing and editorial support provided by The Medicine Group. Su1519. . . . . CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCEREGULATOR CHANNEL…(5*) Su1520. . . . . PREVALENCE OF JOINT HYPERMOBILITYVARIES BETWEEN…(5*) Su1521. . . . . SYMPTOM AND ANORECTAL MANOMETRYCHARACTERISTICS OF…(1*) Su1522. . . . . EFFECTS OF NALDEMEDINE, A PERIPHERALLY ACTING…(3*)| Shionogi & Co., Ltd Su1523. . . . . EXPERIENCE WITH AN EMERGINGCLINICAL TRIAD:…(2*) Su1524. . . . . OPTIMIZED TIBIAL NERVE STIMULATIONIMPROVES OPIATE-INDUCED…(5*) Su1525. . . . . USE OF METHYLNALTREXONE INCANCER PATIENTS…(5*) Su1526. . . . . THE RELATIONSHIP OF PATIENT-REPORTEDTREATMENT SATISFACTION…(3*)| Allergan, plc, and Ironwood Pharmaceuticals, Inc. Su1527. . . . . ASSOCIATION OF SLEEP DISORDERSAND RELATED…(5*) Su1528. . . . . RECTAL GAS VOLUME: AUSEFUL SCREENING…(5*) Su1529. . . . . THE DIAGNOSTIC VALUE OFBALLOON EXPLUSION…(5*) Su1530. . . . . FECAL BURDEN ON ABDOMINALCOMPUTERIZED TOMOGRAPHY…(5*) Su1531. . . . . THE UROGUANYLIN ANALOG PLECANATIDEACTIVATES GUANYLATE…(3*)|Funding for these trials and editorial support were provided by Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals Inc. also provided the


* = Primary Source



plecanatide and placebo used for the study. Writing and editorial support provided by The Medicine Group. Su1532. . . . . INDIRECT TREATMENT COMPARISON: PLACEBO-ADJUSTEDRESULTS FROM…(3*)| Allergan, plc, and Ironwood Pharmaceuticals, Inc. Su1533. . . . . RESULTS FROM THE BURDENâ€“CICSTUDY (BETTER…(3*)| Funding for these trials and editorial support were provided by Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals Inc. also provided the plecanatide and placebo used for the study. Writing and editorial support provided by The Medicine Group. Su1534. . . . . SECRETORY DIARRHEA AND HYPOKALEMIAASSOCIATED WITH…(5*) Su1535. . . . . ADVANCED GLYCATION END PRODUCTSINDUCE COLONIC…(5*)| National Natural Science Foundation of China (No. 81470813) Su1536. . . . . AGREEMENT BETWEEN DYNAMIC TRANSRECTALULTRASOUND AND…(5*) Su1537. . . . . HERBAL LAXATIVE USE ISCOMMON AND…(7*) Su1538. . . . . PAINFUL CONSTIPATION: ABDOMINAL PAININ PATIENTS…(5*) Su1539. . . . . IMPACT OF AGE ANDGENDER TO…(1*) Su1540. . . . . PERIOPERATIVE INFLAMMATORY MARKER ASA PREDICTIVE…(5*) Su1541. . . . . GASTROINTESTINAL TRANSIT PATTERNS IDENTIFIEDIN CHILDREN…(2*) Su1542. . . . . LINACLOTIDE FOR THE TREATMENTOF PATIENTS…(5*) Su1543. . . . . DOSE-FINDING OF LINACLOTIDE FORPATIENTS WITH…(3*)| Supported by Astellas Pharma, Inc.

Su1544. . . . . ATTRIBUTABLE BENEFIT -- INTERPRETINGRESULTS FROM…(5*) Su1545. . . . . A NOVEL SYSTEM ANDMETHODOLOGY FOR…(2*) Su1546. . . . . CLINICAL UTILITY OF THEGASTRIC EMPTYING…(5*) Su1547. . . . . DEVELOPMENT AND PSYCHOMETRIC EVALUATIONOF THE…(3*)| This study was supported by Motus Therapeutics, Inc. Su1548. . . . . INTRAGASTRIC MEAL DISTRIBUTION (IMD)DURING ROUTINE…(2*) Su1549. . . . . SYMPTOMS ASSOCIATED WITH GASTROPARESISIN COMMUNITY-BASED…(5*) Su1550. . . . . DIFFERENCES BETWEEN OBESE ANDNON-OBESE PATIENTS…(2*) Su1551. . . . . HOSPITALIZATIONS AND READMISSIONS FORGASTROPARESIS: CHARACTERIZATION…(5*) Su1552. . . . . RELATIONSHIPS BETWEEN SLOW WAVEFREQUENCY, CONDUCTION…(2*) Su1553. . . . . HIGH INCIDENCE OF GASTRICBEZOARS AND…(5*) Su1554. . . . . RELATION OF OPIATE USETO CLINICAL…(2*) Su1555. . . . . SMARTPILL GASTRIC EMPTYING TIMESTRONGLY CORRELATES…(2*) Su1556. . . . . GASTRIC EMPTYING AND SYMPTOMSDURING A…(2*) Su1557. . . . . SIGNIFICANT ALTERATIONS WITHIN THEPLASMA CYTOKINE…(5*) Su1558. . . . . DELAYED GASTRIC EMPTYING ISASSOCIATED WITH…(5*)

Su1559. . . . . BASIS OF ELECTROGASTROGRAPHY (EGG)REVISITED USING…(2*) Su1560. . . . . SUBTYPES OF GASTROPARESIS (GP):CHARACTERISTICS OF…(5*) Su1561. . . . . CONCOMITANT USE OF PROKINETICMEDICATIONS AFTER…(5*) Su1562. . . . . THE SAFETY PROFILE OFWIRELESS MOTILITY…(5*) Su1563. . . . . LONG TERM EFFICACY OFGASTRIC ELECTRICAL…(5*) Su1564. . . . . GASTRIC ELECTRICAL STIMULATION ISASSOCIATED WITH…(2*) Su1565. . . . . ARE BREATH TESTS HELPFULIN PREDICTING…(1*) Su1566. . . . . SMALL INTESTINAL BACTERIAL OVERGROWTHACCELERATES TRANSIT…(6*) Su1567. . . . . ASSESSMENT OF SMALL BOWELMOTILITY IN…(4*) Su1568. . . . . TGFB SUPPRESSES ENTERIC NEUROGENESIS:A POTENTIAL…(2*) Su1569. . . . . INITIAL PARADOXICAL PEAKS ONBREATH TESTING…(3*)| This study was supported jointly by Commonwealth Laboratories, LLC, and Synthetic Biologics, Inc. Su1570. . . . . ELEVATED METHANE LEVELS INSMALL INTESTINAL…(5*) Su1571. . . . . EFFECT OF REPAGLINIDE ONTHE SMOOTH…(2*) Su1572. . . . . EFFECTS OF ANTIDIABETIC AGENTSON GASTROINTESTINAL…(4*) Su1573. . . . . PATIENTS ARE UNCOMFORTABLE WITHTHE USE…(2*)


* = Primary Source



Su1574. . . . . UNDERSTANDING WHY OLDER PATIENTSCONTINUE LOW-VALUE…(5*) Su1575. . . . . VALUE OF MAGNIFICATION ENDOSCOPYWITH ACETIC…(5*) Su1576. . . . . ASSOCIATION BETWEEN EDUCATION ANDCOLORECTAL CANCER…(5*) Su1577. . . . . PREDICTORS OF INADEQUATE BOWELPREPARATION IN…(5*) Su1578. . . . . A MULTILEVEL QUALITY IMPROVEMENTINITIATIVE TO…(5*) Su1579. . . . . PATIENTS AND PHYSICIANS AREAMENABLE TO…(5*) Su1580. . . . . COMPARING THE REAL WORLDEFFECTIVENESS OF…(4*) Su1581. . . . . SCREENING COLONOSCOPY IN ANORTHWESTERN POPULATION…(5*) Su1582. . . . . A NATIONAL SURVEY ONPHYSICIAN'S ACCEPTANCE…(4*) Su1583. . . . . THE USE OF APOPULATION SPECIALIST…(5*) Su1584. . . . . ENDOSCOPY IS OF LOWYIELD IN…(5*) Su1585. . . . . RISK FACTORS FOR THEDEVELOPMENT OF…(5*) Su1586. . . . . FRAILTY AND AGE MAYNOT ADEQUATELY…(5*) Su1587. . . . . STRAYING FROM SURVEILLANCE COLONOSCOPYGUIDELINES FOR…(5*) Su1588. . . . . SHOULD EVERYONE WITH ADVANCEDADENOMATOUS LESIONS…(5*) Su1589. . . . . CAN WE PREDICT THEDISCOVERY OF…(5*)

Su1590. . . . . DO WE PRACTICE WHATWE PREACH?…(5*) Su1591. . . . . HEPATITIS C SCREENING RATESIN BABY…(5*) Su1592. . . . . PREVALENCE OF SESSILE SERRATEDADENOMATOUS POLYPS…(5*) Su1593. . . . . TARGETED METABOLIC PROFILING OFTYROSINE IN…(5*) Su1594. . . . . COLORECTAL CANCER SCREENING WITHCOLOGUARD IN…(5*) Su1595. . . . . GILBERT SYNDROME IS NOTTHAT INNOCENT!…(4*) Su1596. . . . . EFFICACY OF CIMETROPIUM BROMIDEON POLYP…(5*) Su1597. . . . . ENVIRONMENTAL FACTORS FROM APROSPECTIVE STUDY…(2*) Su1720. . . . . POOLED INCIDENCE OF FECALOCCULT BLOOD…(5*) Su1721. . . . . DIFFERENCES IN COLONOSCOPY ASSOCIATEDCOSTS BETWEEN…(5*) Su1722. . . . . COST-EFFECTIVENESS OF PATIENT OUTREACHTO INCREASE…(2*) Su1723. . . . . COST-EFFECTIVENESS OF SURVEILLANCE GUIDELINESFOR PATIENTS…(2*) Su1724. . . . . INTERVAL CANCERS IN FIT-BASEDSCREENING PROGRAM…(5*) Su1725. . . . . REPEAT ANNUAL FECAL IMMUNOCHEMICALTESTING PATTERNS…(2*) Su1726. . . . . DOES THE LEVEL OFA NEGATIVE…(5*) Su1727. . . . . CRC SCREENING IN WOMENAGE 50-59…(2*)

Su1728. . . . . RISK OF COLORECTAL NEOPLASMSIN FIRST-DEGREE…(2*) Su1729. . . . . INTER-OBSERVER AGREEMENT AMONG PATHOLOGISTSIN THE…(5*) Su1730. . . . . TIME TO DIAGNOSTIC COLONOSCOPYAND COLONOSCOPIC…(5*) Su1731. . . . . PERFORMANCE OF MULTITARGET STOOLDNA TESTING…(2*)| Multitarget sDNA analyses provided by Exact Sciences, Inc. Su1732. . . . . RISK OF ADVANCED COLORECTALNEOPLASIA ACCORDING…(5*) Su1733. . . . . EVALUATION OF A GENEEXPRESSION PANEL…(2*)|(4) Su1734. . . . . ISOLATED SMALL RIGHT-SIDED HYPERPLASTICPOLYPS CONFER…(5*) Su1735. . . . . IMMUNOHISTOCHEMISTRY PROFILE OF BASELINESESSILE SERRATED…(2*)|(7)|American College of Gastroenterology Su1736. . . . . GENETIC PROFILE OF POLYPSAND RISK…(5*) Su1737. . . . . SYMPTOMATIC PATIENTS PARTICIPATING INCOLORECTAL CANCER…(5*) Su1738. . . . . ANNUAL FECAL IMMUNOCHEMICAL TESTINGIS AS…(2*) Su1739. . . . . ADENOMATOUS LESIONS AMONG ADULTSURVIVORS OF…(5*) Su1740. . . . . EVALUATION OF A MULTIMODALCOLORECTAL CANCER…(2*) Su1741. . . . . YOUNG-ONSET COLORECTAL CANCER INA MULTI-ETHNIC,…(6*)| Scripps Health Foundation Su1742. . . . . COLORECTAL CANCER RISK FACTORSIN VETERANS…(2*)|(4)


* = Primary Source



Su1743. . . . . CONSENSUS RECOMMENDATIONS FOR COLORECTALCANCER SCREENING…(6*) Su1744. . . . . IMPACT OF THE ORGANIZEDSCREENING PROGRAM…(4*) Su1745. . . . . AN ONLINE RISK ASSESSMENTTOOL DEMONSTRATES…(5*) Su1746. . . . . AN ONLINE RISK ASSESSMENTTOOL DEMONSTRATES…(5*) Su1747. . . . . FOLLOW-UP OF PATIENTS UNNDERGOINGCOLONOSCOPY ASSESSEMENT…(4*) Su1748. . . . . COST-EFFECTIVENESS ANALYSIS OF COLONOSCOPYCOLORECTAL CANCER…(6*)|(2) Su1749. . . . . COLORECTAL CANCER SCREENING INA FIT…(2*) Su1750. . . . . A NURSE-LED MODEL INCREASESCONCORDANCE WITH…(5*) Su1751. . . . . UPTAKE OF A COLORECTALCANCER SCREENING…(4*) Su1752. . . . . ANALYSIS OF THE CUT-OFFVALUE OF…(5*) Su1753. . . . . JAPANESE COLORECTAL CANCERS DATADEPENDING ON…(5*) Su1754. . . . . POST-COLONOSCOPY COLORECTAL CANCERS IDENTIFIEDBY POPULATION…(4*) Su1755. . . . . FECAL HEMOGLOBIN CONCENTRATION, AGOOD PREDICTOR…(5*) Su1756. . . . . EFFICACY AND TOLERABILITY OFVARIOUS BOWEL…(2*) Su1757. . . . . COLORECTAL CANCER SCREENING DETECTSTUMOURS AT…(4*)

Su1758. . . . . INCREASED DETECTION OF SERRATEDLESIONS: IS…(5*) Su1759. . . . . ELUCIDATING THE ROLE OFFIT AND…(5*) Su1760. . . . . NON-STEROIDAL ANTI-INFLAMMATORY DRUGS USEAND RELATIVE…(5*) Su1761. . . . . ASSOCIATION OF VITAMIN DDEFICIENCY AND…(5*) Su1762. . . . . COSTS AND OUTCOMES OFLYNCH SYNDROME…(6*) Su1763. . . . . CLINICOPATHOLOGICAL, MOLECULAR AND ONCOLOGICALFEATURES OF…(5*) Su1764. . . . . POORLY CONTROLLED DIABETES ANDMORBID OBESITY…(5*) Su1765. . . . . SPECT IMAGING EVALUATION OF111INDIUM-CHELATED CETUXIMAB…(4*) Su1766. . . . . STOOL DNA TESTING FORCOLORECTAL CANCER…(5*) Su1767. . . . . ADENOMA AND CANCER DETECTIONRATES IN…(5*) Su1768. . . . . COLORECTAL CANCER INCIDENCE INLYNCH SYNDROME…(5*) Su1769. . . . . FAMILIAR COLORECTAL CANCER ANDGENETIC SUSCEPTIBILITY:…(4*)|(1) Su1770. . . . . PREVALENCE OF GERMLINE MUTATIONSIN CONSECUTIVE,…(3*)|(4) Su1771. . . . . PREVALENCE OF GERMLINE MUTATIONSIN INDIVIDUALS…(5*) Su1772. . . . . UBIQUITOUS NEUROCOGNITIVE DYSFUNCTION INPATIENTS WITH…(4*)|(2) Su1773. . . . . OUTCOMES OF SURVEILLANCE ENDOSCOPYIN THE…(5*)

Su1774. . . . . THE PREVALENCE OF SESSILESERRATED POLYPS…(5*) Su1775. . . . . A MINORITY OF PATIENTSWITH COLORECTAL…(5*) Su1776. . . . . IS UNIVERSAL TUMOR TESTINGFOR LYNCH…(5*) Su1777. . . . . INHERITED SUSCEPTIBILITY TO BILIARYTRACT AND…(3*)| Ambry Genetics provided support in the form of salaries for some of the authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Su1778. . . . . SOMATIC APC MOSAICISM CAUSESA HIGH…(2*) Su1779. . . . . UNIQUE FEATURES OF GREM1RELATED HEREDITARY…(5*) Su1780. . . . . INTEGRATION OF CHROMOENDOSCOPY INCOLONOSCOPIC SURVEILLANCE…(5*) Su1781. . . . . PREVALENCE OF GENE MUTATIONSIN PATIENTS…(5*) Su1782. . . . . GENETIC TESTING OF COLORECTALCANCER TISSUE…(5*) Su1783. . . . . BARRETT'S ESOPHAGUS AMONG THEDIFFERENT FAMILIAL…(5*) Su1784. . . . . ENDOSCOPIC FOLLOW UP CANSELECT PATIENTS…(5*) Su1785. . . . . BREAST CANCER ANTI-ESTROGEN RESISTANCE3 (BCAR3)…(2*) Su1786. . . . . UPREGULATED CLAUDIN-2 EXPRESSION ININTESTINAL EPITHELIUM…(2*) Su1787. . . . . EXOSOMES DERIVED FROM COLONCANCER CELLS…(2*) Su1806. . . . . HEDGEHOG-DEPENDENT YAP SIGNALING ACTIVATESSERINE BIOGENESIS…(2*)


* = Primary Source



Su1807. . . . . MMP-9 MODULATION OF INTESTINALEPITHELIAL TIGHT…(7*)| Crohn's and Colitis Foundation of America (CCFA) Su1808. . . . . NGF ACCELERATES GASTRIC ULCERHEALING IN…(2*) Su1809. . . . . INHIBITION OF Î“-GLUTAMYL TRANSPEPTIDASEATTENUATES HEPATIC…(4*) Su1810. . . . . Î”9-TETRAHYDROCANNABINOL INHIBITS TRANSFORMING GROWTHFACTOR Î’1…(4*) Su1811. . . . . SEPSIS-INDUCED HEPATIC INJURY INRATS IS…(5*) Su1813. . . . . 15-PGDH INHIBITORS PROMOTE HEALINGOF GASTRIC…(2*)| This research was supported by Basic Science Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Education(NRF-2015R1D1A1A01059181). Su1814. . . . . EXTRACELLULAR MATRIX FRAGMENTS ASMARKERS OF…(4*) Su1815. . . . . COBALT CHLORIDE COMPROMISES TRANSEPITHELIALBARRIER PROPERTIES…(4*) Su1816. . . . . INTESTINAL EPITHELIAL BARRIER FUNCTIONIS DISRUPTED…(2*) Su1817. . . . . OMENTAL INFARCT MIMICKING COLORECTALCANCER …(5*) Su1818. . . . . DECREASED FEEDING BOUT FREQUENCYIS ATTRIBUTABLE…(5*) Su1819. . . . . ALLYL ISOTHIOCYANATE, A PUNGENTINGREDIENT OF…(2*) Su1820. . . . . LOSS OF MUCOUS LAYERIS THE…(5*)

Su1821. . . . . THE EFFECT OF SMALL-CONDUCTANCECA2+-ACTIVATED K+…(5*) Su1822. . . . . INCREASE OF SMALL INTESTINALPERMEABILITY IN…(2*) Su1823. . . . . L-TRYPTOPHAN DIET ACCELERATES THEHEALING OF…(5*) Su1824. . . . . CHARACTERIZATION AND TARGETING OFTHE HUMAN…(2*) Su1825. . . . . MECP2-MEDIATED EPIGENETIC SILENCING OFMIR-137 CONTRIBUTES…(2*) Su1826. . . . . THE COHESIN SA1 REGULATESEARLY METABOLIC…(2*) Su1827. . . . . EPIGENETIC ALTERATIONS AT DIAGNOSISPREDICT SUSCEPTIBILITY,…(2*) Su1828. . . . . RNA-SEQ OF FORMALIN-FIXED, PARAFFIN-EMBEDDEDINTESTINAL TISSUE…(2*)|(6) Su1829. . . . . HYPOXIA-INDUCIBLE FACTOR 1 ALPHA(HIF1A) STIMULATES…(2*)|(4) Su1830. . . . . P38-Î‘ MITOGEN-ACTIVATED PROTEIN KINASE(MAPK) MEDIATES…(2*) Su1831. . . . . INFLUENCE OF ANTIDEPRESSANTS INPREGNANCY ON…(4*)|(6) Su1832. . . . . METHIONINE CHOLINE-DEPRIVATION IMPACT GROWTHAND VISCERAL…(2*) Su1833. . . . . THE FATTY ACID IMBALANCEOF CYSTIC…(2*) Su1834. . . . . TOPICAL DELIVERY OF IL-10USING A…(4*) Su1835. . . . . RECOMBINANT PRODUCTION OF HUMANBETA-DEFENSIN 2…(3*)| Novozymes provided the hBD2, conducted the immune-

modulatory assays and sponsored the animal studies presented in this abstract. Su1836. . . . . CURCUMA LONGA-DERIVED NANOPARTICLES REDUCE.COLITISAND PROMOTE…(2*) Su1837. . . . . REGULATION OF IL-12P40 BYHIF CONTROLS…(2*)| Aerpio Therapeutics provided a travel grant to attend DDW. Su1838. . . . . Tolerance with Viaskin requiresTGF-β and…(2*)|(4)| DBV Technologies Su1839. . . . . HIGHLY BIOAVAILABLE CURCUMIN INDUCESREGULATORY IMMUNE…(5*) Su1840. . . . . SURFACTANT PROTEIN D ASTHE NOVEL…(5*) Su1841. . . . . CREATING AN ANIMAL MODELOF PERIANAL…(2*) Su1842. . . . . EXACERBATION OF ALLERGIC INFLAMMATIONIN PBMC-ENGRAFTED…(4*) Su1843. . . . . AUTONOMIC-CYTOKINE MECHANISMS OF SACRALNERVE STIMULATION…(2*) Su1844. . . . . GUT MICROBIOME ALTERATIONS ASSOCIATEDWITH AN…(2*)|(6) Su1845. . . . . ANTI-INFLAMMATORY SUPRAMOLECULAR NANOFIBERS TOMODULATE INFLAMMATION…(4*)|(6) Su1846. . . . . NTPDASE8 PROTECTS MICE FROMINTESTINAL INFLAMMATION…(2*)|(4) Su1847. . . . . P2RY6-/- MICE EXHIBIT EXACERBATEDINTESTINAL INFLAMMATION…(4*)|(2) Su1848. . . . . PROTECTIVE EFFECT OF ANOVEL NECROSIS…(5*) Su1849. . . . . TOPICAL THERAPY OF ANTISENSETNF-Î‘ WITH…(2*)


* = Primary Source



Su1850. . . . . INDIGO NATURALIS AMELIORATES MURINEDEXTRAN SODIUM…(2*) Su1851. . . . . EX VIVO EFFECTS OFSILYMARIN FRACTIONS…(4*) Su1852. . . . . DEFICIENCY OF CCR7 DETERIORATESNON-STEROIDAL ANTI-INFLAMMATORY…(4*) Su1853. . . . . TH1 CELLS PLAY APIVOTAL ROLE…(2*) Su1854. . . . . A NOVEL HYBRID TREATMENTWITH SIMVASTATIN-CONJUGATED…(5*) Su1855. . . . . CARAMEL FOOD COLORANT 2-ACCETYL-4-TETRAHYDROXYBUTYLIMIDAZOLE (THI)…(4*) Su1856. . . . . ORAL ADMINISTRATION OF ACHOLERA VACCINE…(2*) Su1857. . . . . ASTAXANTHIN, A XANTHOPHYLL CAROTENOID,SUPPRESSES THE…(5*) Su1858. . . . . DIGOXIN ATTENUATES MURINE EXPERIMENTALCOLITIS BY…(5*) Su1859. . . . . USEFULNESS OF COMPLEMENT C1QIN ASSESSING…(5*) Su1860. . . . . HELMINTHES DERIVATIVE FOR TREATINGACUTE AND…(3*)|(6)| This study has partially supported by TEVA Company and partially by the Moris family foundation, Los Angeles, USA. Su1861. . . . . EFFICACY AND SAFETY OFSINGLE FECAL…(5*) Su1862. . . . . RISK OF POSTOPERATIVE COMPLICATIONSAMONG INFLAMMATORY…(5*) Su1863. . . . . Evaluation of safety andefficacy of…(2*)|(4) Su1864. . . . . ESCALATION OF THERAPY ININFLAMMATORY BOWEL…(5*)

Su1865. . . . . VEDOLIZUMAB CLINICAL AND POST-MARKETINGSAFETY EXPERIENCE…(3*)| Studies funded by Takeda Pharmaceuticals. Medical writing support sponsored by Takeda Pharmaceuticals Su1866. . . . . UV EXPOSURE AND SKINTYPE ARE…(5*) Su1867. . . . . SHOULD ENDOSCOPIC BALLOON DILATIONBE CONSIDERED…(5*) Su1868. . . . . THE RELATIONSHIP BETWEEN THIOPURINEUSE DURING…(5*) Su1869. . . . . PREOPERATIVE USTEKINUMAB TREATMENT ISNOT ASSOCIATED…(5*) Su1870. . . . . THE INCIDENCE OF CARDIOVASCULAREVENTS IN…(3*)| Financial support for the study was provided by AbbVie. Su1871. . . . . THE EFFECT OF METHOTREXATEON SPERM…(4*)|(3)| ReproSource, Inc. Su1872. . . . . ADVERSE EVENTS WITH USEOF USTEKINUMAB:…(5*) Su1873. . . . . THE IMPACT OF STEROIDUSE ON…(5*) Su1874. . . . . HISTOPLASMOSIS IN THE SETTINGOF BIOLOGIC…(5*) Su1875. . . . . OUTCOMES OF TREATMENT FORLATENT TUBERCULOSIS…(5*) Su1876. . . . . POST-MARKETING EXPERIENCE OF VEDOLIZUMABIN INFLAMMATORY…(3*)| This study was funded by Takeda Pharmaceuticals. Medical writing support sponsored by Takeda Pharmaceuticals. Su1877. . . . . INCIDENCE OF PNEUMONIA ANDOTHER RESPIRATORY…(3*)| This study was funded by Takeda Pharmaceuticals. Medical writing support was sponsored by Takeda.

Su1878. . . . . RAPID INFLIXIMAB INFUSIONS ARESAFE AND…(5*) Su1879. . . . . EBV STATUS AND IMMUNOSUPPRESSANTUSE IN…(4*) Su1880. . . . . PERIOPERATIVE USE OF VEDOLIZUMABIS NOT…(5*) Su1881. . . . . INFLAMMATORY BOWEL DISEASE ANDSKIN CANCER:…(5*) Su1882. . . . . FREQUENCY AND TYPE OFDRUG-RELATED SIDE…(2*) Su1883. . . . . BIOLOGIC AND/OR THIOPURINE USEDURING PREGNANCY…(5*) Su1884. . . . . AUTOIMMUNE PARADOXICAL REACTIONS ININFLAMMATORY BOWEL…(6*) Su1885. . . . . USEFULNESS OF NUDT15 ANDTPMT GENETIC…(5*) Su1886. . . . . THE USE OF TUMORNECROSIS FACTOR…(5*) Su1887. . . . . PREDICTORS OF ACUTE INFLIXIMABINFUSION REACTIONS…(5*) Su1888. . . . . SAFETY OF VEDOLIZUMAB USEIN PATIENTS…(5*) Su1889. . . . . LONG-TERM EFFICACY AND SAFETYOF USTEKINUMAB…(3*)| |Janssen Research & Development, LLC supported this study.) Su1890. . . . . IMPROVED QUALITY OF LIFEWITH ANTI-TNF…(2*) Su1891. . . . . EFFICACY AND SAFETY OFTOPICAL 5-AMINOSALICYLIC…(5*) Su1892. . . . . BIOSIMILAR INFLIXIMAB IN REAL-LIFECROHN'S DISEASE…(5*) Su1893. . . . . EVALUATION OF THE PHARMACOKINETICPROFILES OF…(3*)| |This study was supported by Samsung Bioepis Co., Ltd.)


* = Primary Source



Su1894. . . . . SWITCHING FROM REMICADEÂ® TOBIOSIMILAR CT-P13…(5*) Su1895. . . . . NOVEL BIO-ENHANCED CURCUMIN WITHMESALAMINE FOR…(5*) Su1896. . . . . COMPARISON OF THE DURABILITYOF SUBCUTANEOUS…(5*) Su1897. . . . . A COST-EFFECTIVENESS ANALYSIS OFPOST-OPERATIVE PREVENTION…(5*) Su1898. . . . . UTILIZING A MARKOV MODELTO DETERMINE…(5*) Su1899. . . . . A MARKOV MODEL EVALUATINGTHE COST-EFFECTIVENESS…(5*) Su1900. . . . . A COST-EFFECTIVENESS ANALYSIS EVALUATINGTHE ROLE…(5*) Su1901. . . . . EVALUATION OF PHARMACOKINETIC PROFILESOF SB2…(3*)| Samsung Bioepis Co., Ltd. Su1902. . . . . STRUCTURE AND BIOLOGICAL ACTIVITYOF INFLIXIMAB…(3*) Su1903. . . . . LONG TERM OUTCOME OFULCERATIV E.COLI…(5*) Su1904. . . . . APPROPRIATENESS OF CONCOMITANT IMMUNOMODULATORAND BIOLOGIC…(3*)| Abbvie Janssen Takeda Su1905. . . . . OUTCOMES AND ECONOMIC IMPACTOF SWITCHING…(3*)| Abbvie Su1906. . . . . COMBINING PATIENT PREFERENCES ANDCOMPARATIVE EFFECTIVENESS…(2*) Su1907. . . . . PHARMACOLOGIC THERAPIES FOR SEVERESTEROID REFRACTORY…(5*) Su1908. . . . . FIRST-LINE AND SECOND-LINE BIOLOGICSIN THE…(5*)

Su1909. . . . . FIRST-LINE AND SECOND-LINE BIOLOGICAGENTS AND…(5*) Su1910. . . . . COMPARISON OF PHARMACOLOGICAL THERAPIESFOR MILD-MODERATE…(5*) Su1911. . . . . BT-11: A NOVEL LANTHIONINESYNTHETASE C-LIKE…(2*)| We thank the Virginia Biosciences Health and Research Corporation (VBHRC) and the NIH SBIR program (SBIR R43DK097940 and STTR R41DK099027) for funding. Su1912. . . . . COMPARATIVE PERSISTENCE OF BIOLOGICSIN THE…(3*)| The study was completed during my internship at Biogen. The data was provided by Biogen. Su1913. . . . . EFFICACY OF FERRIC CARBOXYMALTOSEIN RELATION…(5*) Su1914. . . . . COMPARATIVE EFFECTIVENESS ANALYSIS OFFLARES, HOSPITALISATIONS,…(3*)| This study was funded by Takeda Pharmaceuticals, Inc. Su1915. . . . . EFFECT OF MAINTENANCE USTEKINUMABON CORTICOSTEROID-FREE…(3*)| |Janssen Research & Development, LLC supported these studies.) Su1916. . . . . EFFICACY OF USTEKINUMAB FORINDUCTION AND…(3*)| These studies were supported by Janssen Research & Development, LLC Su1917. . . . . PHARMACOKINETICS AND EXPOSURE-RESPONSE OFTOFACITINIB IN…(3*)| Pfizer Inc Su1918. . . . . COMPARISON OF RATES OFACTIVE TUBERCULOSIS…(3*)| Janssen Research & Development, LLC supported these studies. Su1919. . . . . TELEMEDICINE FOR PATIENTS WITHINFLAMMATORY BOWEL…(2*) Su1920. . . . . EFFICACY OF FILGOTINIB, ASELECTIVE JAK1…(3*)

Su1921. . . . . EFFECT OF VEDOLIZUMAB TREATMENTON EXTRAINTESTINAL…(3*)|This study was funded by Takeda Development Centre Europe Su1922. . . . . HISTOLOGICAL REMISSION IS PREDICTIVEOF IMPROVED…(3*)|This study was sponsored by Receptos, a wholly owned subsidiary of Celgene. Su1923. . . . . CHARACTERIZATION OF ULCERATIVE.COLITIS PATIENTSIN THE…(3*)| Janssen Research & Development, LLC Su1924. . . . . EFFICACY AND SAFETY OFABRILUMAB (AMG…(3*)|Amgen and AstraZeneca/MedImmune sponsored this study. Su1925. . . . . LONG-TERM SAFETY AND TOLERABILITYOF ORAL…(3*)| Pfizer Inc Su1926. . . . . ADHERENCE TO AN ANTI-INFLAMMATORYDIET PREVENTS…(4*) Su1927. . . . . ETROLIZUMAB TREATMENT IMPROVES HISTOLOGICALACTIVITY AS…(3*)| Roche Su1928. . . . . A PHASE 2-Jan RANDOMIZED,PLACEBO-CONTROLLED, DOUBLE-BLIND…(3*)| Qu Biologics Inc Su1929. . . . . IMPACT OF REAL WORLDHOME-BASED REMOTE…(2*)|(6)| NIH K 23 and CCFA Career Development Grant Su1930. . . . . MAINTENANCE OF CLINICAL EFFECTIN PATIENTS…(3*)| Galapagos NV Su1931. . . . . LONG-TERM EFFECTIVENESS AND SAFETYOF VEDOLIZUMAB…(3*)|Study sponsored by Takeda Pharmaceuticals. Medical writing support of abstract supported by Takeda Pharmaceuticals. Su1932. . . . . MAINTENANCE OF QUALITY OFLIFE IMPROVEMENT…(3*)| Pfizer Inc


* = Primary Source



Su1933. . . . . FILGOTINIB (GLPG0634, GS-6034), AJAK-1 SELECTIVE…(3*)| Galapagos NV, Gilead Sciences Su1934. . . . . LONG-TERM EFFECTIVENESS AND SAFETYOF VEDOLIZUMAB…(3*)| The study was funded by Takeda Development Centre Europe Su1935. . . . . ETROLIZUMAB DEMONSTRATED NO DIFFERENCEAMONG DOSES…(3*)|Roche Su1936. . . . . ETROLIZUMAB TREATMENT LEADS TOEARLY IMPROVEMENT…(3*)| Roche Su1937. . . . . SUBCLINICAL FIBROSIS IN INFLAMMATORYBOWEL DISEASE…(4*) Su1938. . . . . COLONIC TREG LEVELS AREREDUCED IN…(3*)| Roche Su1939. . . . . SUSTAINED REMISSION WITH VEDOLIZUMABIN PATIENTS…(3*)| This study was funded by Takeda Development Centre Europe Ltd. Su1940. . . . . HISTOLOGICAL REMISSION IN UC:AN ANALYSIS…(3*)| Study supported by Janssen Research & Development, LLC Su1941. . . . . ANTI-MICROBIAL ANTIBODIES AND INFLAMMATORYMARKERS ARE…(3*)| Support for this study was provided by Janssen Pharmaceuticals and Prometheus Laboratories under a Cooperative Research and Development Agreement entitled ‘Antimicrobial antibodies as predictors of inflammatory bowel diseases’ NCRADA number NMR-11-3920. Su1942. . . . . THE ANTI-GLYCAN ANTIBODIES AMCAAND ALCA…(1*)|(2) Su1943. . . . . GASTROINTESTINAL INFECTIOUS AGENTS DETECTEDBY BIOFIRE…(4*)|(3)|BÜHLMANN Laboratories AG, Switzerland Su1944. . . . . ULTRASOUND ELASTICITY IMAGING PREDICTSTHERAPEUTIC OUTCOME…(2*)

Su1945. . . . . PROXIMITY EXTENSION ASSAY BASEDPROTEINS SHOW…(2*) Su1946. . . . . COMPARISON OF THE NONINVASIVEBIOMARKER PERFORMANCE…(2*)| Funding: This work was supported by National Natural Science Foundation of China (CN) (81570501,81472311,81330014). Su1947. . . . . OPPORTUNISTIC SCREENING FOR BONEDISEASE USING…(5*) Su1948. . . . . THERAPEUTIC DRUG MONITORING OFBIOSIMILARS OF…(6*) Su1949. . . . . EXPRESSION DATA FROM CROHN'SDISEASE SMALL…(4*) Su1950. . . . . THE SENSITIVITY AND SPECIFICITYOF NON-INVASIVE…(5*) Su1951. . . . . INGESTION OF 100ML AND300ML BLOOD…(4*) Su1952. . . . . DIGITAL HOLOGRAPHIC MICROSCOPY RELIABLYDETECTS FIBROSIS…(5*) Su1954. . . . . DYNAMIC STATE TRANSITION ANALYSIS(DSTA) OF…(4*)|(6) Su1955. . . . . CHARACTERIZATION OF IMMUNE PHENOTYPESAS PREDICTIVE…(4*)|(3)|Takeda Su1956. . . . . ROLE OF CYCLE TIMESOF POLYMERASE…(4*) Su1957. . . . . SERIAL TUBERCULIN SKIN TESTIMPROVES THE…(5*) Su1958. . . . . EFFECTS OF TIME ONURINARY METABOLIC…(4*) Su1959. . . . . DECREASED LEVELS OF CIRCULATIGPROTEIN S…(5*) Su1960. . . . . THE EFFECTS OF GLIAL#NAME? NEUROTROPHIC…(5*)

Su1961. . . . . IL23/MTOR AXIS IN CX3CR1RESIDENTIAL MACROPHAGES…(2*)|(6) Su1962. . . . . TRANSCRIPTOMIC PROFILING OF INTESTINALMACROPHAGES ISOLATED…(4*) Su1963. . . . . INFLAMED INTESTINE-CHIP: MIMICKING THEMUCOSAL MICROENVIRONMENT…(3*)| |Merck & Co, Inc) Su1964. . . . . TGFÎ’ SIGNAILING IN DENDRITICCELLS IS…(2*) Su1965. . . . . RESETTING OF THE MUCOSALT CELL…(6*)|(2) Su1966. . . . . DIFFERENTIAL EFFECTS OF VEDOLIZUMABAND ETROLIZUMAB-S…(2*)|(4)|The etrolizumab surrogate antibody FIB504 was provided by Genentech, San Francisco, CA. The company was neither involved in the conception and conduction of the study nor in the analysis and interpretation of the results. Su1967. . . . . NEONATAL FC RECEPTOR COOPERATESWITH CLASSICAL…(2*) Su1968. . . . . BALANCE OF NLRP3-MEDIATED IL-1Î’AND IL-18…(6*)|(4) Su1969. . . . . MOLECULAR SIGNALING PATHWAY GOVERNINGGPR15 EXPRESSION…(7*) Su1970. . . . . A NOVEL WHOLE BLOODASSAY DETECTS…(6*) Su1971. . . . . DISTINCT PATTERNS OF SHORTCHAIN FATTY…(3*)| Repha GmbH Biologische Arzneimittel Su1972. . . . . DIETARY WHEAT ALPHA-AMYLASE/TRYPSIN INHIBITORSREDUCE INNATE…(4*) Su1973. . . . . GAMMADELTA T CELLS DEFICIENCYIN THE…(4*) Su1974. . . . . TNFAIP3 (A20) IS AKEY PLAYER…(4*)


* = Primary Source



Su1975. . . . . EXCLUSIVE ENTERAL NUTRITION MEDIATESGUT METABOLIC…(5*) Su1976. . . . . CHANGES IN FECAL AMINOACID PROFILE…(5*) Su1977. . . . . LONG-TERM OUTCOMES AFTER RESTORATIVEPROCTOCOLECTOMY AND…(5*) Su1978. . . . . FECAL CALPROTECTIN ACCURATELY PREDICTSSYMPTOMATIC RELAPSE…(5*) Su1979. . . . . MAYO ENDOSCOPIC SUBSCORE DOESNOT PREDICT…(5*) Su1980. . . . . CAPSULE ENDOSCOPY COMPLEMENTS MAGNETICRESONANCE ENTEROGRAPHY…(5*) Su1981. . . . . CYTOMEGALOVIRUS INFECTION IN PEDIATRICACUTE SEVERE…(5*) Su1982. . . . . WEEK SIX: INFLIXIMAB TROUGHLEVELS ARE…(3*)| Janssen Pharmaceuticals Su1983. . . . . THE NOVEL TUMOR SUPPRESSIVEROLE OF…(2*) Su1984. . . . . GIT1 PHOSPHORYLATION BY GRK2REGULATES INTESTINAL…(2*) Su1985. . . . . GENE EXPRESSION PROFILES INCOLLAGENOUS COLITIS…(2*) Su1986. . . . . GUT LYMPHATIC PLASTICITY INRESPONSE TO…(2*) Su1987. . . . . LONG NONCODING RNA UC-173PROMOTES GROWTH…(2*) Su1988. . . . . GRANULOCYTE FUNCTION IN PATIENTSWITH FUNCTIONAL…(2*) Su1989. . . . . A GLYCOCERAMIDE PLATFORM FORMUCOSAL DELIVERY…(2*)

Su1990. . . . . NESFATIN-1 AMELIORATES BOWEL INJURYIN A…(5*) Su1991. . . . . CYTOLETHAL DISTENDING TOXIN B(CDTB) EXPOSURE…(4*) Su1992. . . . . INFECTION WITH STREPTOCOCCUS GALLOLYTICUSINCREASES APOPTOSIS…(5*) Su1993. . . . . ORALLY INGESTED TITANIUM DIOXIDENANOPARTICLES EXACERBATES…(4*) Su1994. . . . . PROBIOTIC-MEDIATED PROTECTION AGAINST CHRONICWATER-AVOIDANCE STRESS…(2*)|(4) Su1995. . . . . MEASURING THE ACTIVE ANDPASSIVE CHARACTERISTICS…(5*) Su1996. . . . . MESENCHYMAL STEM CELLS RESCUEDEFECTIVE ENTEROID…(2*)|(7) Su1997. . . . . ENTEROID FORMATION IS DEFECTIVEIN SAMP/YITFC…(2*) Su1998. . . . . MATRIX METALLOPROTEINASE/MMP-9 GENE KNOCKOUTDOES NOT…(2*)|(4) Su1999. . . . . SKIN INFLAMMATORY CHANGE AFFECTSGUT MICROBIAL…(5*) Su2000. . . . . WHEN TO START ASECOND FECAL…(2*)|(1) Su2001. . . . . THE FECAL MICROBIOME DIFFERENTIATESPATIENTS WITH…(2*) Su2002. . . . . DETECTION OF GUT DYSBIOSISDUE TO…(5*) Su2003. . . . . IN CROHN'S DISEASE, ANAGGRESSIVE DISEASE…(4*) Su2004. . . . . OUTCOMES OF GASTROINTESTINAL PERFORATIONSAMONG MEDICARE…(4*)

Su2005. . . . . GUT MICROBIOTA AND VENDORDIFFERENCES INFLUENCE…(3*)| Biomodels, LLC Su2006. . . . . LOOKING FOR THE MOSTUSEFUL TAXA…(5*) Su2007. . . . . PROFILES OF SMALL INTESTINALMICROBIOTA: POSSIBLE…(3*)| TSUMURA & CO. Su2008. . . . . SUCCESSFUL USE OF PROBIOTICVSL#3 FOR…(5*) Su2009. . . . . GUT MICROBIOTA: PREDICTOR OFSUCCESS IN…(4*) Su2010. . . . . GASTROINTESTINAL MICROBIOTA ACTIVELY MAINTAINSTHE ADULT…(2*) Su2011. . . . . SHARED GUT MICROBIOME DYSBIOSISIN CROHN'S…(2*)|(6) Su2012. . . . . INCREASED PULMONARY CO2 EXCRETIONIN PATIENTS…(3*)| The study was jointly supported by Commonwealth, LLC, and Synthetic Biologics, Inc. Su2013. . . . . DYSBIOSIS OF THE GASTRICMICROBIOTA ALTERS…(4*) Su2014. . . . . BOWEL OBSTRUCTION LEADS TOMICROBIOTA IMBALANCE,…(2*)|(4) Su2015. . . . . JEJUNAL FLORA OF PATIENTSWITH SMALL…(4*) Su2016. . . . . LOSS OF SHORT CHAINFATTY ACID-PRODUCING…(7*) Su2017. . . . . THE ASSOCIATION OF DONORSTOOL CONSISTENCY…(6*)| Niel and Anna Rasmussen Foundation Anna-Maria and Stephen Kellen Foundation Su2018. . . . . THE ASSOCIATION OF STOOLDONOR DIET…(6*) Su2019. . . . . EFFECT OF GUT MICROBIOTAON GLP-1…(5*)


* = Primary Source



Su2020. . . . . THE ROLE OF INTESTINALEPITHELIAL VITAMIN…(2*)|(4) Su2021. . . . . GUT MICROBIOME ANALYSIS REVEALSMAJOR DYSBIOSIS…(2*) Su2022. . . . . FECAL MICROBIOTA DIFFERENCES ACCORDINGTO THE…(2*) Su2023. . . . . INFLUENCE OF POTASSIUM-COMPETITIVE ACIDBLOCKERS AND…(5*) Su2024. . . . . THE INTESTINAL DYSBIOSIS FOUNDIN IBD-PATIENTS…(4*) Su2025. . . . . DIETARY FIBER INTAKE ISASSOCIATED WITH…(5*) Su2026. . . . . MOXIBUSTION MODULATES THE GUTMICROBIOTA IN…(4*) Su2027. . . . . THE INFLUENCE OF HELICOBACTERPYLORI ERADICATION…(2*)|(4) Su2028. . . . . CHARACTERISTICS OF PATIENTS UNDERGOINGFECAL MICROBIOTA…(5*) Su2029. . . . . EFFECTS OF LIRAGLUTIDE ONGASTRIC EMPTYING,…(2*) Su2030. . . . . BAR130, A HYODEOXYCHOLIC ACIDDERIVATIVE AS…(3*)| BAR Pharmaceuticals, Italy Su2031. . . . . HUMANIZATION OF A GASTRICINHIBITORY POLYPEPTIDE…(4*) Su2032. . . . . A SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED,16-WEEK TRIAL…(2*) Su2033. . . . . ARGON PLASMA COAGULATION ISEFFECTIVE IN…(4*) Su2034. . . . . MORPHOLOGICAL BRAIN ALTERATIONS ANDCHANGES IN…(2*)|(4)

Su2035. . . . . IMPROVEMENT IN GLUCOSE METABOLISMAFTER BARIATRIC…(5*) Su2036. . . . . EFFECT OF LAPAROSCOPIC SLEEVEGASTRECTOMY ON…(4*) Su2037. . . . . MOST GASTRIC BYPASS PATIENTSWITH ABNORMAL…(5*) Su2038. . . . . SURGICAL INTERVENTION OF ORTHOPEDICCONDITIONS DOES…(4*) Su2039. . . . . TRANSORAL OULET REDUCTION WITHFULL THICKNESS…(5*) Su2040. . . . . INTRAGASTRIC BALLOON TREATMENT FOROBESITY: MEDIUM,…(5*) Su2041. . . . . ENDOSCOPIC MANAGEMENT OF GASTRICLEAKS AFTER…(5*) Su2042. . . . . AUGMENTATION OF MEAL-RELATED SYMPTOMSFOLLOWING PLACEMENT…(4*)|(2) Su2043. . . . . OBESITY TREATMENT USING NONADJUSTABLE INTRAGASTRIC…(5*) Su2044. . . . . IMPROVEMENTS OF LIVER ANDGLYCAEMIC PARAMETERS…(4*)|(2) Su2045. . . . . COMMON BILE DUCT DILATIONAFTER BARIATRIC…(5*) Su2046. . . . . THE IMPACT OF INTRAGASTRICBALLOONS ON…(4*) Su2049. . . . . EXERCISE-DERIVED MYOKINES ALTER THEFATTY ACID…(2*) Su2050. . . . . GASTRIC CANCER AND O-GLCNACYLATION …(5*) Su2051. . . . . HUMAN TRANSCRIPTOME ARRAY REVEALSASSOCIATION OF…(4*)

Su2052. . . . . DUAL INHIBITOR SENSITIZES PANCREATICCANCER CELLS…(2*)|(4) Su2053. . . . . USE OF A COMBINATIONOF LENTIVIRUS…(4*) Su2054. . . . . DEVELOPMENT OF IPSC-BASED Î“Î”T-CELLIMMUNOTHERAPY FOR…(2*) Su2055. . . . . BLOCKING HYALURONIC ACID BINDINGTO TLR4…(2*) Su2056. . . . . ARE THERE PROGNOSTIC PARAMETERSFOR THE…(4*)| Rashid Hussain Trust, Kuala Lumpur, Malaysia Su2057. . . . . REAL TIME PHENOMENON ONNUCLEUS &…(5*) Su2058. . . . . DEVELOPMENT AND RELIABILITY OFTHE NEW…(5*) Su2059. . . . . LOCATION AND KUDO PITPATTERN REFLECT…(5*) Su2060. . . . . TREAT TO TARGET INCROHN'S DISEASE:…(5*) Su2061. . . . . CROHN'S DISEASE OF THETERMINAL ILEUM:…(5*) Su2062. . . . . PREDICTION OF TREATMENT RESPONSEIN CROHN'S…(5*) Su2063. . . . . WATER EXCHANGE (WE) SIGNIFICANTLYRAISES ADENOMA…(2*)|(4) Su2064. . . . . ULTRASONOGRAPHY WITH COLOR DOPPLERANALYSIS IN…(4*) Su2065. . . . . POINT OF CARE ULTRASOUNDACCURATELY DISTINGUISHES…(5*) Su2066. . . . . GASTROINTESTINAL PROBLEMS IN CHILDRENENROLLED IN…(4*)


* = Primary Source



Su2067. . . . . AGE-DEPENDENT VALUES OF FECALCALPROTECTIN IN…(6*)| CF Australia Research Trust Grant Su2068. . . . . DETERMINING THE AGE-RELATED LEVELSOF FECAL…(6*)| CF Australia Research Trust Grant Su2069. . . . . PREVALENCE OF KNOWN CONGENITALSUCRASE-ISOMALTASE DEFICIENCY…(3*)| QOL Medical, LLC sponsored this study. Su2070. . . . . LOSS OF NHE8 EXPRESSIONIMPAIRS CRYPT…(2*) Su2071. . . . . HYPERTENSION AND AGING AREASSOCIATED WITH…(5*) Su2072. . . . . AGE-RELATED CHANGES IN ABDOMINALPAIN IN…(3*)| This abstract is based on two studies, an intervention study and the Maastricht IBS cohort. Both studies were partly funded by Top Institute of Food and Nutrition. This is a public private partnership of science, industry and government conducting strateg Su2073. . . . . DIAGNOSING THE CHILD WITHDYSPHAGIA TO…(5*) Su2074. . . . . EZH2 INHIBITION PREVENTS AGE-RELATEDSENESCENCE OF…(2*)|(4) Su2075. . . . . CTRC G60G VARIANT ISCOMMON IN…(2*)|(6) Su2076. . . . . FECAL MICROBIOTA TRANSPLANTATION INCHILDREN DOES…(2*) Su2077. . . . . PREVALENCE OF ROME IVFUNCTIONAL GASTROINTESTINAL…(6*) Su2078. . . . . PREVALENCE OF FUNCTIONAL GASTROINTESTINALDISORDERS IN…(6*) Su2079. . . . . IMPAIRED POSTPRANDIAL COLONIC RESPONSEIN THE…(5*) Su2080. . . . . THE PROGNOSTIC VALUE OFMANOMETRY TESTING…(5*)

Su2081. . . . . USE OF MULTIDIMENSIONAL CLINICALPROFILES (MDCP)…(5*) Su2082. . . . . BASELINE CHARACTERISTICS AND OUTCOMEPREDICTORS IN…(5*) Su2083. . . . . INTRA- AND INTERRATER RELIABILITYOF THE…(5*) Su2084. . . . . GATORADEÂ© IS NO GOODSUBSTITUTE FOR…(5*) Su2085. . . . . SAFETY, TOLERABILITY, AND EFFICACYOF SERUM-DERIVED…(3*)| EnteraHealth Su2086. . . . . HIGH RESOLUTION ESOPHAGEAL MANOMETRYIN THE…(4*) Mo1002. . . . . POST-REFLUX SWALLOW-INDUCED PERISTALTIC WAVEINDEX AND…(5*) Mo1003. . . . . GASTRIN 17 IN SINGLINGOUT PATIENTS…(1*) Mo1004. . . . . EVALUATION OF GASTROESOPHAGEAL REFLUXBY DETECTING…(5*) Mo1005. . . . . ANALYSIS OF PROXIMAL ESOPHAGEALREFLUX EVENTS…(5*) Mo1006. . . . . PROXIMAL ESOPHAGEAL BASELINE IMPEDANCELEVELS ARE…(1*) Mo1007. . . . . THE EFFECT OF BILEREFLUX ON…(4*) Mo1008. . . . . VIGOR OF CONTRACTION ISDIRECTLY RELATED…(4*) Mo1009. . . . . POST-PRANDIAL HIGH RESOLUTION IMPEDANCEMANOMETRY IDENTIFIES…(2*) Mo1010. . . . . DISTAL CONTRACTILE INTEGRAL DURINGREGULAR SWALLOWS…(5*) Mo1011. . . . . PREDICTING ABNORMAL PH INPATIENTS WITH…(5*)

Mo1012. . . . . IMPEDANCE PH MONITORING HASA LIMITED…(5*) Mo1013. . . . . OBESITY IS ASSOCIATED WITHINCREASED ESOPHAGEAL…(2*) Mo1014. . . . . VALIDATION OF THE KOREANVERSION OF…(3*)| |AstraZeneca) Mo1015. . . . . THE DIAGNOSTIC YIELD OFGASTRIC PH-METRY…(4*) Mo1016. . . . . USEFULNESS OF ENDOSCOPIC-GUIDED MEASUREMENTOF MUCOSAL…(5*) Mo1017. . . . . EFFECTIVENESS OF ESOPHAGOGASTRODUODENOSCOPY INCHANGING TREATMENT…(5*) Mo1018. . . . . DUAL SENSOR PH MONITORINGUSING AN…(5*) Mo1019. . . . . OUTCOMES IN PRESUMED GERDPATIENTS WITH…(5*) Mo1020. . . . . LOW NOCTURNAL BASELINE IMPEDANCEIS PREVALENT…(5*) Mo1021. . . . . MEAN NOCTURNAL BASELINE IMPEDANCEMEASURED ON…(5*) Mo1022. . . . . TRADITIONAL DIAGNOSTIC CRITERIA FORESOPHAGEAL REFLUX…(5*) Mo1023. . . . . INEFFECTIVE ESOPHAGEAL MOTILITY: CLINICAL,MANOMETRIC AND…(5*) Mo1024. . . . . PREVALENCE OF GASTROESOPHAGEAL REFLUXDISEASE AMONG…(4*) Mo1025. . . . . INCREASED UPRIGHT REFLUX ONWIRELESS CAPSULE…(5*) Mo1026. . . . . INADEQUATE SYMPTOM CONTROL ONLONG-TERM PPI…(3*)| EndoStim BV


* = Primary Source



Mo1027. . . . . INCREASED FREQUENCY OF AIRSWALLOWS DURING…(5*) Mo1028. . . . . GERDQ IS HIGHLY PREDICTIVEOF EROSIVE…(5*) Mo1029. . . . . BILE ACID-INDUCED APE-1 MEDIATESSTAT3 ACTIVATION…(2*) Mo1030. . . . . IN NON-NEOPLASTIC BARRETT'S EPITHELIALCELLS, ACID…(2*) Mo1031. . . . . ANTI-TUMOR EFFECT OF THERACURMINÂ®,HIGHLY BIOAVAILABLE…(5*) Mo1032. . . . . CLINICAL OUTCOMES AND RISKOF LYMPH…(1*) Mo1033. . . . . ABERRANTLY METHYLATED VIMENTIN ISA SENSITIVE…(2*) Mo1034. . . . . THE EFFECT OF SPECIFICREFLUXATE COMPONENTS…(4*) Mo1035. . . . . ENDOSCOPIC TREATMENT VS. ESOPHAGECTOMYFOR PATIENTS…(5*) Mo1036. . . . . BILE ACIDS MAY INDUCEESOPHAGEAL CARCINOGENESIS…(2*) Mo1037. . . . . CELLULAR PATHWAYS ARE DIFFERENTIALLYACTIVATED IN…(4*) Mo1038. . . . . INHIBITION OF THE BMPPATHWAY PREVENTS…(2*) Mo1039. . . . . HIGH EXPRESSION OF CLAUDIN5 IN…(4*) Mo1040. . . . . THE LONG-TERM RESULTS OFRADIOFREQUENCY ABLATION…(5*) Mo1041. . . . . DOES THE INCIDENCE OFTHE ESOPHAGEAL…(5*) Mo1138. . . . . THE EXPRESSION OF MIR-19B-3PAND HIPK3…(2*)

Mo1139. . . . . INVERSE CORRELATION OF PLECKSTRINMRNA AND…(2*) Mo1140. . . . . MiR-143-3p induced by Helicobacterinfection inhibits…(2*) Mo1141. . . . . TOLL-LIKE RECEPTOR 10 POLYMORPHISMSAFFECT SUSCEPTIBILITY,…(4*) Mo1142. . . . . CARCINOGENIC HOST MICROENVIRONMENTS TARGETAND MODIFY…(2*) Mo1143. . . . . GENETIC MANIPULATION OF HELICOBACTERPYLORI CAG+…(2*) Mo1144. . . . . TH17 IMMUNE RESPONSE INH. PYLORI…(5*) Mo1145. . . . . MUC5AC NULL MICE AREPREDISPOSED TO…(2*) Mo1146. . . . . HELICOBACTER PYLORI GENETIC ANCESTRYIN CENTRAL…(2*) Mo1147. . . . . HYPUSINATION IS A MASTERREGULATOR OF…(2*) Mo1148. . . . . Induction of the Cystathionineγ-Lyase/Hydrogen Sulfide…(2*) Mo1149. . . . . GASTRIC MICROBIOTA ASSOCIATED TOHELICOBACTER PYLORI…(4*) Mo1150. . . . . UNRAVELLING THE IMMUNE RESPONSETO HELICOBACTER…(3*)| This study was sponsored by Ondek Pty. Ltd. Mo1151. . . . . CLINICAL OUTCOMES OF ENDOSCOPICRESECTION FOR…(5*) Mo1152. . . . . PREDICTORS OF SURVIVAL INPATIENTS WITH…(5*) Mo1153. . . . . DELTA-LIKE 3 EXPRESSION INGASTROINTESTINAL NEUROENDOCRINE…(5*) Mo1154. . . . . GASTROENTEROPANCREATIC

NEUROENDOCRINE TUMORS: SIZEAS AN…(5*) Mo1155. . . . . HETEROGENEITY OF TYPE 1GASTRIC NEUROENDOCRINE…(5*) Mo1156. . . . . COMPARISON OF OUTCOMES AFTERDIFFERING SURGICAL…(5*) Mo1157. . . . . TYPE 3 GASTRIC NEUROENDOCRINENEOPLASMS: RELATIONSHIP…(5*) Mo1158. . . . . EXPRESSION AND ONCOGENIC FUNCTIONOF NEUROTENSIN…(2*) Mo1297. . . . . PANCREATIC CYSTS WITHOUT WORRISOMEFEATURES AT…(5*) Mo1298. . . . . LONG-TERM FOLLOW-UP OF PATIENTSWITH BRANCH-DUCT…(5*) Mo1299. . . . . AGREEMENT BETWEEN MAGNETIC RESONANCECHOLANGIOPANCREATOGRAPHY (MRCP)…(5*) Mo1300. . . . . DIFFERENCES IN PANCREATIC CANCERDEVELOPMENT AND…(5*) Mo1301. . . . . ASSOCIATION WITH DEGREE OFDIABETES MELLITUS…(5*) Mo1302. . . . . PREDICTION OF ADVANCED NEOPLASIAIN PANCREATIC…(5*) Mo1303. . . . . PREDICTIVE FACTORS FOR SURVIVALIN A…(5*) Mo1304. . . . . PREDICTORS OF PROGRESSION AMONGLOW RISK…(5*) Mo1305. . . . . IPMN SURVEILLANCE DOES NOTREDUCE PANCREATIC-CANCER…(5*) Mo1306. . . . . FEASIBILITY AND COST-EFFECTIVENESS OFINTRA-OPERATIVE ISLET…(5*)


* = Primary Source



Mo1307. . . . . THE EFFECT OF MEDICALCANNABIS ON…(5*) Mo1308. . . . . RECURRENCE RATES AFTER SURGICALRESECTION OF…(5*) Mo1309. . . . . HIGH VARIABILITY IN SERIALPANCREATIC CYST…(5*) Mo1310. . . . . PREOPERATIVE AND POSTOPERATIVE ANALYSISOF SEROUS…(5*) Mo1312. . . . . THE ACTUAL INCIDENCE OFSYMPTOMS IN…(5*) Mo1313. . . . . PATHOLOGICAL EVALUATION AND REPORTINGOF INTRADUCTAL…(5*) Mo1314. . . . . PATIENT AND DISEASE CHARACTERISTICSASSOCIATED WITH…(2*) Mo1315. . . . . PROGNOSIS OF TYPE 1AUTOIMMUNE PANCREATITIS…(5*) Mo1316. . . . . ARTERIAL PSEUDOANEURYSM IN ACUTEAND CHRONIC…(5*) Mo1317. . . . . IMPAIRED GLUCOSE HOMEOSTASIS DOESNOT PREDICT…(5*) Mo1318. . . . . ORAL PANCREATIC ENZYME REPLACEMENTTHERAPY (PERT)…(4*) Mo1319. . . . . IDENTIFYING MALNUTRITION AND ITSCONSEQUENCES IN…(5*) Mo1320. . . . . THE BURDEN OF CHRONICPANCREATITIS IN…(2*) Mo1321. . . . . DEVELOPMENT OF AN EXVIVO PANCREAS…(3*)| |Alcresta Therapeutics, Inc.) Mo1322. . . . . PREDICTORS OF POSITIVE SECRETINPANCREATIC FUNCTION…(5*) Mo1323. . . . . A COMPARISON OF SMOKERSWITH NON-SMOKERS…(5*)

Mo1324. . . . . IS OBSTRUCTIVE CHRONIC PANCREATITISDUE TO…(5*) Mo1325. . . . . INCIDENCE ,ADMISSION RATES ANDECONOMIC BURDEN…(5*) Mo1326. . . . . INDICATIONS AND CLINICAL OUTCOMESFOR ISLET…(5*) Mo1327. . . . . PRESCRIPTION PRACTICES OF PANCREATICENZYME REPLACEMENT…(5*) Mo1328. . . . . CONCORDANCE BETWEEN IMAGING, ULTRASONOGRAPHICAND FUNCTIONAL…(5*) Mo1329. . . . . CHRONIC PANCREATITIS (CP). CLINICALCHARACTERISTICS AND…(5*) Mo1330. . . . . RESULTS OF NON-OPERATIVE MANAGEMENTFOR INTRADUCTAL…(5*) Mo1331. . . . . DO FECAL ELASTASE LEVELSPREDICT CHRONIC…(5*) Mo1453. . . . . ANALYSIS OF PRE- ANDPOST-TREATMENT METABOLIC…(5*) Mo1454. . . . . BAR501, A SELECTIVE GPBAR1AGONIST, PROMOTES…(3*)| BAR Pharmaceutical, Italy Mo1455. . . . . ABSOLUTE RISK OF HEPATOCELLULARCARCINOMA IN…(2*) Mo1456. . . . . LONG-TERM OUTCOMES OF PATIENTSWITH NON-OBESE…(1*) Mo1457. . . . . MULTIPLE EFFECTS OF PROSTAGLANDINI2-IP SIGNALING…(4*) Mo1458. . . . . ARE THERE DIFFERENT PREDICTORSOF MORTALITY…(4*) Mo1459. . . . . INDUCIBLE NITRIC OXIDE SYNTHASEIS INDEPENDENTLY…(4*) Mo1460. . . . . APOLIPOPROTEIN (APO)A-V DEFICIENCY ENHANCESHEPATIC SYNTHESIS…(2*)

Mo1461. . . . . DIETARY INTERVENTIONS AND THEROLE OF…(4*) Mo1462. . . . . MYOKINES AS A MEDIATOROF ANTI-NAFLD…(4*) Mo1463. . . . . THE HIGH PREVALENCE OFNAFLD IN…(4*) Mo1464. . . . . SPECTRUM AND PREDICTORS OFADVANCED DISEASE…(5*) Mo1465. . . . . ALTERED BILE ACID SYNTHESISPATHWAY IN…(5*) Mo1466. . . . . THE IMPACT OF AUTONOMICDYSFUNCTION ON…(4*) Mo1467. . . . . MULTIDISCIPLINARY WEIGHT LOSS PROGRAMSLEAD TO…(5*) Mo1468. . . . . PILOT STUDY OF THEPREVALENCE OF…(4*) Mo1469. . . . . HEPATIC INFLAMMATION IN RATSINDUCED BY…(5*) Mo1470. . . . . INDEPENDENT ASSOCIATION BETWEEN NONALCOHOLICFATTY LIVER…(5*) Mo1471. . . . . HELICOBACTER PYLORI INFECTION INCREASESRISK FOR…(5*) Mo1472. . . . . DIABETES, HEART FAILURE, ANDCHRONIC KIDNEY…(5*) Mo1477. . . . . ESOPHAGOGASTRIC JUNCTION OUTFLOW OBSTUCTION(EGJOO): INCREASING…(5*) Mo1478. . . . . ESOPHAGEAL HIGH RESOLUTION MANOMETRYVARIABLES IN…(5*) Mo1479. . . . . ELEVATED INTRABOLUS PRESSURE (IBP)AS A…(4*) Mo1480. . . . . CLINICAL AND PSYCHOLOGICAL CHARACTERISTICSOF PATIENTS…(5*)


* = Primary Source



Mo1481. . . . . INFLUENCE OF THE VISCOSITYOF THE…(5*) Mo1482. . . . . COMPARISON OF GASTROESOPHAGEAL REFLUXAFTER ANTERIOR…(5*) Mo1483. . . . . CORRELATION OF PHARYNGEAL PHASEOF SWALLOWING…(2*) Mo1484. . . . . RHO KINASE-ASSOCIATED MYOGENIC CONTRACTIONCOMPENSATES FOR…(5*) Mo1485. . . . . CHANGE IN ECKARDT SCOREWITH PERORAL…(5*) Mo1486. . . . . 200ML RAPID DRINK CHALLENGEDURING HIGH…(4*) Mo1487. . . . . PREDICTIVE VALUE OF TIMEDBARIUM SWALLOW…(5*) Mo1488. . . . . TIMED BARIUM SWALLOW: DIAGNOSTICROLE IN…(5*) Mo1489. . . . . BOLUS FLOW PATTERN INPATIENTS WITH…(2*) Mo1490. . . . . LACK OF LONG-TERM ACHALASIAFOLLOW UP…(5*) Mo1491. . . . . LOW-VOLUME MULTIPLE RAPID SWALLOWBETTER DISTINGUISH…(4*) Mo1492. . . . . HIGH-VOLUME RAPID DRINKING TESTBETTER DISTINGUISH…(4*) Mo1493. . . . . IS INTEGRATED RELAXATION PRESSUREA PROMISING…(5*) Mo1494. . . . . IMPROVING HIGH-RESOLUTION IMPEDANCE MANOMETRY:A PROSPECTIVE…(6*) Mo1495. . . . . IDENTIFICATION OF HIATUS HERNIABY HIGH…(5*) Mo1496. . . . . CHANGE IN THE INTERSTITIALCELLS OF…(5*)

Mo1497. . . . . TIME BARIUM ESOPHAGRAM ASSISTSWITH THERAPY…(5*) Mo1498. . . . . SHORT-TERM OUTCOME OF PERORAL ENDOSCOPIC…(2*) Mo1499. . . . . RETAINED ESOPHAGEAL CONTRAST ONMODIFIED BARIUM…(5*) Mo1500. . . . . THE ROLE OF TRIMEBUTINEIN THE…(1*) Mo1501. . . . . INVESTIGATION OF SHORT-TERM EFFICACYOF N-ACETYLCYSTEINE…(5*) Mo1502. . . . . 24-H HIGH RESOLUTION MANOMETRYWITH IMPEDANCE…(3*)| Part of the materials needed for performance of 24h-HRIM were sponsored by Standard Instruments. Mo1503. . . . . GASTROESOPHAGEAL REFLUX DISEASE SYMPTOMCORRELATION WITH…(5*) Mo1504. . . . . THE SOLUBLE GUANYLATE CYCLASESTIMULATOR IW-1701…(3*)| Ironwood Pharmaceuticals Mo1505. . . . . ASSOCIATION BETWEEN SCLERODERMA ESOPHAGUSAND SYSTEMIC…(5*) Mo1506. . . . . MANOMETRIC CHARACTERISTICS OF ESOPHAGEALSTRIATED MUSCLE…(2*) Mo1507. . . . . ESOPHAGEAL FOOD IMPACTION WITHAND WITHOUT…(5*) Mo1508. . . . . ESOPHAGEAL DISTENSIBILITY IN PROTONPUMP INHIBITOR…(4*) Mo1509. . . . . EFFECTS OF LARYNGEAL RESTRICTIONON CERVICAL…(2*) Mo1510. . . . . MYOARCHITECTURE OF THE HUMANESOPHAGEAL HIATUS…(2*) Mo1511. . . . . THE PHENOTYPES OF PATIENTSWITH HEARTBURN…(5*)

Mo1512. . . . . CHARACTERIZATION OF HIGH RESOLUTIONMANOMETRY (HRM)…(5*) Mo1513. . . . . THE NATURAL HISTORY OFACHALASIA: EVIDENCE…(5*) Mo1514. . . . . ESOPHAGEAL STASIS ON BARIUMESOPHAGOGRAM IN…(5*) Mo1515. . . . . FAILED SWALLOWS INCREASE RISKOF EARLY…(5*) Mo1516. . . . . DIAGNOSIS OF ESOPHAGEAL MOTILITYABNORMALITIES, AND…(4*) Mo1517. . . . . THE HISTOPATHOLOGY RESEARCH OFACHALASIA …(5*) Mo1518. . . . . TREATMENT OUTCOMES IN PATIENTSWITH INEFFECTIVE…(5*) Mo1519. . . . . EFFECT OF EXPERIMENTAL PERTURBATIONOF PHARYNGEAL…(2*) Mo1520. . . . . EFFECTS OF ESOPHAGEAL VARICEALBAND LIGATION…(5*) Mo1521. . . . . IMPACT OF PARAESOPHAGEAL HERNIAON ESOPHAGEAL…(5*) Mo1522. . . . . COMPLICATIONS PRIOR AND AFTERSURGICAL REPAIR…(2*)|(4) Mo1523. . . . . PELVIC FLOOR PHYSICAL THERAPYIS EFFECTIVE…(5*) Mo1524. . . . . CAN PRE-OPERATIVE NJ FEEDINGOR GASTRIC…(5*) Mo1525. . . . . PPI TREATMENT IN CHILDRENWITH ESOPHAGEAL…(5*) Mo1526. . . . . FUNCTIONAL ABDOMINAL PAIN DISORDERSAMONG CHILDREN…(2*) Mo1527. . . . . A NOVEL APPROACH TOMEASURE PHARYNGEAL…(2*)


* = Primary Source



Mo1528. . . . . PREVALENCE OF PSYCHIATRIC COMORBIDITYIN URBAN…(4*) Mo1529. . . . . THE PREVALENCE OF ROMEIV NON-EROSIVE…(2*)|(4)|(4)|(4)|) Mo1530. . . . . IMPROVING THE CLINICAL UTILITYOF ELECTROGASTROGRAPHY…(4*) Mo1531. . . . . THE CLINICAL FEEDING EVALUATIONHAS POOR…(2*) Mo1532. . . . . ADEQUATE DETERMINATION OF THETRANSITION ZONE…(5*) Mo1533. . . . . METABOLOMICS ANALYSIS IDENTIFIES NOVELBIOMARKERS OF…(2*)|(4) Mo1534. . . . . PRESENTING SYMPTOMS AND TIMINGOF SYMPTOMS…(2*) Mo1535. . . . . THE ROLE OF PUBERTYIN THE…(5*) Mo1536. . . . . MORTALITY, MORBIDITY AND LENGTHOF HOSPITAL…(5*) Mo1537. . . . . IMPACT OF ANTIBIOTIC-INDUCED MICROBIOTADEPLETION ON…(4*) Mo1538. . . . . SCN3A-ENCODED VOLTAGE-GATED SODIUM CHANNELNAV1.3 BESTOWS…(2*) Mo1539. . . . . Îœ-OPIOID RECEPTORS CO-EXPRESSED INCHOLINERGIC NEURONS…(2*) Mo1540. . . . . TOLL-LIKE RECEPTOR 4 MODULATESNEUROMUSCULAR FUNCTION…(4*) Mo1541. . . . . ORAL ADMINISTRATION OF THEGUT-RESTRICTED GUANYLATE…(3*)| Allergan, plc and Ironwood Pharmaceuticals, Inc. Mo1542. . . . . OUTLET OBSTRUCTION DOES NOTCONFOUND THE…(4*)|(3)

Mo1543. . . . . TRAUMA SEVERITY AND LACKOF CONFIDING…(2*) Mo1544. . . . . EHLERS DANLOS SYNDROME ISASSOCIATED WITH…(6*) Mo1545. . . . . PATIENTS WITH IBS-C REPORTMORE SEVERE,…(3*)| |The National GI Survey was funded by Ironwood Pharmaceuticals.) Mo1546. . . . . ASSESSING LONG-TERM PERSISTENCE WITHPHARMACOTHERAPY FOR…(5*) Mo1547. . . . . VOLATILE ORGANIC COMPOUNDS PREDICTRESPONSE TO…(2*) Mo1548. . . . . LINACLOTIDE IS EFFECTIVE ANDSAFE FOR…(3*)| |Supported by Astellas Pharma, Inc.) Mo1549. . . . . PREDICTORS OF QUALITY OFLIFE IN…(2*) Mo1550. . . . . CLINICAL FACTORS AND ANTIBIOTICUSE DURING…(2*)|(7) Mo1551. . . . . PREVALENCE OF EATING DISORDERS,ESPECIALLY DSM-5'S…(4*) Mo1552. . . . . INCREASED SLEEP DISTURBANCES INIRRITABLE BOWEL…(2*) Mo1553. . . . . ABDOMINAL DISTENTION SYMPTOM COMPLEXWITHOUT FUNCTIONAL…(4*)|(7) Mo1554. . . . . NO DISTINCTION OF MULTIDIMENSIONALCLINICAL PROFILES…(2*) Mo1555. . . . . APPLICATION OF ROME IIIVS. ROME…(4*) Mo1556. . . . . PROTON PUMP INHIBITORS, IRRITABLEBOWEL SYNDROME…(3*)|(4)| Prometheus Laboratories Mo1557. . . . . SELF-REPORTED ASTHMA AND FOODALLERGY ARE…(3*)|(4)| Prometheus Laboratories

Mo1558. . . . . EVIDENCE FOR AN ASSOCIATIONBETWEEN CONDITIONS…(3*)|(4)| Prometheus Laboratories Mo1559. . . . . IBS WITH CONSTIPATION ISCHARACTERIZED BY…(1*)|(3)| This study, in part, was funded by an unrestricted grant from Allmirall. Mo1560. . . . . ANTIBODIES TO VINCULIN ANDCYTOLETHAL DISTENDING…(1*)|(3)| This study was funded in part by Almirall via an unrestricted grant Mo1561. . . . . BILE ACID MALABSORPTION ISNUMERICALLY LESS…(5*) Mo1562. . . . . THE LOW FODMAP DIETIS EQUALLY…(4*)|(3)| Prometheus Laboratories, Inc Mo1563. . . . . ASSESSMENT OF BODY MASSINDEX, OBESITY,…(4*) Mo1564. . . . . THE EFFICACY AND TOLERABILITYOF MEBEVERINE…(4*)|(5) Mo1565. . . . . DECLINING RATES OF REFERRALTO TERTIARY…(5*) Mo1566. . . . . PREVALENCE, INCIDENCE, AND VARIABILITYOF IRRITABLE…(5*) Mo1567. . . . . STRESS INDUCES SPECIFIC GENDER-RELATEDMOLECULAR ALTERATIONS…(2*) Mo1568. . . . . INTEGRATED MULTI-OMIC ANALYSIS REVEALSFEMALE PREDOMINANCE…(2*) Mo1569. . . . . FOOD ANTIGEN-SPECIFIC ANTIBODIES ANDMAST CELL…(2*) Mo1570. . . . . LUMINAL PROTEASES MODULATE INTESTINALBARRIER FUNCTION…(2*)|(4) Mo1571. . . . . EXPRESSION PROFILING OF SIGMOIDBIOPSIES IN…(2*)


* = Primary Source



Mo1572. . . . . DYSREGULATION OF THE LONG-NONCODINGRNA, GHRLOS,…(2*) Mo1573. . . . . SPINAL 5-HT3 RECEPTOR INHIBITIONENHANCES VISCERAL…(2*) Mo1574. . . . . OVARIECTOMY INCREASES VISCERAL SENSITIVITYIN SEROTONIN…(2*) Mo1575. . . . . SEX-DEPENDENT ALTERATIONS OF COLONICEPITHELIAL PERMEABILITY…(2*) Mo1576. . . . . INCREASE IN VISCERAL PAINSENSITIVITY TO…(2*) Mo1577. . . . . HEMATOLOGICAL, IL-10, AND MICRORNAPERTURBATIONS IN…(2*)|(6)| Howard Hughes Medical Institute, Burroughs Wellcome Fund Mo1578. . . . . AUTONOMIC NERVOUS SYSTEM FUNCTIONIN PATIENTS…(4*)|(3)| Supported by Da Nutricia Research) Mo1579. . . . . AN EXPLORATORY FACTOR ANALYSISOF PSYCHOLOGICAL…(5*) Mo1580. . . . . EPHRINB2/EPHB2 PROMOTED SYNAPTIC PLASTICITYOF ENTERIC…(4*)| Funding: This study was supported by grant from the National Natural Science Foundation of China (NSFC 81570486, 81070300). Mo1581. . . . . IS THE ASSOCIATION BETWEENPSYCHOLOGICAL DISTRESS…(5*) Mo1582. . . . . SOMATISATION INDIRECTLY EFFECTS THERELATIONSHIP BETWEEN…(5*) Mo1583. . . . . ABNORMAL ILEAL STEM-, NEUROGENIN3-AND ENTEROENDOCRINE-CELLS…(4*) Mo1584. . . . . WHOLE EXOME SEQUENCING OFA HIGH-PENETRANCE…(4*)

Mo1585. . . . . CONTRIBUTION OF GASTROINTESTINAL MICROBIOTAIN THE…(2*) Mo1586. . . . . CORTICOTROPIN-RELEASING FACTOR (CRF) INDUCEDINTESTINAL HYPERMOTILITY…(2*) Mo1587. . . . . FROM GENE POLYMORPHISM TOSERUM INTERLEUKIN-6…(5*) Mo1588. . . . . DIOSMECTITE TREATMENT SUPPRESSES GUTVISCERAL HYPERSENSITIVITY…(3*)|(2)| Funded by IPSEN Pharma Mo1589. . . . . ALTERED BRAIN STRUCTURE ANDFUNCTIONAL CONNECTIVITY…(2*)|(4) Mo1590. . . . . MATURATION PHENOTYPE OF PERIPHERALBLOOD MONOCYTE/MACROPHAGE…(4*) Mo1591. . . . . INCREASE IN PERIPHERAL BLOODNON-CLASSICAL MONOCYTES…(4*) Mo1592. . . . . COLONIC FEATURES OF THENORMOGLYCEMIC BIOBREEDING…(2*)|(4) Mo1593. . . . . DIFFERENCE OF CHROMOGRANIN ACELL DENSITY…(4*) Mo1594. . . . . RELATIONSHIP BETWEEN INTESTINAL MOTILITYAND SMALL…(5*) Mo1595. . . . . LONG TERM GASTRIC ELECTRICALSTIMULATION HAS…(2*) Mo1596. . . . . OPTOGENETIC ACTIVATION OF CENTRALAMYGDALOID CIRCUITRY…(2*)|(6) Mo1597. . . . . ROLES OF ENDOGENOUS OPIOIDACTIVITY IN…(2*)|(4) Mo1598. . . . . COLONIC SUPERNATANTS FROM CHRONICMORPHINE EXPOSED…(2*)

Mo1599. . . . . PROTEASES IN COLONIC TISSUEFROM IBS…(2*)|(6) Mo1600. . . . . TIBIAL NERVE STIMULATION IMPROVESVISCERAL HYPERSENSITIVITY…(5*) Mo1601. . . . . UPREGULATION OF ESOPHAGEAL PROSTAGLANDINE2 LEVELS…(4*) Mo1602. . . . . IDENTIFICATION OF A RETKINASE INHIBITOR,…(3*) Mo1603. . . . . MECHANISMS INVOLVED IN THELONG-TERM EFFECTS…(2*) Mo1604. . . . . PREDICTORS OF INADEQUATE BOWELPREPARATION FOR…(5*) Mo1605. . . . . EFFICACY OF VARIOUS ENDOSCOPICMODALITIES IN…(5*) Mo1606. . . . . CT COLONOGRAPHY (CTC) VSOPTICAL COLONOSCOPY…(5*) Mo1607. . . . . CELIAC DISEASE AND INCREASEDRISK OF…(5*) Mo1608. . . . . COMPARATIVE EFFICACY OF COLDBIOPSY VERSUS…(5*) Mo1609. . . . . HOSPITAL-ACQUIRED CLOSTRIDIUM DIFFICILE INFECTIONRISK COMPARISONS,…(5*) Mo1610. . . . . EFFICACY AND SAFETY OF5-HYDROXYTRYPTAMINE 3…(5*) Mo1611. . . . . COMPARISON OF KEY QUALITYMEASURES BETWEEN…(5*) Mo1612. . . . . THE DIFFERENTIAL ROLE OFHUMAN CATIONIC…(2*) Mo1613. . . . . IS THE RATE OFSESSILE SERRATED…(2*) Mo1614. . . . . DEMOGRAPHIC VARIATION AND TEMPORALTRENDS IN…(5*)


* = Primary Source



Mo1615. . . . . EDTA COMPOUNDS, AS USEDIN FOOD…(7*) Mo1616. . . . . TACROLIMUS AS RESCUE THERAPYFOR STEROID…(2*) Mo1617. . . . . THE PROTECTIVE EFFECT OFBOJANGGUNBI-TANG ESSENCE…(2*)| Korea Evaluation Institute of Industrial Technology (No. 10060251). Mo1618. . . . . NUTRITIONAL WHEAT ALPHA-AMYLASE/TRYPSIN PROMOTEAZOXYMETHANE/DEXTRAN SULFATE…(4*) Mo1619. . . . . DIVERTICULITIS IS ASSOCIATED WITHINCREASED ABDOMINAL…(2*) Mo1620. . . . . EMU OIL ATTENUATES DISEASESEVERITY AND…(4*) Mo1639. . . . . THE ROLE OF PH-SENSINGRECEPTOR TDAG8…(2*)|(4) Mo1640. . . . . CROSSTALK BETWEEN EPITHELIAL IKKÎ’AND STAT3…(2*)|(4) Mo1641. . . . . PROTEIN KINASE D (PKD)MEDIATES YES-ASSOCIATED…(2*) Mo1642. . . . . IMMUNE REGULATORY EFFECT OFPHOSPHATASE AND…(4*) Mo1643. . . . . REDUCED INFLAMMASOME ACTIVATION UPONLOSS OF…(2*)|(4) Mo1644. . . . . MUCOSAL BARRIER DYSFUNCTION MAYDEVELOP GASTRIC…(5*) Mo1645. . . . . THE TRANS-GOLGI NETWORK PROTEINAFTIPHILIN IS…(2*)|(6) Mo1646. . . . . HYPOXIA AMELIORATES INFLAMMATION THROUGHTHE INHIBITION…(2*) Mo1647. . . . . MITOCHONDRIA IN GASTRIC EPITHELIALCELLS ARE…(2*)

Mo1648. . . . . POLY(I:C) REGULATES THE INTESTINALBARRIER FUNCTION…(5*) Mo1649. . . . . RIP3, A REGULATOR OFNECROPTOSIS, PROMOTES…(5*) Mo1650. . . . . DIPOTASSIUM GLYCYRRHIZATE MODULATES GENESWITH A…(5*) Mo1651. . . . . INACTIVATION OF EPHRINA1/EPHA2 KINASEATTENUATES LIPOPOLYSACCHARIDE-INDUCED…(4*)| Funding: This study was supported by grant from the National Natural Science Foundation of China (NSFC 81570486). Mo1652. . . . . IMPACT OF PROINFLAMMATORY CYTOKINESAND MESALAMINE…(3*)|(4)| This work was supported by an unrestricted research grant by Shire to D. C. Baumgart. The grants and contracts have been checked by the legal Department of Charité Universitätsmedizin (Berlin, Germany) and have been approved by the directorate of the Facu) Mo1653. . . . . PATIENTS IN REMISSION AREMORE LIKELY…(6*) Mo1654. . . . . NATURAL HISTORY OF DYSPLASIAAND COLORECTAL…(5*) Mo1655. . . . . CORRELATION BETWEEN PHYSICIAN ANDPATIENT DISEASE…(3*)| AbbVie Mo1656. . . . . FACTORS IMPACTING PATIENT REPORTEDHEALTH-RELATED QUALITY…(2*) Mo1657. . . . . CHOLECYSTECTOMY FOR BILIARY DYSKINESIA:CAN WE…(5*) Mo1658. . . . . FREQUENT FLYERS'� IN EMERGENCYDEPARTMENTS: WHY…(5*) Mo1659. . . . . EFFECT OF ADALIMUMAB DOSEESCALATION ON…(3*)| AbbVie Mo1660. . . . . EFFECT OF ADALIMUMAB ONEXTRAINTESTINAL MANIFESTATIONS…(3*)| AbbVie

Mo1661. . . . . ADALIMUMAB LONG-TERM EFFECTIVENESS INADALIMUMAB-NAÃ�VE PATIENTS…(3*)| AbbVie Mo1662. . . . . PRESENCE OF ANGIODYSPLASIA ISASSOCIATED WITH…(5*) Mo1663. . . . . ADALIMUMAB EFFICACY AND SAFETYBY DISEASE…(3*)| AbbVie Mo1664. . . . . DOES PERORAL ENDOSCOPIC MYOTOMY(POEM) IMPROVE…(5*) Mo1665. . . . . THE WAITING ROOM QUESTIONNAIRE:VALIDATION OF…(5*) Mo1666. . . . . DIFFERENCES IN DEMOGRAPHIC ANDSYMPTOM-RELATED CHARACTERISTICS…(3*)| Allergan plc and Ironwood Pharmaceuticals Mo1667. . . . . UNDERSTANDING SYMPTOM BURDEN ANDATTITUDES IN…(3*)| This study was supported by Allergan plc. Mo1668. . . . . EFFECTS OF PATIENT EDUCATIONON ADHERENCE…(5*) Mo1669. . . . . ASSOCIATION BETWEEN PHARMACOKINETICS OFADALIMUMAB AND…(5*) Mo1670. . . . . DISPARITIES IN THE INTEGRATIONOF MENTAL…(4*) Mo1671. . . . . INFLAMMATORY BOWEL DISEASE (IBD)PATIENT EXPERIENCES…(4*) Mo1672. . . . . COMPARATIVE SHORT AND LONGTERM EFFICACY…(5*) Mo1673. . . . . FACTORS ASSOCIATED WITH ANXIETYABOUT COLONOSCOPY:…(2*) Mo1674. . . . . PREDICTORS OF SELF-EFFICACY INMANAGEMENT OF…(5*) Mo1675. . . . . EFFECTS OF BEHAVIORAL TREATMENTON ANXIETY…(1*)


* = Primary Source



Mo1676. . . . . PREDICTORS OF IN-HOSPITAL MORTALITYIN PATIENTS…(5*) Mo1677. . . . . SALIVARY CORTISOL AS ABIOMARKER OF…(5*) Mo1678. . . . . PATIENT FACTORS AS PREDICTORSOF BOWEL…(4*) Mo1679. . . . . RANDMIZED, OPEN-LABEL TRIAL COMPARINGEFFICACYOF BURDOCK…(5*) Mo1680. . . . . THIOPURINES IS A BETTEROPTION OVER…(5*) Mo1681. . . . . A QUALITATIVE ANALYSIS OFPATIENT ATTITUDES…(2*) Mo1682. . . . . DEVELOPMENT OF A COREOUTCOME SET…(5*) Mo1683. . . . . DEVELOPMENT OF A COREOUTCOME SET…(5*) Mo1684. . . . . NUTRITIONAL HABITS AND FODMAPSIN RELATION…(4*) Mo1685. . . . . LOW-FODMAP DIET RESULTED EFFECTIVEIN RELIEVING…(5*) Mo1686. . . . . FACTORS THAT PREDICT INTESTINALRESECTION IN…(5*) Mo1687. . . . . TOWARDS A PATIENT-REPORTED OUTCOMESBASED SEVERITY…(3*)| This study was supported by Allergan plc. Mo1688. . . . . THE SAFETY OF ENDOSCOPISTDIRECTED NURSE…(5*) Mo1689. . . . . A PROSPECTIVE COHORT STUDYTO ASSESS…(5*) Mo1690. . . . . PHENOTYPIC CHARACTERISTICS CAN PREDICTTHE NEED…(5*) Mo1691. . . . . PERCEIVED UTILITY OF SOCIALMEDIA AND…(5*)

Mo1692. . . . . USEFULNESS OF ABDOMINAL ULTRASONOGRAPHYFOR PATENCY…(5*) Mo1693. . . . . SCREENING FOR H. PYLORIINFECTION BY…(5*) Mo1694. . . . . VEDOLIZUMAB INDUCES SIGNIFICANTLY HIGHERENDOSCOPIC REMISSION…(5*) Mo1695. . . . . VEDOLIZUMAB AND METHOTREXATE COMBINATIONFOR MODERATE…(1*)|(4) Mo1696. . . . . THERAPEUTIC STRATEGIES FOR MUCOSALHEALING IN…(5*) Mo1697. . . . . DIETARY FIBER AND WATERIMPROVE BOWEL…(4*) Mo1698. . . . . HIGH-RESOLUTION ANORECTAL MANOMETRY ANDSENSORY FUNCTION…(1*) Mo1699. . . . . EFFICACY AND PREDICTORS FORBIOFEEDBACK THERAPEUTIC…(5*) Mo1700. . . . . PROPER PREPARATION FOR COLONOSCOPYBASED ON…(1*) Mo1701. . . . . THE CYTOKINE RECEPTOR PAIRTL1A/DR3 MEDIATES…(2*) Mo1702. . . . . NEONATAL COLONIC INFLAMMATION SENSITIZESTHE COLON…(4*)|(2) Mo1703. . . . . GENETIC DELETION OF FIBROBLASTGROWTH FACTOR-INDUCIBLE…(2*) Mo1704. . . . . TOB1 DEFICIENCY PROMOTES INTESTINALMUCOSAL INFLAMMATION…(2*) Mo1705. . . . . MUCIN 2 EXPRESSION ISDEPENDENT UPON…(4*)|(2) Mo1706. . . . . LOSS OF PTPN2 INDENDRITIC CELLS…(2*)|(4)

Mo1707. . . . . THE ROLE OF PROTEINO-GLCNACYLATION IN…(5*) Mo1708. . . . . THE Î‘7 NICOTINIC ACETYLCHOLINERECEPTOR AGONIST…(5*) Mo1709. . . . . A ROLE OF IRHOM2IN CHRONIC…(5*) Mo1710. . . . . SUPPRESSION OF EXPERIMENTAL ULCERATIVECOLITIS BY…(4*)|(3)| Sterna Biologicals Mo1711. . . . . A MECHANISM OF ACTIONFOR CYCLOSPORINE…(4*) Mo1712. . . . . BALANCING JAK/STAT-SIGNALING WITH TOFACITINIBIN MONOCYTES…(3*)| EUROPE ASPIRE 2014 Research Award (60.000 €) Mo1713. . . . . THE ROLE OF THERS8005161 POLYMORPHISM…(2*) Mo1714. . . . . EXPANSION OF IL-23 RECEPTORBEARING TNFR2+…(2*) Mo1715. . . . . ROLE OF INNATE LYMPHOIDCELLS IN…(5*) Mo1716. . . . . MATERNAL IBD AND IBDTHERAPIES MAY…(4*) Mo1717. . . . . AN ABERRANT SUMOYLATION DEPENDENTSUB-PROGRAMMING OF…(5*) Mo1718. . . . . THE SYSTEMIC INFLAMMATORY RESPONSETO CLOSTRIDIUM…(4*) Mo1719. . . . . Systemic TNF-α Reduction byBlocking IgE-Mediated…(3*)| STC Biologics, Cambridge, MA Mo1720. . . . . UTILITY OF SERUM CYTOKINEANALYSIS BY…(2*) Mo1721. . . . . SERUM POLYUNSATURATED FATTY ACIDSCORRELATE WITH…(2*)


* = Primary Source



Mo1722. . . . . CIRCULATING INTEGRIN ALPHA4/BETA7+ LYMPHOCYTESTARGETED BY…(2*)|(4) Mo1723. . . . . PROTEIN PROFILING OF CIRCULATINGINFLAMMATORY MARKERS…(2*) Mo1724. . . . . ROLE OF IL-38 ANDITS ANTAGONIST…(4*) Mo1725. . . . . MURIN E.COLITIS INDUCED INFLAMMATORYVASCULAR LEAK…(4*) Mo1726. . . . . EVALUATION OF THE PRO-INFLAMMATORYER STRESS…(2*)|(4) Mo1727. . . . . THE ACTIVATION OF ADENOSINEA3 RECEPTOR…(2*)| Supported by Science and Technology Innovation Committee of Shenzhen City (No. JCYJ20150331142757394) and Natural Science Foundation of Guangdong Province (No. 2016A030313009) Mo1728. . . . . DEEP PROFILING OF INTEGRINÎ’7 THROUGHOUT…(3*)| Genentech, Inc. Mo1729. . . . . ANTI-INFLAMMATORY EFFECTS OF SMAC-MIMETICBV6 ON…(4*)|(6) Mo1730. . . . . HIGHER EXPRESSION OF MIP-1Î’AND IL23…(4*) Mo1731. . . . . EXPRESSION OF TRANSIENT RECEPTORPOTENTIAL CHANNELS…(2*) Mo1732. . . . . PLACENTAL MADCAM1 EXPRESSION ANDPOTENTIAL CONSEQUENCES…(3*)| Takeda Mo1733. . . . . ABP 501:00:00 MATCHING THECRITICAL FUNCTIONS…(3*)| Amgen, Inc. Mo1734. . . . . EXERCISE-INDUCED MYOKINES IMPROVE INTESTINALWOUND HEALING:…(4*) Mo1735. . . . . CALCIUM-SENSING RECEPTOR REGULATION OFTIGHT JUNCTION…(2*)

Mo1736. . . . . THE ROLE OF EGCGON FORMATION…(4*) Mo1737. . . . . THE PHARMACOLOGICAL PROFILE OFTOP1288, A…(3*)| Topivert Pharma Mo1738. . . . . BINDING PROPERTIES OF HUMANTLR-9 RECEPTOR…(3*)| Index Pharmaceuticals Mo1739. . . . . IL-10 INDUCTION PROPERTIES OFTHE TLR-9…(3*)| Index Pharamceuticals Mo1740. . . . . POSITIVE ASSOCIATION BETWEEN LEPTINSERUM LEVELS…(1*)|(2) Mo1741. . . . . INCREASED BASELINE TNF-DRIVEN PATHWAYSOBSERVED IN…(2*)|(3)| Grant support: AbbVie, MSD and Takeda Mo1742. . . . . PHOSPHO-FLOW CYTOMETRY: A METHODFOR INVESTIGATING…(3*)| Topivert Pharma Ltd Mo1743. . . . . SERUM CYTOKINE PROFILE ANDIGG4 LEVELS…(5*) Mo1744. . . . . MADCAM1 EXPRESSION IN INTESTINALLAMINA PROPRIA…(5*) Mo1745. . . . . UTILIZING NAILFOLD CAPILLAROSCOPY TOMONITOR DISEASE…(5*) Mo1746. . . . . SERUM MARKER PANEL FOREARLY DETECTION…(2*)|(4) Mo1747. . . . . CAN MRE BE USEDAS AN…(5*) Mo1748. . . . . A MULTICENTER STUDY TOVALIDATE MAGNETIC…(3*)| Genentech, Inc. Mo1749. . . . . TRANSMURAL HEALING IS BETTERTHAN MUCOSAL…(5*) Mo1750. . . . . DISAGREEMENT AMONG GASTROENTEROLOGISTS INTHE ENDOSCOPIC…(5*)

Mo1751. . . . . DETECTION OF CALPROTECTIN ININFLAMMATORY BOWEL…(5*) Mo1752. . . . . DIPEPTIDYL PEPTIDASE 4 (DPP-4):AN EMERGING…(7*) Mo1753. . . . . FECAL IMMUNOCHEMICAL TEST ANDFECAL CALPROTECTIN…(5*) Mo1754. . . . . LONGITUDINAL EVALUATION WITH CAPSULEENDOSCOPY FOR…(3*)| This study was funded by Medtronic Mo1755. . . . . PATIENTS WITH UC ANDCONCOMITANT PSC…(4*) Mo1756. . . . . ASSESSMENT OF DISEASE ACTIVITYAND PREDICTING…(4*) Mo1757. . . . . CENTRALLY-DETERMINED STANDARDIZATION OF FLOWCYTOMETRY METHODS…(5*) Mo1758. . . . . TREAT TO TARGET: RECOMMENDATIONSIN ULCERATIVE…(5*) Mo1759. . . . . FAECAL CALPROTECTIN AND MAGNETICRESONANCE IMAGING…(5*) Mo1760. . . . . HIGH FECAL CALPROTECTIN LEVELSIN ULCERATIVE.COLITIS…(4*) Mo1761. . . . . FECAL CALPROTECTIN CORRELATES TOENDOSCOPIC AND…(5*) Mo1763. . . . . FECAL CALPROTECTIN VERSUS FECALIMMUNOCHEMICAL TEST…(5*) Mo1764. . . . . DUBLIN (DEGREE OF ULCERATIVECOLITIS BURDEN…(5*) Mo1765. . . . . ADALIMUMAB THERAPY RATHER THANAZATHIOPRINE AND…(4*) Mo1766. . . . . RATES OF AND CLINICALPREDICTORS OF…(5*)


* = Primary Source



Mo1767. . . . . LOW-DOSE METRONIDAZOLE IS ASSOCIATEDWITH A…(4*)|(2)| This research was supported in part by the NIH NIDDK grant #T35DK062719-29. Mo1768. . . . . DISEASE DURATION OF ULCERATIVE.COLI TIS…(5*) Mo1769. . . . . ROLE OF PET-CT TOASSESS DISEASE…(5*) Mo1770. . . . . IDENTIFICATION OF NOVEL SERUMBIOMARKERS FOR…(5*) Mo1771. . . . . FAECAL DIVERSION IS ASSOCIATEDWITH A…(4*) Mo1772. . . . . ALBUMIN AS A PROGNOSTICMARKER FOR…(5*) Mo1773. . . . . RAPIDITY OF ONSET OFRESPONSE TO…(3*)| The design, study conduct, and financial support for the clinical trial was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. Mo1774. . . . . ELEVATED C-REACTIVE PROTEIN LEVELDURING CLINICAL…(5*) Mo1775. . . . . CLINICAL, ENDOSCOPIC, AND HISTOLOGICGI MANIFESTATIONS…(2*) Mo1776. . . . . SERUM SEPSIS MARKERS SOLUBLECD14 SUBTYPE…(4*) Mo1777. . . . . FECAL LACTOFERRIN IS CORRELATEDWITH THE…(3*)| TechLab Inc. Blacksburg, VA Mo1778. . . . . POST-OPERATIVE COMPLICATIONS IN ELDERLY-ONSETINFLAMMATORY BOWEL…(5*) Mo1779. . . . . MULTICENTRE COHORT STUDY TOEVALUATE THE…(4*) Mo1780. . . . . SERUM CHITINASE-3-LIKE PROTEIN 1(YKL-40) PREDICTS…(2*)|(3)

Mo1781. . . . . RISK OF MALIGNANT ANDNON-MALIGNANT COMPLICATIONS…(5*) Mo1782. . . . . NOVEL DIAGNOSTIC TOOLS TODIFFERENTIATE C.…(3*)| TechLab Inc. Blacksburg, VA Mo1783. . . . . NON ALCOHOLIC FATTY LIVERDISEASE IN…(5*) Mo1784. . . . . ABDOMINAL PAIN MODIFIERS ININFLAMMATORY BOWEL…(5*) Mo1785. . . . . RATES AND PREDICTORS OFSURGERY IN…(4*)|(3)| Statistical analyses were conducted at the University of California, San Diego and funded in part by Takeda Pharmaceuticals Mo1786. . . . . IL-26 GENETIC POLYMORPHISMS IMPAIRCYTOKINE RESPONSE…(6*) Mo1787. . . . . INCIDENCE OF AND RISKFACTORS FOR…(5*) Mo1788. . . . . EFFICACY AND SAFETY OFENDOSCOPIC BALLOON…(5*) Mo1789. . . . . VENOUS THROMBOEMBOLISM REMAINS ASIGNIFICANT COMPLICATION…(5*) Mo1790. . . . . OBESITY IS ASSOCIATED WITHINCREASED RISK…(5*) Mo1791. . . . . RISK OF TUBERCULOSIS ININFLAMMATORY BOWEL…(4*) Mo1792. . . . . IBD PATIENTS WITH SEVEREDISEASE ARE…(5*) Mo1793. . . . . SURGERY FOR ULCERATIVE.COLITIS INGERIATRIC PATIENTS…(5*) Mo1794. . . . . SYMPTOMATIC VENOUS THROMBOEMBOLISM ISA RARE…(5*) Mo1795. . . . . CORTICOSTEROIDS MAY INFLUENCE OUTCOMESIN INFLAMMATORY…(4*)

Mo1796. . . . . IRON-DEFICIENCY WITHOUT ANEMIA INCROHN'S DISEASE:…(5*) Mo1797. . . . . RISK FACTORS FOR THEDEVELOPMENT OF…(4*) Mo1798. . . . . LOSS OF TOLERANCE TOTHE NOVEL…(1*)|(2) Mo1799. . . . . NEW HUMAN GUT XENOGRAFTMOUSE MODEL…(7*) Mo1800. . . . . PERSISTENT SYMPTOMS, CRP ELEVATIONAND TREATMENT…(5*) Mo1801. . . . . RISK FACTORS FOR VITAMIND DEFICIENCY…(5*) Mo1802. . . . . EARLY ONSET OF DISEASEAND INCREASED…(5*) Mo1803. . . . . THE PRESENCE OF OPERATIVECOMPLICATIONS INCREASES…(2*) Mo1804. . . . . RISK FACTORS ASSOCIATED WITHINCREASED LENGTH…(5*) Mo1805. . . . . SYSTEMATIC REVIEW AND META-ANALYSIS:RISK OF…(5*) Mo1806. . . . . OUTCOME OF ENDOSCOPIC RESECTIONOF LARGE…(5*) Mo1807. . . . . CROHN'S DISEASE DIAGNOSIS AFTERPROCTOCOLECTOMY AND…(5*) Mo1808. . . . . A RETROSPECTIVE ANALYSIS OFCLOSTRIDIUM DIFFICILE…(5*) Mo1809. . . . . NATURAL HISTORY OF PERIANALCROHN'S DISEASE…(5*) Mo1810. . . . . VARIATIONS IN HEALTH INSURANCESPOLICIES REGARDING…(5*) Mo1811. . . . . IMPROVING HEALTH MAINTENANCE INVETERANS WITH…(5*)


* = Primary Source



Mo1812. . . . . MANAGEMENT OF IRON DEFICIENCYANEMIA WITHIN…(3*)| Luitpold Pharmaceuticals Mo1813. . . . . MULTI-CENTER INTERVENTION TO IMPROVEDOCUMENTED REPORTING…(4*) Mo1814. . . . . TARGETED PHYSICIAN EDUCATION ANDSTANDARDIZING DOCUMENTATION…(5*) Mo1815. . . . . MULTIFACETED TARGETED INTERVENTIONS IMPROVETHE DOCUMENTED…(4*) Mo1816. . . . . A POPULATION-BASED STUDY EVALUATINGAN INTEGRATED…(2*)|(6)|Saskatchewan Health Research Foundation (SHRF), Crohn's and Colitis Canada (CCC), and Canadian Foundation for Innovation Mo1817. . . . . INFLAMMATORY BOWEL DISEASE RELATED30 DAYS…(5*) Mo1818. . . . . HOW ARE PATIENT OUTCOMESIMPACTED BY…(5*) Mo1819. . . . . PREDICTING 30-DAY READMISSION RATEIN INFLAMMATORY…(5*) Mo1820. . . . . REAL-WORLD PRESCRIPTION DRUG UTILIZATIONAND COSTS…(2*) Mo1821. . . . . FAECAL CALPROTECTIN DIFFERENTIALLY PREDICTSPOSTOPERATIVE ENDOSCOPIC…(5*) Mo1822. . . . . VARIATION IN ANNUAL RATEOF STEROID…(4*) Mo1823. . . . . DEMOGRAPHIC AND HEALTHCARE FACTORSASSOCIATED WITH…(4*)|(6) Mo1824. . . . . COST BENEFIT ANALYSIS OFRAPID INFLIXIMAB…(5*) Mo1825. . . . . INDIVIDUALS AT HIGH-RISK FORAN ACUTE…(5*)

Mo1826. . . . . HEALTH INSURANCE STATUS OFHOSPITALIZED PATIENTS…(5*) Mo1827. . . . . QUANTIFYING THE POTENTIAL CLINICALIMPACT OF…(5*) Mo1828. . . . . MALADAPTIVE COPING, SELF-EFFICACY ANDPATIENT REPORTED…(5*) Mo1829. . . . . IMPACT OF PATIENT REPORTEDOUTCOMES, COPING…(5*) Mo1830. . . . . AFFECTIVE SPECTRUM DISORDERS SIGNIFICANTLYINFLUENCE TOTAL…(5*) Mo1831. . . . . CAUSES AND CONSEQUENCES OFAFFECTIVE SPECTRUM…(5*) Mo1832. . . . . FEMALE GENDER, SOMATIZATION ANDPRESENCE OF…(1*) Mo1833. . . . . HEALTH MAINTENANCE DIFFERENCES INPATIENTS WITH…(5*) Mo1834. . . . . PSYCHO-SOCIAL PREDICTORS OF NONCOMPLIANCEWITH CHRONIC…(6*) Mo1835. . . . . IMPROVED MATERNAL AND NEONATALOUTCOMES IN…(5*) Mo1836. . . . . INCREASED HEALTH CARE RESOURCEUTILIZATION IN…(5*) Mo1837. . . . . TRANSITION READINESS AND COLLEGEADJUSTMENT IN…(3*)| |Abbvie) Mo1838. . . . . NATIONAL SURVEY OF INFLAMMATORYBOWEL DISEASE…(4*)|(6) Mo1839. . . . . SELF-REPORT IS NOT ASENSITIVE METHOD…(6*)|(2) Mo1840. . . . . RESILIENCE IS ASSOCIATED WITHLOWER RATES…(5*) Mo1841. . . . . LOOKING BEYOND THE PATIENT:THE IMPACT…(5*)

Mo1842. . . . . THE IMPACT OF SOMATICVS COGNITIVE…(5*) Mo1843. . . . . NUTRITIONAL PROFILE OF PATIENTSWITH CROHN'S…(5*) Mo1844. . . . . DEVELOPMENT AND PILOTING OFA COGNITIVE-BEHAVIORAL…(6*) Mo1845. . . . . POOR SLEEP QUALITY INCROHN'S DISEASE…(5*) Mo1846. . . . . EVALUATION OF KNOWLEDGE TRANSLATIONRESOURCES FOR…(2*) Mo1847. . . . . ILLNESS PERCEPTION IN IBDPATIENTS: A…(5*) Mo1848. . . . . SLEEP QUALITY IN PATIENTSWITH INACTIVE…(4*) Mo1849. . . . . THE IMPACT OF TRANSITIONTO ADULT…(3*) Mo1850. . . . . AN ANALYSIS OF SOCIALMEDIA USE…(5*) Mo1851. . . . . MIR-646 REGULATES CELL PROLIFERATION,MIGRATION AND…(2*) Mo1852. . . . . ZINC-FINGER PROTEIN 471 FUNCTIONSAS A…(4*) Mo1853. . . . . SERINE THREONINE KINASE 17AREGULATES INVASION…(2*) Mo1854. . . . . CROSSTALK BETWEEN INSULIN/IGF-1 RECEPTORAND G…(2*) Mo1855. . . . . MICRORNA-155 IS REGULATED BYAPC MUTATIONS…(6*) Mo1856. . . . . PERIOSTIN PROMOTES MALIGNANT POTENTIALBY INDUCTION…(2*) Mo1857. . . . . AXL UPREGULATES C-MYC EXPRESSION:A NOVEL…(2*)|(2)


* = Primary Source



Mo1859. . . . . UNRAVELING THE SERRATED NEOPLASIAPATHWAY: IMMUNOHISTOCHEMISTRY…(6*) Mo1860. . . . . THE PROTECTIVE ROLE OFVITAMIN D3…(4*) Mo1861. . . . . LONG NONCODING RNA NEAT1MEDIATES GASTRIC…(2*) Mo1862. . . . . TARGETED LOSS OF FORKHEADBOX A1…(2*)|(4) Mo1864. . . . . HIGH FREQUENCY OF RNF43R117H MISSENSE…(4*) Mo1865. . . . . WELL-BEING IN A DOUBLE-BLINDRANDOMIZED CLINICAL…(3*)| Bioprojet Pharma France Mo1866. . . . . DIARRHEA ASSOCIATED SYMPTOMS INA DOUBLE-BLIND…(3*)| Bioprojet Pharma France Mo1867. . . . . STUDY OF SMALL-INTESTINAL MUCOSALINJURY IN…(5*) Mo1868. . . . . EVALUATION OF THE DIAGNOSTICAND PROGNOSTIC…(5*) Mo1869. . . . . NOVEL PROTOCOL TO TESTTHE IMPACT…(4*)|(3)|Biocodex Mo1870. . . . . CLINICAL SYMPTOMS AND GASTROINTESTINALHISTOPATHOLOGIY IN…(5*) Mo1871. . . . . EFFICACY AND SAFETY OF5-AMINOSALICYLIC ACID…(2*)| Ministry of Food and Drug Safety Mo1872. . . . . UPPER AND LOWER GASTROINTESTINALENDOSCOPIC FINDINGS…(5*) Mo1873. . . . . IMPACT OF ENDOSCOPIC CLASSIFICATIONDICATION…(5*) Mo1874. . . . . NATURAL HISTORY OF SYMPTOMATICUNCOMPLICATED DIVERTICULAR…(5*) Mo1875. . . . . FECAL MICROBIOTA, FECAL ANDURINARY METABOLIC…(5*)

Mo1876. . . . . INFLUENCE OF CYTOCHROME P4502C19 POLYMORPHISMS…(5*) Mo1877. . . . . A ROLE FOR SALIVARYPEPTIDES IN…(2*) Mo1878. . . . . CHILDHOOD AND ADULT IRRITABLEBOWEL SYNDROME…(2*) Mo1879. . . . . THE ROLE OF SMALLINTESTINAL BACTERIAL…(5*) Mo1880. . . . . THE EFFECT OF SEVERELYREDUCED KIDNEY…(5*) Mo1881. . . . . GASTROINTESTINAL AND EXTRAINTESTINAL SYMPTOMSOCURRING DURING…(5*) Mo1882. . . . . REBLEEDING RATE AND RELATEDRISK FACTORS…(5*) Mo1883. . . . . RISK FACTORS OF RENALDYSFUNCTION CAUSED…(1*) Mo1884. . . . . SMALL BOWEL BACTERIAL OVERGROWTH(SIBO) IN…(5*) Mo1885. . . . . USE OF INFLIXIMAB INTHE TREATMENT…(5*) Mo1886. . . . . TIME TRENDS OF THEPREVALENCE OF…(5*) Mo1887. . . . . ENTEROPATHY ASSOCIATED WITH RITUXIMAB-INDUCEDHYPOGAMMAGLOBINEMIA …(5*) Mo1888. . . . . ANTI-PD-1 INDUCED COLITIS: ACASE SERIES…(5*) Mo1889. . . . . RESOLUTION OF CHRONIC DIARRHEAIN PEDIATRIC…(3*)| LiveLeaf. Inc. Mo1890. . . . . FECAL MICROBIOME IN PARENTERALNUTRITION DEPENDENT…(2*)|(4) Mo1891. . . . . AN AMINO ACID-BASED ORALREHYDRATION

SOLUTION…(3*)|(4)| Entrinsic Health Solutions, LLC Mo1892. . . . . MAGNETIC RESONANCE ENTEROGRAPHY DISTINGUISHESINTESTINAL TUBERCULOSIS…(5*) Mo1893. . . . . NEW INDICATIONS FOR TEDUGLUTIDEIN TEMPORARY…(5*) Mo1894. . . . . PREVALENCE OF COLONIC DIVERTICULOSISIN PATIENTS…(5*) Mo1895. . . . . NICKEL ALLERGIC CONTACT MUCOSITIS:DUODENAL HISTOLOGICAL,…(4*) Mo1896. . . . . ELEVATED CLINICAL INFLAMMATORY MARKERSAND CYTOKINE…(5*) Mo1897. . . . . DIETARY EMULSIFIER POLYSORBATE-80 INCREASESTHE GENUS…(5*) Mo1898. . . . . VONOPRAZAN, A NOVEL ACTIVEPOTASSIUM-COMPETITIVE ACID…(4*) Mo1899. . . . . OKADAELLA GASTROCOCCUSIKE BACTERIA POSITIVEREACTIVE GASTROPATHY…(5*) Mo1900. . . . . THE EFFECTS OF FOURWEEKS PECTIN…(3*)| This study has been funded bij Top Instutute of Food and Nutrition. TI Food and Nutrition is a public private partnership of science, industry and government conducting strategic research in food and nutrition. Mo1901. . . . . INULIN AND STREPTOCOCCUS SALIVARIUSREDUCE HALITOSIS…(4*) Mo1902. . . . . ANTIBACTERIAL RESISTANCE AGAINST MRSAORAL INFECTION…(5*) Mo1903. . . . . IMPROVED URINARY TRACT INFECTIONSWITH FECAL…(5*) Mo1904. . . . . A NEW MOUSE MODELFOR HUMAN…(2*)


* = Primary Source



Mo1905. . . . . UTILITY OF ANTIGEN DETECTIONOF HELICOBACTER…(5*) Mo1906. . . . . THIRTY DAYS OF MULTI-STRAINPROBIOTIC SUPPLEMENTATION…(3*)|(4)| The present research was funded in part by a grant from Physician's Exclusive LLC to the University of North Texas. The authors were not directly compensated for the completion of this work. Mo1907. . . . . EVALUATION OF METHODS FORTHE PRESERVATION…(2*) Mo1908. . . . . PROBIOTIC SEPSIS IN PATIENTSWITH INFLAMMATORY…(5*) Mo1909. . . . . DIRECT NUCLEIC ACID DETECTIONOF DIARRHEAL…(2*) Mo1910. . . . . COMMON BACTERIAL AND VIRALINFECTION IN…(5*) Mo1911. . . . . BACTERIOME AND MYCOBIOME ANALYSISUNDERSCORE THE…(2*) Mo1912. . . . . PSYCHOLOGICAL STRESS INDUCES DIFFERENTPATTERNS OF…(5*) Mo1913. . . . . LACTOBACILLUS CASEI DGÂ® INPATIENTS WITH…(3*)| SOFAR SPA Trezzano Rosa, ITALY Mo1914. . . . . PROBIOTICS' EFFECTS ON PERCEPTIONOF HEALTH…(3*) Mo1915. . . . . PERTURBATION OF GUT MICROBIOMELEADS TO…(6*) Mo1916. . . . . DOES GUT MICROBIOTA-INDUCED METABOLICIMPROVEMENT AFTER…(4*)|(7) Mo1917. . . . . CHANGES IN THE BODYMASS INDEX…(5*) Mo1918. . . . . GASTRIC MICROBIOTA OF THEANTRUM IS…(4*) Mo1919. . . . . THE HISTONE H3K4 DEMETHYLASEKDM5 MODULATE…(2*)

Mo1920. . . . . ANTIBIOTIC SUSCEPTIBILITY OF PROBIOTICSTRAINS. IS…(3*)| Biocodex Laboratory Mo1921. . . . . ULCERATIVE COLITIS-ASSOCIATED ESCHERICHIA COLICOLONIZE THE…(4*) Mo1922. . . . . GAMMA-GLUTAMYLTRANSPEPTIDASE EXPRESSION BY HELICOBACTERSAGUINI, A…(2*) Mo1923. . . . . RIFAXIMIN DECREASES VIRULENCE OFCROHNS DISEASE…(3*)| This study was supported by Alfa Wassermann (Bologna, Italy). Mo1924. . . . . EVALUATION OF MULTIPLEX PCRFOR DIAGNOSIS…(5*) Mo1925. . . . . THE EFFECT OF METHANEON CALCIUM…(5*) Mo1926. . . . . TOWARDS UNDERSTANDING THE MECHANISMSOF HOW…(4*) Mo1927. . . . . PLASMA GHRELIN AND LEPTININ PATIENTS…(4*) Mo1928. . . . . BITTER TASTE RECEPTOR T2R138IN MOUSE…(2*) Mo1929. . . . . DIETARY REGULATION OF ENTEROENDOCRINECELL FUNCTION…(2*) Mo1930. . . . . NATURE AND THE SITEOF IMPAIRMENT…(2*) Mo1931. . . . . GENDER DIFFERENCE IN ANOREXIAFOLLOWING STRESS…(3*)| |Tsumura & Co.) Mo1932. . . . . DYNAMIC HEPATOSCINTIGRAPHY IN THEEARLY DIAGNOSIS…(1*)|(2) Mo1933. . . . . DUODENAL LAYER MORPHOMETRY TOGUIDE DUODENAL…(3*)| Study sponsored by Fractyl Laboratories, Inc.

Mo1934. . . . . SINGLE CATHETER FOR DUODENALMUCOSAL RESURFACING…(3*)| This trial is sponsored by Fractyl Laboratories Inc. Mo1935. . . . . GLU CAG+ ON LIKEPEPTIDE-1 (GLP-1)…(4*) Mo1936. . . . . META-ANALYSIS ASSESSING THE EFFECTOF LAPAROSCOPIC…(4*) Mo1937. . . . . FOREGUT EXCLUSION IS IMPORTANTIN THE…(4*) Mo1938. . . . . A HMG-COA REDUCTASE INHIBITOR,ROSUVASTATIN, AS…(5*) Mo1939. . . . . IMPACT OF ADIPOSITY ANDGLUCOSE HOMOEOSTASIS…(2*)|(4) Mo1940. . . . . MYOKINES SECRETED FROM EXERCISINGSKELETAL MUSCLES…(4*) Mo1941. . . . . HIGH RESOLUTION MANOMETRY REPRESENTSTHE HIGH…(5*) Mo1942. . . . . TYPE 2 DIABETES RESOLUTIONFOLLOWING ROUX-EN-Y…(4*) Mo1943. . . . . PROTECTIVE ROLE OF FLAVONOIDSAGAINST COLONIC…(4*) Mo1944. . . . . ROLE OF GUT-ADIPOSE-MUSCLE AXISIN BENEFICIAL…(5*) Mo1945. . . . . SHORT-TERM FOOD INTAKE, INTESTINALTRANSIT AND…(4*) Mo1946. . . . . PREDICTORS AND CORRELATES OFPRONENESS TO…(2*)|(4) Mo1947. . . . . THE IMPACT OF INDIVIDUALCOMPONENTS OF…(5*) Mo1948. . . . . BODY-MASS INDEX AND COLORECTALNEOPLASIA ACCORDING…(5*)


* = Primary Source



Mo1949. . . . . ASSOCIATIONS AMONG ADIPOSITY, MEDIATINGBIOMARKERS AND…(5*) Mo1950. . . . . RISK OF SUICIDE ANDSELF-HARM IS…(5*) Mo1951. . . . . PSYCHIATRIC DISEASE DOES NOTNEGATIVELY IMPACT…(4*) Mo1952. . . . . ASSOCIATIONS OF OBESITY-RELATED NON-ALCOHOLICFATTY LIVER…(4*) Mo1953. . . . . SUCCESSFUL WEIGHT LOSS WITHLOW CARBOHYDRATE…(5*) Mo1954. . . . . FREQUENCY OF FUNCTIONAL GASTROINTESTINALDISORDERS IN…(5*) Mo1955. . . . . A COST-UTILITY ANALYSIS COMPARINGENDOSCOPIC, SURGICAL…(5*) Mo1956. . . . . THE IMPACT OF OBESITYON THE…(4*) Mo1957. . . . . ELEVATED SERUM TRANSFERRIN-IRON SATURATIONAND FERRITIN…(5*) Mo2042. . . . . LONG-TERM USE OF PROTONPUMP INHIBITORS…(5*) Mo2043. . . . . PROTECTIVE EFFECTS OF ALDA-1,AN ALDH2…(4*) Mo2044. . . . . VITAMIN D AND LOSARTANSUPPRESS COLONIC…(2*)|(4) Mo2045. . . . . IS CARDIORESPIRATORY FITNESS (VO2MAX)ASSOCIATED WITH…(4*)|(6) Mo2046. . . . . EICOSAPENTAENOIC ACID-FREE FATTY REDUCESFECAL CALPROTECTIN…(6*) Mo2047. . . . . HELICOBACTER PYLORI ERADICATION ASSOCIATEDWITH REDUCED…(2*)

Mo2048. . . . . EFFECT OF BENZO[A]PYRENE ALONGWITH ACID…(4*)|(6) Mo2049. . . . . METFORMIN AMELIORATES PANCREATIC LESIONFORMATION IN…(4*) Mo2050. . . . . MORPHOLOGIC CHARACTERIZATION OF RESIDUALDNA METHYLATION…(3*)|(4) Mo2051. . . . . IMPACT OF PHYSICAL ACTIVITYAND OBESITY…(5*) Mo2053. . . . . REJUVENATING AND AUTOPHAGY INDUCINGACTIONS OF…(5*) Mo2054. . . . . VIP PROMOTES GASTRIC CANCERPROGRESSION VIA…(2*) Mo2055. . . . . CURCUMIN, A NUTRACEUTICAL, PREVENTSACID AND…(4*) Mo2056. . . . . HELICOBACTER PYLORI PROMOTES CISPLATINRESISTANCE IN…(2*) Mo2057. . . . . EFFICACY AND SAFETY OFTWELVE CHEMOPREVENTIVE…(7*) Mo2058. . . . . STATINS INHIBIT PROLIFERATION OFPANCREATIC DUCTAL…(2*) Mo2059. . . . . STATINS POTENTLY INHIBIT YAPACTIVITY AND…(2*) Mo2060. . . . . STATINS POTENTLY INHIBIT YAPFUNCTION AND…(2*) Mo2061. . . . . A 3-YEAR OBSERVATIONAL STUDYOF PERSONS…(3*)| Exact Sciences Laboratories Mo2062. . . . . VITAMIN D SUPPLEMENTATION EFFECTSON GLOBAL…(2*)|(7) Mo2063. . . . . MAGNIFYING NARROW-BAND IMAGING (NBI)FEATURES OF…(2*)|(4)

Mo2064. . . . . PREDICTORS OF ADVANCED NEOPLASIAIN AVERAGE-RISK…(5*) Mo2065. . . . . PHASE II RANDOMIZED, DOUBLE-BLINDED,PLACEBO-CONTROLLED TRIAL…(2*)| NIH Grant 5R01CA132991 Mo2066. . . . . QUANTIFYING AREAS OF CONCERNON VOLUMETRIC…(5*) Mo2067. . . . . SPECTRAL PATTERN OF PANCREATICCANCER AND…(2*) Mo2068. . . . . COMPUTER-ASSISTED ANALYSIS OF HYPO-SCATTERINGGLANDULAR STRUCTURES…(2*) Mo2069. . . . . THE AVAILABILITY OF LINKEDCOLOR IMAGING,…(5*) Mo2070. . . . . INITIAL EXPERIENCE OF ELECTRONICCHROMOENDOSCOPY FOR…(5*) Mo2071. . . . . ABSENCE OF CONCERNING FINDINGSON VOLUMETRIC…(3*)| |NinePoint Medical, Inc.) Mo2072. . . . . ASSOCIATION BETWEEN CROSS-SECTIONAL ANDEN FACE…(2*) Mo2073. . . . . X-LINKED INHIBITOR OF APOPTOSISPROTEIN (XIAP)…(4*) Mo2074. . . . . DISTINCTIVE DNA MISMATCH REPAIRAND APC…(2*) Mo2075. . . . . MORPHOLOGIC AND MOLECULAR FEATURESOF SESSILE…(5*) Mo2076. . . . . DISCOVERY AND DERIVATION OFSPECIFIC BIOSIGNATURES…(2*) Mo2077. . . . . NUDT15 R139C-RELATED THIOPURINE LEUKOCYTOPENIAIS MEDIATED…(5*) Tu1050. . . . . DECISION AID FOR SHAREDDECISION MAKING…(5*)


* = Primary Source



Tu1051. . . . . IMPACT OF AFFORDABLE CAREACT ON…(4*) Tu1052. . . . . FEASIBILITY OF MOBILE CBTFOR GENERALIZED…(3*)|(4)| Thrive Network, Inc (DBA, Lantern), the company which created and owns the mobile application, provided the virtual CBT app at no cost to the 12 participants of the study. Tu1053. . . . . SAFETY AND EFFICACY OFNON-ANESTHESIOLOGIST ADMINISTRATION…(5*) Tu1054. . . . . THE INCORPORATION OF MEDICALSCRIBES INTO…(1*) Tu1055. . . . . EFFECTIVENESS OF TELEPHONE REMINDERSVS. SHORT…(4*) Tu1056. . . . . ACADEMIC GASTROENTEROLOGY: THE TOPONE PERCENT…(5*) Tu1057. . . . . REGIONAL PRACTICE VARIABILITY OFREPEAT ESOPHAGOGASTRODUODENOSCOPY… (2*)|(4) Tu1058. . . . . THE IMPACT OF TRAVELDISTANCE ON…(5*) Tu1059. . . . . A CAUSE FOR HEARTBURN:A CLOSER…(5*) Tu1060. . . . . THE EFFECT OF ACETAMINOPHEN(PARACETAMOL) LEGISLATION…(5*) Tu1061. . . . . TELEMEDICINE: A MODERN APPLICATIONIN THE…(5*) Tu1062. . . . . PRACTICE PATTERNS OF CHOLECYSTECTOMYFOLLOWING ERCP…(4*) Tu1063. . . . . DESPITE HIGH INTEREST INTELEMEDICINE VIDEO…(2*) Tu1064. . . . . BURDEN AND YIELD OFREPEAT HELICOBACTER…(5*)

Tu1065. . . . . DEVELOPMENT OF A COLORECTALCANCER SCREENING…(5*) Tu1066. . . . . PEDIATRIC ACCESS TO FECALMICROBIOTA TRANSPLANTATION…(6*)|(5) Tu1067. . . . . TEMPORAL TRENDS IN PRE-DIAGNOSISSCREENING AND…(5*) Tu1068. . . . . OUTCOMES OF HCV MANAGEMENTBY MID-LEVEL…(5*) Tu1069. . . . . ERADICATION RATES OF HELICOBACTERPYLORI WITH…(5*) Tu1070. . . . . PROSPECTIVE IMPLEMENTATION OF ALGORITHMICPATIENT SELECTION…(5*) Tu1071. . . . . PREDICTORS OF PATIENT RELUCTANCETO USE…(2*) Tu1072. . . . . INCONSISTENCY BETWEEN ELECTRONIC DATAOF PATIENT'S…(5*) Tu1073. . . . . ANALYSIS OF UNMET NEEDSOF INDIVIDUALS…(2*)|(6) Tu1074. . . . . CAN WE PREDICT ADHERENCETO TREATMENT…(5*) Tu1075. . . . . MANAGEMENT OF CONSTIPATION INSECONDARY CARE.…(5*) Tu1076. . . . . TRENDS IN SOCIAL MEDIAPRESENCE AND…(5*) Tu1077. . . . . SYMPTOM CHECKERS VS. DOCTORS,THE ULTIMATE…(5*) Tu1078. . . . . EFFECT OF ENHANCED RECOVERYPROGRAMMES ON…(5*) Tu1079. . . . . CURRENT MANAGEMENT OF OGILVIE'SSYNDROME …(5*) Tu1080. . . . . FILAGGRIN AND TIGHT JUNCTIONPROTEINS ARE…(5*)

Tu1081. . . . . CLINICAL FEATURES AT BASELINEARE NOT…(3*)| |Shire International GmbH) Tu1082. . . . . FOOD ALLERGEN TRIGGERS AREINCREASED IN…(5*) Tu1083. . . . . EMSY GENE SILENCING INTHE ESOPHAGEAL…(2*) Tu1084. . . . . COW'S MILK ELIMINATION FORTREATMENT OF…(6*) Tu1085. . . . . DIAGNOSTIC UTILITY OF ALLERGYTESTING IN…(6*) Tu1086. . . . . AGE-ASSOCIATED DECLINE IN ESOPHAGEALAUTOPHAGY FLUX…(2*)|(4) Tu1087. . . . . RISING INCIDENCE AND PREVALENCEOF ADULT…(5*) Tu1088. . . . . CYP2C19 GENOTYPE AND RESPONSETO PROTON…(7*) Tu1089. . . . . IMPACT OF SMOKING, ALCOHOLCONSUMPTION, AND…(2*) Tu1090. . . . . CLINICAL AND ENDOSCOPIC CHARACTERIZATIONOF EOSINOPHILIC…(2*) Tu1091. . . . . TREATMENT OF EOSINOPHILIC ESOPHAGITISIN ADULTS…(2*) Tu1092. . . . . CLINICAL AND MOLECULAR PREDICTORSOF HISTOLOGIC…(2*) Tu1093. . . . . IMPROVEMENT OF DYSPHAGIA INPATIENTS WITH…(5*) Tu1094. . . . . CLINICAL SYMPTOM TOOL RAISESINDEX OF…(5*) Tu1095. . . . . SERUM AUTOANTIBODIES ARE ASSOCIATEDWITH EOSINOPHILIC…(2*) Tu1096. . . . . A NOVEL INFLAMMATION-ACTIVATED DRUGDELIVERY SYSTEM…(6*)


* = Primary Source



Tu1097. . . . . A PEDIATRIC PATIENT WITHSEVERE REFRACTORY…(5*) Tu1098. . . . . PROTON PUMP INHIBITOR THERAPYIMPROVES ESOPHAGEAL…(4*) Tu1099. . . . . DIFFERENT PROTON PUMP INHIBITORSARE EQUALLY…(4*) Tu1100. . . . . EARLY LIFE FACTORS AREASSOCIATED WITH…(2*) Tu1101. . . . . ASSESSMENT OF PROXIMITY TOSWINE FARMING…(2*) Tu1102. . . . . INCREASED PREVALENCE OF ESOPHAGEALEOSINOPHILIA IN…(5*) Tu1103. . . . . A PILOT STUDY OFIGG4 STAINING…(4*) Tu1104. . . . . LARGE INCREASE IN INCIDENCEOF EOSINOPHILC…(5*) Tu1105. . . . . DIFFERENCES IN CLINICAL ANDENDOSCOPIC FEATURES…(4*) Tu1106. . . . . RELATIONSHIP BETWEEN SUBEPITHELIAL EOSINOPHILICINFLAMMATION, EPITHELIAL…(5*) Tu1107. . . . . ADULT EOE PATIENTS' SATISFACTIONWITH DIFFERENT…(2*)|(5) Tu1108. . . . . PRACTICE DIFFERENCES IN THEDIAGNOSIS AND…(5*) Tu1109. . . . . ASSESSING ADHERENCE AND BARRIERSTO LONG…(5*) Tu1110. . . . . TREATMENT WITH COMPOUNDED ORALVISCOUS BUDESONIDE…(2*) Tu1111. . . . . TIME TO DIAGNOSIS OFEOSINOPHILIC ESOPHAGITIS…(2*) Tu1112. . . . . COMBINED AND ALTERNATING TOPICALCORTICOSTEROIDS AND…(2*)

Tu1113. . . . . LONG-TERM EFFICACY OF AFOOD ELIMINATION…(2*) Tu1114. . . . . EOSINOPHIL PEROXIDASE IS AMARKER OF…(4*) Tu1115. . . . . CLINICAL CHARACTERISTICS AND LONG-TERMPROGNOSIS OF…(5*) Tu1116. . . . . PERSISTENT BASAL CELL HYPERPLASIAIN PATIENTS…(2*)|(4) Tu1117. . . . . EOSINOPHIL DEGRANULATION PATTERNS ONTRANSMISSION ELECTRON…(4*) Tu1118. . . . . FREQUENT CLINICOPATHOLOGIC OVERLAP PRECLUDESAN ACCURATE…(5*) Tu1119. . . . . SYSTEMATIC REVIEW AND META-REGRESSIONS:MANAGEMENT OF…(5*) Tu1120. . . . . MBP-1 GRANULE PROTEIN DEPOSITIONMAY EXPLAIN…(4*) Tu1121. . . . . OPTIMAL FOOD ELIMINATION STRATEGYFOR EOSINOPHILIC…(5*) Tu1122. . . . . THE PREVALENCE OF EOSINOPHILICESOPHAGITIS IN…(5*) Tu1123. . . . . SOCIAL IMPACTS ON HEALTHRELATED QUALITY…(4*) Tu1124. . . . . A DIAGNOSIS OF EOSINOPHILICESOPHAGITIS IS…(5*) Tu1125. . . . . EOSINOPHIL INTEGRIN Î‘M (CD11B/MAC-1)PROMOTES EOSINOPHILIC…(4*) Tu1126. . . . . POLLEN-FOOD ALLERGY SYNDROME ISA COMMON…(4*) Tu1127. . . . . IMPACT OF CONCURRENT IMMUNOTHERAPYON PATIENTS…(2*) Tu1128. . . . . DISTAL/MID ESOPHAGEAL BIOPSIES ARESUPERIOR TO…(6*)

Tu1129. . . . . ESTABLISHING MACHINE LEARNING ALGORITHMSTO IMPROVE…(4*) Tu1130. . . . . PREVALENCE OF EARLY ANTIBIOTICUSE IN…(5*) Tu1131. . . . . TRENDS OF EOSINOPHILIC ESOPHAGITISIN THE…(5*) Tu1132. . . . . PREVALENCE OF ESOPHAGEAL EOSINOPHILIAIN FIRST…(4*) Tu1133. . . . . POST-PROTON PUMP INHIBITOR TRIALESOPHAGEAL EOSINOPHIL…(5*) Tu1134. . . . . TWICE DAILY PPI ISASSOCIATED WITH…(5*) Tu1135. . . . . LYSYL OXIDASE IS ANOVEL FIBROSTENOTIC…(2*) Tu1136. . . . . THERAPY ASSOCIATED BACTERIAL ANDFUNGAL DYSBIOSIS…(4*) Tu1137. . . . . ELEVATED TRYPTASE IN EOSINOPHILICESOPHAGITIS: WHAT…(5*) Tu1138. . . . . AGE OF PRESENTATION INPATIENTS WITH…(5*) Tu1139. . . . . ENVIRONMENTAL ALLERGENS MAY CONTRIBUTETO SEASONAL…(5*) Tu1140. . . . . SUSTAINED REMISSION FOLLOWING SIXFOOD ELIMINATION…(5*) Tu1141. . . . . SEASONAL VARIATION OF ESOPHAGEALFOREIGN BODY…(5*) Tu1262. . . . . FUNDING DISPARITIES IN DIGESTIVECANCER RESEARCH…(5*) Tu1263. . . . . PERIODONTAL DISEASE, TOOTH LOSS,AND RISK…(5*)


* = Primary Source



Tu1264. . . . . FEW PATIENTS WITH YOUNG-ONSETCOLORECTAL CANCER…(5*) Tu1265. . . . . INCIDENCE AND SURVIVAL INGASTRIC ADENOCARCINOMA…(5*) Tu1266. . . . . SQUAMOUS CELL CARCINOMA OFTHE STOMACH…(5*) Tu1267. . . . . OUTCOMES OF PRIMARY SQUAMOUSCELL CARCINOMA…(5*) Tu1268. . . . . DISTINCT PATIENT AND TUMORCHARACTERISTICS OF…(4*)|(6) Tu1269. . . . . THE ASSOCIATION BETWEEN OBESITY,METABOLIC HEALTH,…(5*) Tu1270. . . . . AN EPIDEMIOLOGICAL ANALYSIS OFGASTRIC CANCER…(5*) Tu1271. . . . . ELIMINATING RACIAL DISPARITIES: ESOPHAGEALCANCER TREATMENT…(5*) Tu1272. . . . . THE COST OF OBESITYON CANCER…(4*) Tu1273. . . . . IMPACT OF RACIAL DISPARITIESON CLINICAL…(5*) Tu1274. . . . . OUTCOMES OF LINITIS PLASTICAOF THE…(5*) Tu1275. . . . . PSYCHIATRIC MORBIDITY AND ITSIMPACT ON…(2*) Tu1276. . . . . INVESTIGATION, PREVALENCE AND HISTOLOGYOF COLORECTAL…(5*) Tu1277. . . . . COMPARATIVE OUTCOMES OF ESOPHAGEALCANCER TREATMENT…(5*) Tu1278. . . . . THE EFFECT OF OBESITYON EARLY…(5*) Tu1279. . . . . ONE EXPLANATION FOR THEREPORTED INCREASE…(5*)

Tu1280. . . . . MELANOMA INVOLVING THE GASTROINTESTINAL(GI) TRACT:…(5*) Tu1281. . . . . WHERE FIT FALLS SHORT:WHY PATIENTS…(5*) Tu1282. . . . . EPIDEMIOLOGICAL TRENDS IN ESOPHAGEALCANCER IN…(5*) Tu1308. . . . . IN VITRO AND EX-VIVOQUANTITATIVE ASSESSMENT…(3*)| Bayer Vital GmbH, Germany Tu1309. . . . . BILE REFLUX INCREASED THEINCIDENCE OF…(5*) Tu1310. . . . . HUMAN ESOPHAGEAL MYOFIBROBLAST IL-6SECRETION REGULATES…(2*) Tu1311. . . . . MACROPHAGE-DERIVED INDIAN HEDGEHOG DRIVESEPITHELIAL PROLIFERATION…(2*) Tu1312. . . . . HYDROTALCITE PROTECTS HUMAN ESOPHAGEALKERATINOCYTE PROGENITOR…(2*) Tu1313. . . . . CASE SERIES OF ESOPHAGEALLICHEN PLANUS:…(5*) Tu1314. . . . . ISOLIQUIRITIGENIN, A FLAVONOID COMPONENTOF LICORICE,…(5*) Tu1315. . . . . THE PREVENTION OF UPPERGASTROINTESTINAL BLEEDING…(3*) Tu1316. . . . . BIOAVAILABILITY OF ASPIRIN INRATS COMPARING…(2*) Tu1317. . . . . HYPOXIA-INDUCED SECRETOME OF ADIPOSE-DERIVEDMESENCHYMAL STEM…(2*) Tu1318. . . . . ROLE OF RELOOK UPPERGASTROINTESTINAL ENDOSCOPY…(5*) Tu1319. . . . . ANASTOMOTIC STRICTURES FOLLOWING ESOPHAGECTOMYFOR CORROSIVE…(5*)

Tu1320. . . . . PROTON PUMP INHIBITORS (PPI)INDUCES INCREASE…(2*) Tu1321. . . . . A RARE CASE OFESOPHAGEAL ACTINOMYCOSIS…(5*) Tu1322. . . . . NO LIGHT AT THEEND OF…(5*) Tu1323. . . . . SEEING IS BELIEVING: ARARE CASE…(5*) Tu1324. . . . . HOW TO COUNTERACT PERFORATEDSTOMACH LESION…(2*) Tu1325. . . . . SENSORY NERVES RELEASING CALCITONINGENE RELATED…(5*) Tu1326. . . . . COUNTERACTION OF PERFORATED CAECUMLESION IN…(2*) Tu1327. . . . . FIRST REPORTED CASE OFPEMBROLIZUMAB-INDUCED IMMUNE…(5*) Tu1328. . . . . CAUSTIC INGESTION: DEVELOPMENT ANDVALIDATION OF…(5*) Tu1329. . . . . AN UNUSUAL CASE OFESOPHAGEAL FOREIGN…(5*) Tu1330. . . . . GASTRIC ISCHEMIA: A RARECAUSE OF…(5*) Tu1331. . . . . LYMPHOCYTIC ESOPHAGITIS: A CASESERIES PROFILING…(5*) Tu1347. . . . . PANCREATIC EPITHELIAL CELL, BUTNOT IMMUNE…(2*) Tu1348. . . . . NF-KB GENETIC ABLATION EXERTSBENEFICIAL, BUT…(2*) Tu1349. . . . . THE EXTRACELLULAR CA2+ PROVIDEDBY RINGER'S…(2*) Tu1350. . . . . PATHOGENIC ALTERATION IN ENDOPLASMICRETICULUM HOMEOSTASIS…(2*)


* = Primary Source



Tu1351. . . . . MUTANT HUMAN PRSS1 R122HEXPRESSION IN…(2*) Tu1352. . . . . NALTREXONE AS A DISEASEMODIFYING THERAPY…(2*) Tu1353. . . . . PATHOGENESIS OF CHRONIC PANCREATITISIS INDEPENDENT…(2*) Tu1354. . . . . SIMULTANEOUS ACTIVATION OF K-RASAND NRF2…(5*) Tu1355. . . . . ACTIVIN IN ACUTE PANCREATITIS:POTENTIAL RISK-STRATIFYING…(7*)|(2) Tu1356. . . . . SITE-1-PROTEASE MEDIATED UNFOLDED PROTEINRESPONSE PROTECTS…(5*) Tu1357. . . . . NOVEL SMALL MOLECULE PKDINHIBITORS SUPPRESS…(2*) Tu1358. . . . . LIPOTOXICITY MAY RESULT ININFLAMMATORY CELL…(5*) Tu1359. . . . . EFFECT OF OCTREOTIDE ONPANCREATIC FIBROSIS…(2*) Tu1360. . . . . EFFECTS OF UNSATURATED FREEFATTY ACIDS…(2*) Tu1361. . . . . EXTRACELLULAR ATP PROMOTES SYSTEMICINFLAMMATION DURING…(2*) Tu1362. . . . . TOTAL SERUM CHOLESTEROL ANDPANCREATIC CANCER:…(2*)| The work was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000003. Tu1363. . . . . DIETARY ISOFLAVONE INTAKE ANDTHE DEVELOPMENT…(5*) Tu1364. . . . . DO PAST COMPUTED TOMOGRAPHYIMAGES HELP…(5*) Tu1365. . . . . CLINICAL USEFULNESS OF SERIALPANCREATIC-JUICE ASPIRATION…(5*)

Tu1366. . . . . NON-ALCOHOLIC FATTY PANCREAS DISEASE(NAFPD) AS…(5*) Tu1367. . . . . NATURAL HISTORY AND SIGNIFICANTFACTOR FOR…(5*) Tu1368. . . . . VASOACTIVE INTESTINAL PEPTIDE-SECRETING TUMORS:24 YEAR…(5*) Tu1369. . . . . PREVALENCE AND OUTCOMES OFPANCREATIC CYSTIC…(5*) Tu1370. . . . . RESECTABLE PANCREATIC NEUROENDOCRINE NEOPLASMS:CLINICOPATHOLOGICAL CHARACTERISTICS…(5*) Tu1371. . . . . TUMOR PROTEIN D52 ISAN AUTOPHAGY…(2*) Tu1372. . . . . TYPE 2 DIABETES ANDPANCREATIC EXOCRINE…(3*)| |AstraZeneca R&D) Tu1373. . . . . LOSS OF E-CADHERIN EXPRESSIONPROMOTES LOCAL…(5*) Tu1374. . . . . PANCREATIC ACINAR CELLS WITHHUMAN PRSS1R122H…(2*) Tu1375. . . . . RAB7 LOCALIZES TO ZYMOGENGRANULE MEMBRANE…(5*) Tu1376. . . . . 12 GENE PANCREATITIS SUSCEPTIBILITYPANEL: CLINICAL…(3*)| Ariel Precision Medicine Tu1377. . . . . ESTABLISHMENT OF INDIVIDUALIZED TREATMENTFOR PANCREATIC…(2*)| Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2014R1A1A1006272) Tu1378. . . . . SBP-101 PRODUCES ATROPHY OFTHE EXOCRINE…(3*)| Sun Biopharma Inc. Tu1379. . . . . BETAINE PROTECTS THE PANCREASFROM ALCOHOL-INDUCED…(5*)

Tu1380. . . . . CILIATED PROTOZOANS RESTORE DIGESTIONAND AN…(2*)|(3)| This work was don as collaboration project, funded by the German ministry for research and education (BMBF). The partner Cilian AG received only part of their expenses from BMBF funding the other part was payed from Cilian's own resources. Tu1381. . . . . IMPACT OF TREATMENTS ONDIABETIC CONTROL…(5*) Tu1382. . . . . PRESENCE OF THE P21-ACTIVATEDKINASE, PAK4,…(2*) Tu1384. . . . . HEREDITARY PANCREATITIS IN THEUNITED STATES:…(5*) Tu1536. . . . . DIAGNOSTIC ESCAPE VARIANTS OFHEPATITIS B…(4*) Tu1537. . . . . BIRTH COHORT HCV SCREENINGRATES REMAIN…(3*)| |Grant from Gilead IN-US-342-4105) Tu1538. . . . . DIAGNOSTIC UTILITY OF LIVERBIOPSY IN…(5*) Tu1539. . . . . DECREASED CIRCULATING KYNURENINE ISASSOCIATED WITH…(4*) Tu1540. . . . . A LOW INCIDENCE OFHEPATOCELLULAR CARCINOMA…(5*) Tu1541. . . . . EFFICACY AND SAFETY OFPARITAPREVIR/RITONAVIR, OMBITASVIR…(5*) Tu1542. . . . . PATIENT EDUCATION AND HEALTHCAREPROVIDER CME:A…(3*)| This quality improvement initiative was funded through an independent medical educational grant from Gilead Sciences Medical Affairs Tu1543. . . . . DIMINISHING ROLE OF LIVERBIOPSY FOR…(5*) Tu1544. . . . . PREDICTORS OF LIVER STIFFNESSREGRESSION AFTER…(5*) Tu1545. . . . . THE PROGNOSIS OF HCVPATIENTS WITH…(5*)


* = Primary Source



Tu1546. . . . . SUSTAINED VIRAL RESPONSE INPATIENTS WITH…(5*) Tu1547. . . . . ARE THERE PRE-DETERMINANTS FORELEVATED LIVER…(5*) Tu1548. . . . . FECAL MICROBIOTA TRANSPLANT USINGA PRECISION…(2*)| Materials Provided by Openbiome Tu1549. . . . . ALBUMIN USE AND ACUTEKIDNEY INJURY…(3*)| Investigator Initiated Grant from Grifols Pharmaceuticals Tu1550. . . . . STATINS DECREASE THE PROGRESSIONOF FIBROSIS,…(5*) Tu1551. . . . . ENDOTHELIAL FUNCTION AS APREDICTOR OF…(4*) Tu1552. . . . . IMPROVED MORTALITY AND LENGTHOF STAY…(5*) Tu1553. . . . . POST EVL (ENDOSCOPIC VARICEALLIGATION) ULCER…(5*) Tu1554. . . . . PREVALENCE AND NEW STARTSOF PROTON…(5*) Tu1555. . . . . MUSCLE VOLUME LOSS ASA PREDICTOR…(5*) Tu1556. . . . . OUTCOMES OF PATIENTS WITHALCOHOLIC RELATED…(5*) Tu1557. . . . . VANCOMYCIN IN ACUTELY DECOMPENSATEDCIRRHOTIC CAUSED…(5*) Tu1558. . . . . PORTAL TRIAD CLAMPING INRATS, AND…(2*) Tu1588. . . . . ADVANCED GLYCATION END PRODUCTSIMPAIR CA2+…(5*) Tu1589. . . . . ADVANCED GLYCATION END PRODUCTSINTERFERE WITH…(5*) Tu1590. . . . . ADVANCED GLYCATION END PRODUCTSACCUMULATED WITH…(5*)

Tu1591. . . . . SELECTIVE INHIBITION OF PROSTASININ HUMAN…(2*)|(4) Tu1592. . . . . THE OBESTATIN/G PROTEIN-COUPLED RECEPTOR39 (GPR39)…(2*) Tu1593. . . . . SORTING NEXIN 27 (SNX27)AFFECTS THE…(2*) Tu1594. . . . . KSR1/2 REGULATES ERK ACTIVATIONAND NEUROTENSIN…(2*) Tu1595. . . . . ACUTE EXPOSURE TO VITAMINC ACTIVATES…(4*) Tu1596. . . . . THE GHRELIN SIGNAL ENHANCEMENTEFFECT OF…(3*)| Tsumura & Co. Tu1597. . . . . ZINC ACTS AS APOTENT INHIBITOR…(4*) Tu1598. . . . . PSYCHOLOGICAL SYMPTOMS PREDICT CHANGESIN GASTROINTESTINAL…(4*) Tu1599. . . . . IMPACT OF RIFAXIMIN ONHEALTH-RELATED QUALITY…(3*)| This study was funded by Salix Pharmaceuticals, Raleigh, NC, USA Tu1600. . . . . PATIENT RESPONDER ANALYSIS FORA TOTAL…(3*)| IM HealthScience Tu1601. . . . . IN PATIENTS WITH IRRITABLEBOWEL SYNDROME-MIXED…(3*)| IM HealthScience Tu1602. . . . . LINACLOTIDE ATTENUATES VISCERAL ORGANCROSSTALK: IMPORTANCE…(3*)| Ironwood Pharmaceuticals, Cambridge, MA, USA. Tu1603. . . . . LYSOZYME MRNA DOWN-REGULATION ISASSOCIATED WITH…(2*) Tu1604. . . . . CHARACTERIZATION OF ABDOMINAL PAINRESPONSE IN…(3*)| Salix Pharmaceuticals, Raleigh, NC, USA Tu1605. . . . . YOUTUBE AS A SOURCEOF INFORMATION…(5*)

Tu1606. . . . . FOOD RELATED QUALITY OFLIFE IN…(4*) Tu1607. . . . . ASSOCIATION BETWEEN PREVALENCE OFFODMAP INTOLERANCE…(5*) Tu1608. . . . . HIGH FODMAP FOOD INTHE EVERYDAY…(6*)| Anemgi onlus Tu1609. . . . . IBS PATIENTS' BELIEFS ONFOOD-RELATED SYMPTOMS…(6*)| Anemgi Onlus Tu1610. . . . . AUTOPROBIOTIC: TREATMENT AND PREVENTIONOF FUNCTIONAL…(5*) Tu1611. . . . . CHANGES OF MICROBIOTA INRAT MATERNAL…(5*) Tu1612. . . . . IRRITABLE BOWEL SYNDROME PATIENTEXPERIENCE IN…(3*)| Allergan Inc. provided the Gastrointestinal Society with an unrestricted grant to conduct this survey. The physicians were not paid. Tu1613. . . . . INVESTIGATION ON SLEEP QUALITYOF PATIENTS…(5*) Tu1614. . . . . THE EFFECT OF ZESPRITMGREEN KIWIFRUIT…(3*)| Funding for the study came from Zespri International Limited Tu1615. . . . . SERUM PROTEOMIC ANALYSIS OFPATIENTS WITH…(5*) Tu1616. . . . . CLINICAL RESPONSE TO THELOW FODMAP…(2*)|(4) Tu1617. . . . . PSYCHOLOGICAL TREATMENTS FOR IRRITABLEBOWEL SYNDROME…(5*) Tu1619. . . . . SUSTAINED RESPONSE AND PREDICTORSOF SUSTAINED…(3*)| |Funding source: Salix Pharmaceuticals, Raleigh, NC.) Tu1620. . . . . CHOLECYSTOKININ RESPONSIVENESS VARIES ACROSSTHE POPULATION…(2*)|(4)


* = Primary Source



Tu1621. . . . . BRAIN MORPHOLOGICAL DIFFERENCES INGASTROINTESTINAL DISORDERS…(2*) Tu1622. . . . . ACUTE STRESS IMPACTS CLOCKGENES AND…(2*) Tu1623. . . . . RELATIONSHIP OF GASTRIC EMPTYINGAND GASTRIC…(2*) Tu1624. . . . . THE EFFECT OF DA-9701INVOLVED IN…(5*)|(4) Tu1625. . . . . FEAR OF THE UNKNOWNAS AN…(2*) Tu1626. . . . . DISPARATE EFFECTS OF GASTRICCAPSAICIN ON…(2*) Tu1627. . . . . RESILIENCE IS ASSOCIATED WITHEARLY LIFE…(2*) Tu1628. . . . . VAGUS NERVE STIMULATION ANDPRUCALOPRIDE HAVE…(2*)|(4) Tu1629. . . . . NEUROPEPTIDE Y2 RECEPTOR ANTAGONISTAMELIORATES ANOREXIA…(3*)| Tsumura & Co. Tu1630. . . . . CORTICAL THICKNESS ABNORMALITIES ASSOCIATEDWITH DISEASE…(2*) Tu1631. . . . . AN INVESTIGATION OF BMIAND SEX-RELATED…(2*)|(4) Tu1632. . . . . COMPARISON OF BRAIN FUNCTIONDURING NORMAL…(2*) Tu1633. . . . . CHRONIC ESOPHAGEAL ACID EXPOSUREMODIFIES FUNCTIONAL…(2*) Tu1634. . . . . FECAL BIOMARKERS OF GUTINFLAMMATION AND…(4*) Tu1635. . . . . ANTI-TNFA TREATMENT IN CROHN'SDISEASE REDUCED…(5*) Tu1636. . . . . SOMATIC-SPINAL-VAGAL PATHWAY INVOLVED INTHE AMELIORATING…(5*)

Tu1637. . . . . CONSTIPATION IN 6-HYDROXYDOPAMINE RATMODEL OF…(2*)|(7) Tu1638. . . . . THE NIGRO-VAGAL PATHWAY ISIMPAIRED PRIOR…(2*) Tu1639. . . . . INVOLVEMENT OF INOS-DERIVED NOIN THE…(2*) Tu1640. . . . . THE INHIBITION OF PROTEINTYROSINE PHOSPHATASE…(2*) Tu1641. . . . . VAGAL AFFERENT DYSFUNCTION INVOLVESSUPPRESSOR OF…(2*) Tu1642. . . . . HIGH-FAT DIET INDUCED MODULATIONOF GLUTAMATERGIC…(2*) Tu1643. . . . . EFFECT OF EARLY-IN LIFEESOPHAGEAL ACID…(2*) Tu1644. . . . . FUNCTIONAL CONNECTIVITY CHANGES INTHE EXECUTIVE…(2*) Tu1645. . . . . HEIGHTENED AWARENESS OF BODYSENSATIONS AND…(2*) Tu1646. . . . . ALTERED COLONIC MOTOR RESPONSETO STRESS…(2*) Tu1647. . . . . THE MAST CELL STABILIZERKETOTIFEN ATTENUATES…(2*) Tu1648. . . . . PILOT OBSERVATIONS FROM AMULTIMODAL IMAGING…(4*) Tu1649. . . . . SUPRASPINAL CONTROL OF DEFECATIONUSING CONCURRENT…(4*) Tu1650. . . . . LONG-LIVED YOLK-SAC DERIVED MACROPHAGESINTERACT WITH…(2*) Tu1651. . . . . ENTERIC GLIAL CELLS (EGCS)IN THE…(2*) Tu1652. . . . . PILOT STUDY IN HUMANGUT MUCOSAL…(2*)

Tu1653. . . . . EAVK AND SEGMENT Câ€�SEQUENCE CONFERS…(2*) Tu1654. . . . . NEURONAL RESPONSES OF CA2+TRANSIENTS IN…(2*) Tu1655. . . . . GASTRIN STIMULATES NUCLEAR EXPORTOF MENIN…(2*) Tu1656. . . . . DISTRIBUTION AND CHARACTERIZATION OFRAD21 IMMUNOREACTIVITY…(2*) Tu1657. . . . . DISTRIBUTION AND CHARACTERIZATION OFANO10 IN…(2*) Tu1658. . . . . CGRPÎ‘ EXPRESSION DEFINES ANOVEL SUBSET…(7*)|(2) Tu1659. . . . . GFAP-POSITIVE CELLS CONTRIBUTE TOBRAIN BUT…(2*) Tu1660. . . . . GASTRIC ELECTRICAL STIMULATION MAYHAVE A…(5*) Tu1661. . . . . VAGAL INNERVATION OF THEESOPHAGUS AND…(2*) Tu1662. . . . . DEFINING INTRAGASTRIC FOOD DISTRIBUTIONAND FUNDIC…(4*) Tu1663. . . . . RELATIONSHIP BETWEEN GASTRIC EMPTYINGOR GASTRIC…(2*) Tu1664. . . . . GASTRIC EMPTYING AND SYMPTOMSOF GASTROPARESIS:…(2*) Tu1665. . . . . SPINAL CORD ELECTRICAL STIMULATIONIMPROVES VISCERAL…(5*) Tu1666. . . . . PSYCHOLOGICAL STRESS IN AGEDFEMALE MICE…(3*)| Tsumura & Co. Tu1667. . . . . AMELIORATING EFFECTS AND MECHANISMSOF ELECTROACUPUNCTURE…(5*) Tu1668. . . . . BITTER TASTE RECEPTORS (TAS2RS)REGULATE GASTRIC…(5*)


* = Primary Source



Tu1669. . . . . THE PREVALENCE, CLINICAL PROFILESAND QUALITY…(4*) Tu1670. . . . . DOES INTRAVENOUS IMMUNOGLOBULIN BENEFITPATIENTS WITH…(5*) Tu1671. . . . . NO DIFFERENCE BETWEEN FUNCTIONALDYSPEPSIA PATIENTS…(5*) Tu1672. . . . . POTENTIAL OF VAGUS NERVESTIMULATION FOR…(5*) Tu1673. . . . . ASSESSMENT OF DUODENO/JEJUNAL BASELINEIMPEDANCE AS…(4*) Tu1674. . . . . MULTI-CENTER, RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND,NON-INFERIORITY, PHASE…(3*)| This study was funded by Korea United Pharm. Inc. Tu1675. . . . . PERCEPTION VERSUS REALITY: DOESMARIJUANA HELP…(5*) Tu1676. . . . . CLINICAL CHARACTERISTICS AND DAILYGASTROINTESTINAL SYMPTOMS…(2*) Tu1677. . . . . TRANSCUTANEOUS ELECTRICAL ACUSTIMULATION SYNCHRONIZEDWITH INSPIRATION…(5*) Tu1678. . . . . PREVALENCE OF GASTRIC MOTILITYDISORDERS IN…(5*) Tu1679. . . . . CHRONIC OPIOID USE INPATIENTS WITH…(5*) Tu1680. . . . . AMELIORATIVE EFFECT OF TJ-116ON DELAYED…(3*)| Tsumura & Co. Tu1681. . . . . STRESS AND STRESS-RELATED PEPTIDEAMPLIFY THE…(4*)|(3)|Tsumura ＆Co Tu1682. . . . . DOES SEVERITY OF GASTROINTESTINALSYMPTOMS CORRELATE…(5*)

Tu1683. . . . . GLUTEN FREE DIET IMPROVESUPPER GI…(4*) Tu1684. . . . . PATHOPHYSIOLOGICAL MECHANISMS OF IMPAIREDGLUCOSE HOMEOSTASIS…(2*) Tu1685. . . . . IMPACT OF FUNCTIONAL DYSPEPSIAAND ITS…(3*)| Supported by the research grant from Astrazeneca K.K. Tu1686. . . . . RELATIONSHIP BETWEEN BMI ANDTEMPORAL TRENDS…(2*) Tu1687. . . . . DETECTION OF POST-ENDOSCOPY INFECTIONOUTBREAKS USING…(4*) Tu1688. . . . . US NATIONAL TREND ANALYSISOF CYCLIC…(5*) Tu1689. . . . . DIARRHEA AND CLOSTRIDUM DIFFICILEINFECTION IN…(2*)| There is no industry or commercial sources of funding. Tu1690. . . . . INCIDENCE AND PREDICTORS OFEARLY HOSPITAL…(5*) Tu1691. . . . . COLDER WEATHER AND FEWERSUNLIGHT HOURS…(5*) Tu1692. . . . . RISK FACTORS FOR COLORECTALCANCER SIGNIFICANTLY…(2*) Tu1693. . . . . ADHERENCE TO A HEALTHYLIFESTYLE REDUCES…(2*) Tu1694. . . . . CHANGING EPIDEMIOLOGY OF LOWERGASTROINTESTINAL HEMORRHAGE…(5*) Tu1695. . . . . OUTCOMES OF WEEKEND VERSUSWEEKDAY ADMISSION…(5*) Tu1696. . . . . EPIDEMIOLOGY OF CONCURRENT USEOF PROTON…(5*) Tu1697. . . . . ASSOCIATION BETWEEN LOWER AIRPRESSURE AND…(5*) Tu1699. . . . . OBESITY INCREASES THE RISKOF GASTROINTESTINAL…(2*)

Tu1700. . . . . DEPRESSIVE PSYCHOLOGICAL STATUS ISASSOCIATED WITH…(5*) Tu1701. . . . . FATIGUE IS NOT ASSOCIATEDWITH VITAMIN…(1*)|(3)| Research grant from Tillots Pharma Tu1702. . . . . THE INFLUENCE OF METEOROLOGICALFACTORS ON…(5*) Tu1703. . . . . ANALYSIS OF RISK FACTORSAND CLINICOPATHOLOGICAL…(5*) Tu1704. . . . . EMERGENCY DEPARTMENT VISITS FORACUTE GASTROINTESTINAL…(5*) Tu1705. . . . . SHARED AUTOIMMUNITY AND CHRONICINFLAMMATORY DISEASE…(5*) Tu1706. . . . . PREVALENCE AND IMPACT OFDIABETES IN…(4*) Tu1707. . . . . AUTOIMMUNE GASTRITIS IN JAPAN:A STUDY…(5*) Tu1708. . . . . THE NUMBER AND LOCATIONOF LESIONS…(5*) Tu1709. . . . . THE ASSOCIATION BETWEEN INFLAMMATORYBOWEL DISEASE…(5*) Tu1710. . . . . INCREASING FREQUENCY OF HOSPITALIZATIONSAMONG YOUNG…(5*) Tu1711. . . . . TRENDS IN INCIDENCE ANDSURVIVAL OF…(5*) Tu1712. . . . . TIME TREND IN THEPREVALENCE OF…(5*) Tu1713. . . . . OUTCOME OF FECAL MICROBIOTATRANSPLANTATION FOR…(4*) Tu1714. . . . . PROCEDURAL-RELATED AND PATIENT-RELATED FACTORSINFLUENCE CLOSTRIDIUM…(5*)


* = Primary Source



Tu1715. . . . . ASPIRIN, STATINS AND STOOLPH LEVELS…(5*) Tu1716. . . . . DONORS ARE UNIVERSAL INTHE FIGHT…(3*)| Rebiotix Inc., Roseville, MN Tu1717. . . . . INCIDENCE, ADMISSION RATES ANDECONOMIC BURDEN…(5*) Tu1718. . . . . INCIDENCE OF CLOSTRIDIUM DIFFICILEIN PATIENT… (5*) Tu1719. . . . . MAGNITUDE AND NATURE OFASSOCIATION BETWEEN…(5*) Tu1720. . . . . STANDARDIZED OPENBIOME PRODUCT ASA TREATMENT…(5*) Tu1721. . . . . LACK OF ASSOCIATION WITHPATIENT DEMOGRAPHICS…(3*)| Rebiotix Inc., Roseville, MN Tu1740. . . . . CAN WE SIMPLIFY THEPEDIATRIC ULCERATIVE.COLITIS…(2*) Tu1741. . . . . ASSOCIATION OF AUTISM SPECTRUMDISORDERS AND…(2*) Tu1742. . . . . HOME OR HOSPITAL-BASED ANALYSISOF STOOL…(3*)| This project was financially supported by BÜHLMANN Laboratories AG, producer of both the IBDoc® method and the fCAL® ELISA assay used in this study. BÜHLMANN did not have a role in the design, execution, analyses, and interpretation of the data, or in the.. Tu1743. . . . . IS MESALAMINE MONOTHERAPY EQUALLYEFFECTIVE IN…(2*) Tu1744. . . . . MEDICATIONS AND SERUM BIOMARKERSARE ASSOCIATED…(2*)|(6) Tu1745. . . . . GREATER CONTRIBUTION OF HLATO RISK…(2*)|(4) Tu1746. . . . . EVALUATION OF ADALIMUMAB EFFECTIVENESSIN ANTI-TUMOR…(3*)| AbbVie

Tu1747. . . . . REDUCED NEUTROPHIL GRANULOCYTE-MACROPHAGE COLONYSTIMULATING FACTOR…(2*)|(6) Tu1748. . . . . LOW NEUTROPHIL REACTIVE OXYGENSPECIES PRODUCTION…(2*)|(6) Tu1749. . . . . HIGHER MUCOSAL CALPROTECTIN EXPRESSIONIS ASSOCIATED…(2*) Tu1750. . . . . C. DIFFICILE INFECTION INTHE FIRST…(2*) Tu1751. . . . . PROCOLLAGEN III N-TERMINAL PROPEPTIDE(PIIINP) AS…(4*) Tu1752. . . . . PREDICTING RESPONSE TO MESALAMINEINDUCTION THERAPY…(2*) Tu1753. . . . . PREDICTING RESPONSE TO ORALCORTICOSTEROID INDUCTION…(2*) Tu1754. . . . . FIBRE INTAKE IS ASSOCIATEDWITH MICROBIOME…(6*)|(2) Tu1755. . . . . SCREENING AND PREVALENCE OFANEMIA IN…(4*) Tu1756. . . . . CLINICAL SYMPTOMS CORRELATE POORLYWITH ENDOSCOPIC…(5*) Tu1757. . . . . CLINICAL EFFICACY AND MICROBIOMEFINDINGS FOLLOWING…(4*) Tu1758. . . . . P2RX3 GENE EXPRESSION ISASSOCIATED WITH…(4*) Tu1759. . . . . SINGLE CENTER EXPERIENCE OFLONG TERM…(5*) Tu1760. . . . . CHOICE OF EXCLUSIVE ENTERALNUTRITION (EEN)…(2*)|(4) Tu1761. . . . . THE SAFETY AND EFFICACYOF THE…(3*)| |Smart Medical Systems Ltd.)

Tu1762. . . . . BARRIERS AND PREDICTORS OFMEDICATION ADHERENCE…(5*) Tu1763. . . . . ORAL AND FECAL MICROBIOMECHARACTERISTICS IN…(4*) Tu1764. . . . . REDUCED TRANSCRIPTION OF GENESREGULATING MITOCHONDRIAL…(2*) Tu1765. . . . . DIFFERENCES IN PHENOTYPE ANDHOSPITAL LENGTH…(5*) Tu1766. . . . . EPITHELIAL AND IMMUNE CELLHSP70 PLAY…(2*) Tu1767. . . . . MDR1-DEFICIENCY UNMASKS MITOCHONDRIAL DYSFUNCTIONAS A…(2*)|(6) Tu1768. . . . . SUMOYLATION OF CHROMATIN-BOUND Î’-CATENINIS A…(2*) Tu1769. . . . . ROLE OF GUT SEROTONININ THE…(2*) Tu1770. . . . . GENETIC DEFECTS IN ERSTRESS AND…(2*) Tu1771. . . . . GUT EPITHELIAL VITAMIN DRECEPTOR CONTROLS…(2*)|(6) Tu1773. . . . . DUAL OXIDASE (DUOX) 2IS INCREASED…(6*) Tu1774. . . . . GENOTOXIC EFFECTS OF PCB153 CAUSE…(2*)|(6) Tu1775. . . . . NORMALITY-SENSING IN THE HUMANGUT: EPITHELIAL…(6*) Tu1776. . . . . ALTERED GUT MICROBIOME ANDINFLAMMASOME ACTIVATION…(2*)|(3)|Emulate Inc. Tu1777. . . . . REG3A IS INDUCED INRESPONSE TO…(3*)


* = Primary Source



Tu1778. . . . . UPREGULATED CLAUDIN-2 EXPRESSION ININFLAMMATORY BOWEL…(2*) Tu1779. . . . . AN EX VIVO MODELTO DETERMINE…(2*) Tu1780. . . . . SECRETED FACTORS FROM LACTOBACILLUSREUTERI SUPPRESS…(2*) Tu1781. . . . . CHRONIC DISRUPTED CIRCADIAN CLOCKWORSEN COLITIS…(2*) Tu1782. . . . . ACTIVATION OF ADENOSINE A3RECEPTOR AMELIORATES…(2*)| Supported by Science and Technology Innovation Committee of Shenzhen City (No. JCYJ20150331142757394) and Natural Science Foundation of Guangdong Province (No. 2016A030313009) Tu1783. . . . . HDAC AS VERSATILE REGULATORSOF THE…(2*) Tu1784. . . . . PYROPTOSIS OF INTESTINAL EPITHELIALCELLS IS…(2*) Tu1785. . . . . TLR4-DRIVEN UPREGULATION OF DUOX2CORRELATES WITH…(5*) Tu1786. . . . . EGCG REVERSES LPS-MEDIATED CHANGESIN CLAUDIN…(4*) Tu1787. . . . . ALPHA SYNUCLEIN: NOVEL PROINFLAMMATORYEFFECTS IN…(2*)|(4) Tu1788. . . . . A NEW PARADIGM ININTESTINAL EPITHELIAL…(2*) Tu1789. . . . . DAIKENCHUTO AND ITS BIOACTIVECOMPARTMENT, GINSENOSIDE…(5*) Tu1790. . . . . PREGNANCY IN IBD: DIRECTEFFECT OF…(5*) Tu1791. . . . . VARIABILITY IN INDUSTRIAL PRODUCTIONAFFECTS PROBIOTICS…(5*)

Tu1792. . . . . INCREASED LEVEL OF FIBROBLASTGROWTH FACTOR…(4*) Tu1793. . . . . CONCOMITANT IMMUNOMODULATOR IS ASSOCIATEDWITH A…(6*) Tu1794. . . . . THE WORLDWIDE INCIDENCE ANDPREVALENCE OF…(5*) Tu1795. . . . . H. PYLORI AND IBDARE INVERSELY…(5*) Tu1796. . . . . HERPES ZOSTER INFECTION ANDHERPES ZOSTER…(5*) Tu1797. . . . . RELATION OF BODY MASSINDEX TO…(5*) Tu1798. . . . . PAST HISTORY OF BARIATRICSURGERY ASSOCIATED…(5*) Tu1799. . . . . POSTOPERATIVE SURGICAL RECURRENCE INCROHN'S DISEASE…(5*) Tu1800. . . . . PREVALENCE OF PSYCHIATRIC DISORDERSIS INCREASED…(2*) Tu1801. . . . . DIETARY TRYPTOPHAN INTAKE ANDRISK OF…(5*) Tu1802. . . . . THE RISK OF HERPESZOSTER IN…(5*) Tu1804. . . . . OBESITY IS ASSOCIATED WITHWORSE DISEASE…(5*) Tu1805. . . . . ETHNICITY IS ASSOCIATED WITHPHENOTYPE AND…(5*) Tu1806. . . . . BETA-BLOCKER USE IS ASSOCIATEDWITH A…(5*) Tu1807. . . . . COMPARISON OF INFLAMMATORY BOWELDISEASE SUBTYPES…(5*) Tu1808. . . . . EARLY LIFE EVENTS ANDRISK OF…(2*)

Tu1809. . . . . THE RELATIONSHIP OF REGIONALDIETS WITH…(5*) Tu1810. . . . . PERIPHERAL ARTERIAL DISEASE ISASSOCIATED WITH…(4*) Tu1811. . . . . SCREENING FOR NON-ALCOHOLIC FATTYLIVER DISEASE…(5*) Tu1812. . . . . PROXIMAL DISEASE EXTENSION INLIMITED ULCERATIVE…(5*) Tu1813. . . . . PRE-MORBID OBESITY IS ASSOCIATEDWITH INCREASED…(7*) Tu1814. . . . . EPIDEMIOLOGY OF HISTOPLASMOSIS INCROHN'S DISEASE…(5*) Tu1815. . . . . HLA-DQ: CELIAC DISEASE VERSUSINFLAMMATORY BOWEL…(2*)|(4)| Spanish Government Funding: This work was supported by the Carlos III Institute and the University Clinic Hospital Research Institute, with a Rio Hortega specialised healthcare post-training contract granted to Bosca-Watts MM (CM07/00240). Tu1816. . . . . HIGH MORTALITY RISK AFTERFIRST HOSPITAL…(6*) Tu1817. . . . . EXPOSURE TO ORAL CONTRACEPTIVESINCREASES RISK…(5*) Tu1818. . . . . GENETIC MARKERS AND ENDOSCOPICDISEASE ACTIVITY…(4*) Tu1819. . . . . PREDICTORS OF INCREASED UTILIZATIONOF HEALTHCARE…(5*) Tu1820. . . . . STUDIES USING HOSPITAL DISCHARGEDATABASES MAY…(2*) Tu1821. . . . . SPORADIC ADENOMAS IN IBDPATIENTS OVER…(5*) Tu1822. . . . . THE EPIDEMIOLOGY OF IBDDIFFERS IN…(5*) Tu1823. . . . . THE IMPACT OF PRIVATEINSURANCE ACCESS…(5*)


* = Primary Source



Tu1824. . . . . CHARACTERIZING THE POST-TRANSFER PERIODAMONGST PATIENTS…(6*) Tu1825. . . . . INCIDENCE, ADMISSION RATES ANDECONOMIC BURDEN…(5*) Tu1826. . . . . SOCIAL MEDIA USE ANDPREFERENCES IN…(6*)| Research Supported by the Crohn’s and Colitis Foundation of America and the Patient Centered Outcomes Research Institute Tu1827. . . . . DISRUPTION OF EPIGENETIC PATHWAYSIN REGULATORY…(2*) Tu1828. . . . . DICHOTOMOUS EFFECTS OF ATG16L1AND LRRK2…(6*) Tu1829. . . . . EARLY FIBROSTENOSIS IN CROHN'SDISEASE IS…(5*) Tu1830. . . . . GENETIC RISK BURDEN AFFECTSINFLAMMATORY BOWEL…(4*)|(6) Tu1831. . . . . GENETIC MARKERS PREDICT PRIMARYNON-RESPONSE AND…(5*) Tu1832. . . . . DIAGNOSING RARE INHERITED DISORDERSUSING TARGETED…(5*) Tu1833. . . . . MULTI-REGION EXOME SEQUENCING REVEALSTHE CLONAL…(4*) Tu1834. . . . . GENOME-WIDE ANALYSIS IDENTIFIES RARECOPY NUMBER…(4*)|(2) Tu1835. . . . . MICRORNA EXPRESSION PATTERNS ASSOCIATEDWITH TISSUE…(2*) Tu1836. . . . . THE ZINC TRANSPORTER ZIP8IS INDUCED…(4*)|(6) Tu1837. . . . . PREDICTION OF NON-RESPONSE TOANTI-TNF THERAPY…(3*)| Janssen Research & Development, LLC

Tu1838. . . . . MIR-665 ACCELERATES ENDOPLASMIC RETICULUMSTRESS-INDUCED APOPTOSIS…(5*) Tu1839. . . . . GENOME-WIDE ASSOCIATION STUDY OFBASELINE DISEASE…(3*)| Janssen Research & Development, LLC Tu1840. . . . . INSIGHTS INTO THE GENETICEPIDEMIOLOGY OF…(2*)|(4) Tu1841. . . . . HUMAN ENDOGENOUS RETROVIRUSES ANDRESIDUES OF…(4*) Tu1842. . . . . GENETIC RISK OF IBD:PREDICTORS OF…(5*) Tu1843. . . . . SMOKING INTERACTS WITH CHRNA5,A NICOTINE…(4*) Tu1844. . . . . MOLECULAR RESPONSE TO USTEKINUMABIN MODERATE-TO-SEVERE…(3*)| Janssen Research & Development, LLC supported this study. Tu1845. . . . . FUCOSYLTRANSFERASE 2 (FUT2) NON-SECRETORSTATUS IN…(4*) Tu1846. . . . . GENOTYPE-SEROTYPE INTERACTIONS SHED LIGHTON OF…(6*) Tu1847. . . . . FUNCTIONAL CHARACTERIZATION OF AHUMANIZED FECAL…(2*)|(6) Tu1848. . . . . CO-HOUSING DSS TREATED MICEWITH HEALTHY…(2*)|(4) Tu1849. . . . . CECAL MICROBIOTA DIRECTLY AFFECTCOLITIS DEVELOPMENT…(2*) Tu1850. . . . . ALTERATION IN MICROBIOTA COMPOSITIONCONTRIBUTES TO…(2*) Tu1851. . . . . FECAL MICROBIOTA TRANSPLANTATION ISHIGHLY EFFECTIVE…(5*) Tu1852. . . . . FECAL MICROBIOTA TRANSPLANTATION ISEFFICACIOUS TO…(5*)

Tu1853. . . . . EB8018, A FIRST-IN-CLASS FIMHBLOCKER, REDUCES…(3*)| Study funded by Enterome Biosciences. Tu1854. . . . . AN INTEGRATED VIEW OFNOTCH SIGNALING…(2*) Tu1855. . . . . IDENTIFICATION OF DISEASE-RELEVANT BACTERIALSIGNATURES IN…(6*) Tu1856. . . . . IMPACT OF ILEOCECAL RESECTIONIN CROHN'S…(4*) Tu1857. . . . . MUCOSAL RECOLONIZATION AFTER ILEOCECALRESECTION DIFFERS…(4*) Tu1858. . . . . MICROBIAL CHARACTERIZATION OF PEDIATRICINFLAMMATORY BOWEL…(4*) Tu1859. . . . . GUT MICROBIOME DYSBIOSIS INCROHN'S DISEASE…(2*)|(6) Tu1860. . . . . MICROBIOME COMPOSITION IS ALTEREDIN PATIENTS…(2*) Tu1861. . . . . POST-OPERATIVE CROHN'S DISEASE RECURRENCEIS ASSOCIATED…(4*)|(6) Tu1862. . . . . PROFILING OF THE FECALMICROBIOTA AND…(4*) Tu1863. . . . . A NOVEL ROLE OFTHE STOMACH…(6*)|(4) Tu1864. . . . . LONGITUDINAL CHARACTERIZATION OF DYSBIOSISAND UNCONJUGATED…(5*) Tu1865. . . . . URSODEOXYCHOLIC ACID AND ITSTAURINE/GLYCINE CONJUGATED…(5*) Tu1866. . . . . INCREASED AND UNIQUE IMMUNOGLOBULINTARGETED COMMENSAL…(4*)|(2) Tu1867. . . . . FIRST ANALYSIS FROM UKIBD TWIN…(6*)


* = Primary Source



Tu1868. . . . . AN ANTIBIOTIC COCKTAIL THATRESULTS IN…(2*) Tu1869. . . . . THE ABUNDANCE OF CLOSTRIDIUMHATHEWAYI, A…(5*) Tu1870. . . . . ANTI-TNF THERAPY SYSTEMATICALLY INFLUENCESINTESTINAL MICROBIAL…(2*) Tu1871. . . . . SPHINGOSINE-1-PHOSPHATE RECEPTOR 3 ORCHESTRATESEPITHELIAL-MESENCHYMAL TRANSITION…(5*) Tu1872. . . . . INHIBITION OF AXL SIGNALINGBY BGB324…(2*) Tu1873. . . . . FIBROSTENOTIC PHENOTYPE OF FIBROBLASTSIN CROHN'S…(4*) Tu1874. . . . . USE OF SECOND HARMONICGENERATION (SHG)…(2*) Tu1875. . . . . OVARIAN CANCER G-PROTEIN-COUPLED RECEPTOR1 DEFICIENCY…(5*) Tu1876. . . . . SEVERE FIBROSTENOTIC ESOPHAGEAL LICHENPLANUS IN…(4*) Tu1877. . . . . RELATIVE PRESERVATION OF TREGFUNCTION IN…(2*) Tu1878. . . . . IL10R DEFICIENCY LEADS TOTHE DEVELOPMENT…(6*)|(2) Tu1879. . . . . EXAGGERATED ONSET AND DELAYEDRESOLUTION OF…(6*)| Wellcome Trust Tu1880. . . . . 5-AMINOSALICYLATES PROMOTE GENERATION OFANTI-INFLAMMATORY HYDROXY…(6*)| Wellcome Trust Tu1881. . . . . ORAL ACETATE REDUCES AHIGH SUGAR…(2*) Tu1882. . . . . ADAPTATION OF ADHERENT-INVASIVE E.COLI TO…(2*)

Tu1883. . . . . NEONATAL COLONIZATION WITH LF82INCREASES SEVERITY…(2*) Tu1884. . . . . LOW INTESTINAL IGA PRODUCTIONIN CVID…(2*) Tu1885. . . . . A ROLE FOR INNATELYMPHOID CELLS…(4*)|(6) Tu1886. . . . . MYCOBACTERIUM AVIUM SSP. PARATUBERCULOSIS(MAP) CAN…(4*) Tu1887. . . . . MACROPHAGES FROM CROHN'S DISEASEPATIENTS SHOWED…(6*)|(4) Tu1888. . . . . HELICOBACTER PYLORI INFECTION ISASSOCIATED WITH…(5*) Tu1889. . . . . CIRCULATING E. COLI OMPCPEPTIDE-SPECIFIC T…(6*)|(4) Tu1890. . . . . HDAC3 CONTROLS THE INFLAMMATORYRESPONSE AND…(3*)|(4) Tu1891. . . . . HDAC MEDIATED REGULATION OFTHE ANTIMICROBIAL…(2*)|(4) Tu1892. . . . . STARCH CONSUMPTION IS ASSOCIATEDWITH SEROLOGIC…(4*)|(6) Tu1893. . . . . IMPACT OF MICROBIOTA ONINTESTINAL IMMUNE…(2*)|(4) Tu1894. . . . . THE ESCHERICHIA COLI SMALLREGULATORY RNA…(6*)|(2) Tu1895. . . . . ACTIVATION OF GUT-ASSOCIATED TERTIARYLYMPHOID TISSUE…(2*) Tu1896. . . . . THE ROLE OF THEMICROBIOME IN…(4*) Tu1897. . . . . HUMAN NOROVIRUS-SPECIFIC T CELLRESPONSES …(2*) Tu1898. . . . . STEROID THERAPY FOR INFLAMMATORYBOWEL DISEASES…(2*)|(4)

Tu1899. . . . . HYALURONAN CONTROLS ADIPOSE TISSUEDEFENSE AGAINST…(5*) Tu1900. . . . . CATHELICIDIN ANTIMICROBIAL PEPTIDE LINKSVITAMIN D…(2*) Tu1901. . . . . PROTEOLYTIC CLEAVAGE OF SURFACEPD-L1 IN…(2*) Tu1902. . . . . THE PROTEIN COMPOSITION OFTHE HUMAN…(2*) Tu1903. . . . . GP96 DEFICIENCY PARTIALLY AFFECTSTLR4 FUNCTIONALITY…(2*)|(4) Tu1904. . . . . CROSS-LINKING OF THE MUC2MUCIN BY…(2*) Tu1905. . . . . GRAM-POSITIVE BACTERIA ARE HELDAT A…(4*) Tu1906. . . . . THE EFFECT OF VITAMIND ON…(7*)| This study was supported by a grant in aid of research from the Dairy Farmers of Canada. Tu1907. . . . . DIRECT INHIBITION OF HMGB1BY NEUTRALIZING…(2*) Tu1908. . . . . CIRCULATING NON-CLASSICAL MONOCYTES AREREDUCED IN…(3*)| This work was funded by an unrestricted grant from Takeda. Tu1909. . . . . THE LACK OF SECRETEDIGA SPONTANEOUSLY…(5*) Tu1910. . . . . THE IMPACT OF DIETAND OBESITY…(2*) Tu1911. . . . . DOES FECAL MICROBIOTA TRANSPLANTATIONFROM AN…(4*) Tu1912. . . . . QUALITY OF BOWEL PREPARATIONDOES NOT…(4*) Tu1913. . . . . FECAL MICROBIOTA TRANSPLANTATION ISSAFE AND…(4*) Tu1914. . . . . SHOULD WE RECOMMEND ANTI-CLOSTRIDIUM DIFFICILE…(4*)


* = Primary Source



Tu1915. . . . . THE NOVEL ROLE OFA SERPIN-PRODUCING…(2*)|(4)|Nestle Research Center Tu1916. . . . . FECAL MICROBIOTA TRANSPLANTATION DIFFERENTIALLYINFLUENCES THE…(6*) Tu1917. . . . . AMINOSALICYLIC ACID DOWN-REGULATES GROWTHAND VIRULENCE…(6*)|(5) Tu1918. . . . . DONOR STOOL PROCESSING TIME:THE EFFECT…(6*) Tu1919. . . . . DONOR BODY MASS INDEX(BMI) DOES…(2*)|(3) Tu1920. . . . . FAECAL MICROBIOTA TRANSPLANTATION FORINFLAMMATORY BOWEL…(5*) Tu1921. . . . . OBESE STOOL DONORS INFECAL MICROBIOTA…(5*) Tu1922. . . . . THE EFFECT OF LACTOBACILLUSREUTERI (DSM…(5*) Tu1923. . . . . THE ROLE OF FECALMICROBIOTA TRANSPLANTATION…(6*) Tu1924. . . . . DOES RIFAXIMIN PRIOR TOFECAL MICROBIOTA…(6*) Tu1925. . . . . FECAL MICROBIOTA TRANSPLANTATION ISSAFE AND…(6*) Tu1926. . . . . EFFECT OF THE HERBALPREPARATION, STW…(3*)| Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt, Germany Tu1927. . . . . ICU PHYSICIAN PROBIOTIC UTILIZATIONRATES: WHEN…(5*) Tu1928. . . . . PEPTOSTREPTOCOCCUS ANAEROBIUS INDUCES INTRACELLULARCHOLESTEROL BIOSYNTHESIS…(4*) Tu1929. . . . . THE INFLUENCE OF WESTERNIZATIONON THE…(2*)|(4)

Tu1930. . . . . A PROSPECTIVE MULTI-NATIONAL STUDYOF THE…(4*) Tu1931. . . . . MUCOSAL MICROBIOTA DYSBIOSIS ACROSSSTAGES OF…(4*) Tu1932. . . . . STOOLS FROM COLORECTAL CANCERPATIENTS PROMOTE…(4*) Tu1933. . . . . SHIFTS IN THE MICROBIOMEASSOCIATED WITH…(5*) Tu1934. . . . . ADHERENT MUCOSAL BACTERIA DYSBIOSISOF ABERRANT…(5*) Tu1935. . . . . HIGH-FAT DIET INCREASES CLOSTRIDIUMCLUSTERS XIVA…(2*)|(4) Tu1936. . . . . ASSOCIATIONS BETWEEN FECAL MICROBIOTACOMPOSITION AND…(2*) Tu1937. . . . . TRANSGLUCOSIDASE IMPROVES THE BOWELMOVEMENTS IN…(4*)|(3)| Amano Enzyme Inc. Tu1938. . . . . ALTERED MICROBIOTA AND MICROBIALMETABOLITES IN…(4*) Tu1939. . . . . THE INCIDENCE RATE OFRIFAMPIN-RESISTANT STAPHYLOCOCCI…(5*) Tu1940. . . . . DIETARY FIBER PROTECT AGAINSTHIGH-FAT DIET-INDUCED…(2*) Tu1941. . . . . Cationic Polystyrene Resolves NonalcoholicSteatohepatitis (NASH),…(2*) Tu1942. . . . . INHIBITORY EFFECTS OF TELAPREVIRON OREXIGENIC…(5*) Tu1943. . . . . DYSFUNCTION OF STARVATION-INDUCED LIVERAUTOPHAGY IS…(5*) Tu1944. . . . . DIETARY INTAKE OF PATIENTSWITH CROHN'S…(6*)

Tu1945. . . . . AGING DETERIORATES ABNORMAL FEEDINGBEHAVIOR IN…(3*)| Tsumura & Co.) Tu1946. . . . . THE PREVALENCE AND CHARACTERISTICSOF VEGETARIAN…(5*) Tu1947. . . . . GLUTEN FREE DIET ANDCARDIOVASCULAR DISORDERS…(5*) Tu1948. . . . . POTENTIAL IMPACT OF WEARABLETECHNOLOGY AS…(4*) Tu1949. . . . . EFFECT OF LAPAROSCOPIC SLEEVEGASTRECTOMY ON…(4*) Tu1960. . . . . LOSS OF TFF1 ACTIVATESBRD2 THROUGH…(2*) Tu1961. . . . . RUFY3-FOXK1 INTERACTION PROMOTES INVASIONAND METASTASIS…(2*) Tu1962. . . . . NOVEL PEPTIDE PROBE TARGETSGPC3 OVEREXPRESSION…(2*)|(4) Tu1963. . . . . GENOME-WIDE ANALYSIS REVEALED AROBUST GENE…(2*) Tu1964. . . . . SERUM MICRORNAS CAN DETECTCOLORECTAL CANCER;…(2*) Tu1965. . . . . EPIGENETIC SILENCING OF MIR-193A,A STAT3…(5*) Tu1966. . . . . NFKB IS ESSENTIAL FORACTIVIN-INDUCED COLORECTAL…(2*) Tu1967. . . . . PANCREATIC CANCER PROTEIN SIGNATURECAN PREDICT…(2*) Tu1968. . . . . A NOVEL MIRNA SIGNATUREFOR THE…(2*) Tu1969. . . . . INCREASES IN MUCOSAL MIR-215PRECEDE NEOPLASTIC…(2*) Tu1970. . . . . THE PRE-MICRORNA 938, TARGETINGIL-17A 3â€™-UTR,…(5*)


* = Primary Source



Tu1971. . . . . DIAGNOSTIC VALUE OF FIVESERUM-BASED MICRORNA…(5*) Tu1972. . . . . 5-HYDROXYMETHYLCYTOSINE (5HMC) DNA PROFILESDISTINGUISH MALIGNANT…(4*)|(2) Tu1973. . . . . COMPARISON OF METHYLATED SEPTIN9 WITH…(2*)| This study was supported by the Health & Medical Research Fund of Hong Kong SAR Government. Tu1974. . . . . MOLECULAR DISPARITIES AND KRASMUTATIONAL SPECTRUM…(2*) Tu1975. . . . . A NOVEL GENE EXPRESSION-BASEDPROGNOSTIC SCORING…(2*) Tu1976. . . . . IDENTIFICATION OF A MIRNACLUSTER WITH…(2*) Tu1977. . . . . HIGH LYMPH NODE YIELDIS ASSOCIATED…(5*) Tu1978. . . . . EVALUATION OF PTGS2 EXPRESSION,PIK3CA MUTATION,…(2*) Tu1979. . . . . STATIN USE, CANDIDATE MEVALONATEPATHWAY BIOMARKERS,…(2*) Tu1980. . . . . EXPRESSION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR2IN HUMAN…(2*) Tu1981. . . . . EVALUATION OF SLUG EXPRESSIONIS USEFUL…(4*) Tu1982. . . . . PLASMA METHYLATED REPRIMO ASA NON-INVASIVE…(2*) Tu1983. . . . . SA1 AND COLORECTAL CANCER:BIOMARKER FOR…(5*) Tu1984. . . . . EXPERIMENTAL AND CLINICAL VALIDATIONOF A…(2*) Tu1985. . . . . INTEGRATIVE BIOINFORMATIC ANALYSES OFA REGULATORY…(2*)

Tu1986. . . . . ROLE OF CDK9 INHIBITIONAS A…(2*)|(6) Tu1987. . . . . THE RELATION BETWEEN EZH2EXPRESSION AND…(2*) Tu1988. . . . . POTENTIAL LINK BETWEEN FUSOBACTERIUMENRICHMENT AND…(4*) Tu1989. . . . . MOLECULAR SUBTYPES COMBINING CPGISLAND METHYLATOR…(2*)|(4) Tu1990. . . . . THE NPG SCORE: ANOVEL NUTRITIONAL…(5*) Tu1991. . . . . GASTRIC CANCER IN AUTOIMMUNEGASTRITIS: A…(2*) Tu1992. . . . . NOVEL RECURRING FUSIONS: PREDICTIVEMARKERS OF…(4*)|(6) Tu1993. . . . . EXPRESSIONS OF ONCOGENIC MODULATORMICRORNA-31AND MICRORNA-21…(2*)| Japan Society for the Promotion of Science Tu1994. . . . . ALTERED EXPRESSION OF AUTOPHAGY-RELATEDGENES IN…(6*) Tu1995. . . . . CLAUDIN-1 AND ERBB2 AREPOTENTIAL BIOMARKERS…(2*) Tu1996. . . . . MACROPHAGE INHIBITORY CYTOKINE 1(MIC1/GDF15) AS…(6*) Tu1997. . . . . INTRATUMORAL CD16- EARLY MYELOIDCELLS PREDICT…(5*) Tu1998. . . . . WNT SIGNALING PROTEIN EXPRESSIONBASED PRIDICTION…(4*)|(2) Tu1999. . . . . TREFOIL-FAMILY-FACTOR-3 AS A NON-INVASIVEBIOMARKER OF…(2*) Tu2000. . . . . COMBINED ANALYSIS OF FECALMICRORNA-221 AND…(5*)

Tu2001. . . . . MIRNAS DYSREGULATION IN GASTRICCANCER AS…(5*) Tu2002. . . . . A PROSPECTIVE, SINGLE-CENTER, CROSS-OVERCONTROLLED TRIAL…(2*)|(5) Tu2003. . . . . USE OF SURFACED ENHANCEDRAMAN SPECTROSCOPY…(1*) Tu2004. . . . . SECOND GENERATION OPTICAL COHERENCETOMOGRAPHY: PRELIMINARY…(5*) Tu2005. . . . . PREDICTORS OF POSITIVE FINDINGSIN PATIENTS…(4*) Tu2006. . . . . PRUCALOPRIDE ACCELERATES GASTRIC ANDSMALL BOWEL…(5*) Tu2007. . . . . THE ROLE OF CTANGIOGRAPHY BEFORE…(5*) Tu2008. . . . . ENDOSCOPIC PREDICTION MODEL FORDEPTH OF…(5*) Tu2009. . . . . ULTRASOUNDX: ADVANCED INTERACTIVE GRAPHICALUSER INTERFACE…(2*) Tu2010. . . . . A NOVEL SOFTWARE TOOLTO REDUCE…(5*) Tu2011. . . . . TRANSCUTANEOUS SHEAR WAVE ELASTOGRAPHYULTRASOUND CAN…(2*)| Siemens provided ultrasound machine. Tu2012. . . . . NGF PROTECTS GASTRIC ENDOTHELIALCELLS FROM…(2*) Tu2013. . . . . ONLY THE PARD6B PARALOGUEOF THE…(2*) Tu2014. . . . . CROSSTALK BETWEEN PROTEIN KINASED1 (PKD1)…(2*) Tu2015. . . . . IL-1 BETA PLAYS ACRUCIAL ROLE…(2*) Tu2016. . . . . ROLE OF SPROUTY PROTEINSIN INFLAMMATORY…(2*)|(4)


* = Primary Source



Tu2017. . . . . P21-ACTIVATED KINASE (PAK)-MEDIATED PHOSPHORYLATIONOF PROTEIN…(2*) Tu2018. . . . . INCREASED LYMPHOCYTE APOPTOSIS INA MOUSE…(2*)|(3)| Abbvie, USA Tu2019. . . . . THE COLONIC SURFACE GOBLETCELLS SECRETE…(2*) Tu2020. . . . . CRITICAL ROLE OF USP9XIN INITIAL…(4*) Tu2021. . . . . THE ROLE OF GÎ‘Q/GÎ‘11SIGNALING IN…(5*) Tu2022. . . . . THE UBIQUITIN HYBRID GENEUBA52 REGULATES…(4*)|(2) Tu2023. . . . . CHARACTERIZATION OF TITANIUM DIOXIDENANOPARTICLE INTESTINAL…(4*)|(2) Tu2024. . . . . SUCCESSFUL FECAL MICROBIOTA TRANSPLANTDEPENDS ON…(6*) Tu2025. . . . . BOMBESIN RECEPTOR SUBTYPE3 (BRS-3):IDENTIFICATION OF…(2*) Tu2026. . . . . STARD10 AS A NOVELDIAGNOSTIC MARKER…(2*)|(4)

Documents

Abstract Funding Sources* AGA Oral and Poster ......Abstract Funding Sources* AGA Oral and Poster Presentations at DDW ® 2017 AGA Institute 4930 Del Ray Avenue Bethesda, MD 20814